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Tissue engineered vascular grafts with long term patency are in great need in the 
clinics. An accessible source of human smooth muscle cell (SMC) is important for 
constructing functional vascular grafts. Human mesenchymal stem cells from the 
umbilical cord (UCMSCs) exhibit multi-lineage differentiation abilities, including the 
potential to differentiate towards vascular lineages such as SMCs. MicroRNAs 
(miRNAs) are short non-coding regulatory RNAs. They widely participate in regulation 
of stem cell differentiation and may play an important role in SMC differentiation. 
Understanding how to generate SMCs from UCMSCs as well as its underlying 
mechanism might greatly contribute to our knowledge of manufacturing functional 
vascular grafts. 
We hypothesise that vascular grafts could be generated with SMCs differentiated 
from human UCMSCs, and further explore the role of miRNAs in the differentiation 
process. We utilised transforming growth factor β 1 (TGFβ1) to stimulate the 
UCMSCs differentiation towards SMCs. A panel of SMC markers including αSMA, 
SM22, Calponin and SMMHC were highly upregulated both at the gene expression 
and the protein level at day 5 of TGFβ1 treatment. Micro-RNA (miR) array analysis 
showed that miR-503 was increased at early time points (6 h and 24 h) after TGFβ1 
treatment, which was confirmed by TaqMan microRNA assay. We further 
demonstrated that miR-503 mimics promoted SMC differentiation both at the gene 
expression and the protein level and miR-503 inhibitors downregulated SMC markers 
at the protein level. Smad7, which is a negative regulator of TGFβ1-related signalling 
pathways, was identified to be a direct target of miR-503 by luciferase reporter 
experiments. The expression level of miR-503 was Smad4-dependent as shown by 
the Smad4 knockdown experiments. Also, Smad4 was demonstrated to be enriched 
at the promoter region of miR-503 as shown by Chromatin immunoprecipitation 
experiments.  
In addition to miR-503, miR-222-5p was also downregulated in the differentiation 
process. The gain-of-function study with the treatment of miR-222-5p mimics 
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significantly inhibited the induction of SMC markers Calponin and αSMA both at the 
gene expression and protein level during differentiation. αSMA was confirmed to be 
a direct target of miR-222-5p. Moreover, ROCK2, which could mediate SMC 
differentiation through RhoA/ROCK pathway, was downregulated by miR-222-5p 
mimics both at the gene expression and protein level. The 3’-UTR segment of ROCK2 
was identified to be a direct target of miR-222-5p. 
Finally, SMCs differentiated from UCMSCs exhibited the ability to migrate into 
decellularised mouse aorta grafts. Seeding of the cells onto the decellularised 
scaffold gave rise to vascular graft with smooth muscle layer that is comparable to its 
analog of the native vessel. In conclusion, we demonstrated the potential of using 
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The aim of my PhD project is to study the potential application of smooth muscle cells 
(SMCs) derived from human umbilical cord mesenchymal stem cells (hUCMSCs) in 
vascular tissue engineering and investigate the miRNA-related mechanism in the 
differentiation process. In the introduction part of this thesis, I would first introduce the 
major studies and concepts in the fields of mesenchymal stem cells (MSCs), 
differentiation of SMCs from stem cells and established mechanisms, miRNAs and 
vascular tissue engineering. Firstly, the discovery history and the basic biology of 
MSCs would be described. Secondly, the differentiation system from various stem 
cell types towards SMCs would be depicted. Thirdly, the differentiation mechanisms 
that have been illustrated in the literature would be reviewed. After that, the 
recognition of regulatory miRNAs in pathological and physiological conditions as well 
as the basic principles of miRNA functioning mode would be explored. In the end, the 
vascular tissue engineering approaches with the focus on the numerous stem cell 
types especially MSCs would be presented.  
1.1. Mesenchymal stem cells (MSCs) 
1.1.1. The discovery of mesenchymal stem cells 
Freidenstein (Friedenstein et al., 1968) was credited for the discovery of 
mesenchymal stem cells in 1968. By analysing the newly formed bone tissue and 
haematopoietic tissue under the renal capsule after the transplantation of fragmented 
marrow there, his laboratory managed to determine that the bone tissue is exclusively 
of donor origin whereas the haematopoietic tissue is of host origin. After secondary 
transplantation of the donor cells isolated from the ectopic bone, they confirmed the 
self-renewal capacity of these cells and established the existence of what he called 
precursors of osteogenic tissues (Friedenstein et al., 1968). This experiment proved 
that precursors of osteogenic tissues are a different cell type from the previously 
discovered haematopoietic stem cells. 
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After Freidenstein’s findings in 1968, he proceeded and devoted his efforts in 
confirming the identity of the cells that were responsible for osteogenesis of the 
transplanted marrow. In a series of studies (Friedenstein and Kuralesova, 1971; 
Friedenstein, 1980, 1995; Friedenstein et al., 1970; Friedenstein et al., 1987; 
Friedenstein et al., 1974; Friedenstein et al., 1976; Friedenstein et al., 1978; Latsinik 
et al., 1970; Owen and Friedenstein, 1988), he observed the development of 
fibroblast colonies in monolayer cultures of guinea pig bone marrow and confirmed 
the bone formation capability of these cells in diffusion chambers (Figure 1-1). He 
used to call these cells colony forming unit fibroblasts, osteogenic precursor cells, 
bone marrow stromal mechanocytes, fibroblast precursors, marrow-derived 
osteogenic precursors and marrow stromal fibroblasts, which are now called 
mesenchymal stem/stromal cells by most researchers in this field. These cells are 
characterised by their rapid adherence to the plastic surface, self-renewal ability and 
their in vitro colony forming capacity when seeded at a suitable density. (Landmark 
studies in the discovery of BMMSCs are summarised in Table 1-1) 
 
 
Figure 1-1 How the diffusion chamber assay works 
The diffusion chamber is composed of a small plastic ring enclosed by two Millipore filters. 
Cells injected in the chamber remained inside as they could not pass through the filter to get 
mixed with the host cells outside. Body fluids (nutrients, salts, and proteins) could pass freely 
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through the filter. After transplantation into the peritoneal cavity of a nude mouse, the diffusion 
chamber was quickly surrounded by host vasculature, allowing it to serve as an in vivo 
incubator. This figure is reproduced from Arnold I. Caplan, 1991.  
Table 1-1 Landmark experiments in the discovery of BMMSCs 
Year  Author Study & Finding 
1867 Cohnheim Cohnheim hypothesis: Marrow-derived fibroblast like cells could enter 
circulation and excavate vessels of injured tissues and take part in tissue 
regeneration 
1868 Goujon Osteogenesis of ectopically transplanted bone marrow 
1963 Till, McCulloch 
and Becker 








Re-observation of osteogenesis in ectopically transplanted bone 
marrow; Not sure whether cells responsible for osteogenesis are of the 
same origin of haematopoietic cells 
1968 Freidenstein Confirmation that cells for neo-bone tissue formation and 




Freidenstein Isolation and culture of colony forming unit fibroblasts with osteogenic 
potential 
1.1.2. Bone marrow-derived mesenchymal stem cells (BMMSCs) 
With the diffusion chamber system in the 1990s, researchers managed to confirm the 
differentiation of bone marrow-derived mesenchymal stem cells (BMMSCs) to bone, 
cartilage and fibrous tissue. In the diffusion chamber with two Millipore filters enclosed 
by a small plastic ring, cells injected in the chamber remained inside as they could 
not pass through the filter to get mixed with the host cells outside. Body fluids 
(nutrients, salts and proteins) could pass freely through the filter. After transplantation 
into the peritoneal cavity of a nude mouse in vivo, the diffusion chamber was quickly 
surrounded by host vasculature, allowing it to serve as an in vivo incubator (Bab et 
al., 1986; Bennett et al., 1991; Caplan, 1991). Figure 1-1 outlines the diffusion 
chamber assay in a nude mice (Caplan, 1991). In addition to the use of diffusion 
chamber, Caplan and his group took advantage of porous calcium phosphate 
ceramics loaded with marrow cells and implanted them at heterotopic sites (eg. 
subcutaneous), with the observation of predominant bone formation, which was 
slightly different from the mixture of bone, cartilage and fibrous tissue formation in the 
diffusion chamber assay (Caplan, 1991; Ohgushi et al., 1989a, b).  
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By manipulating the culture conditions (Beresford et al., 1992), the cells could be 
induced into either adipocytic or osteogenic lineage. This is the preliminary evidence 
for the in vivo and in vitro differentiation of BMMSCs. Subsequently numerous studies 
have been conducted with various differentiation conditions. It is worth noting that, 
Caplan is the first to call these cells multi-potent “mesenchymal stem cells”. 
1.1.3. Mesenchymal stem cells from other stromal tissues 
Since the isolation of MSCs with tri-lineage differentiation potential (i.e. osteogenic, 
chondrogenic and adipogenic differentiation capacities) from the bone marrow, cells 
with similar characteristics have been isolated from multiple human tissue types 
including adipose tissue, synovial membrane, periodontal ligament, tendon, skin, 
cartilage, dental pulp, eye, gut, heart, kidney, liver, lung, muscle, pancreas, spleen, 
thymus, umbilical cord, placenta, aorta, vena cava, cord blood and peripheral blood 
(Alsalameh et al., 2004; Bi et al., 2007; Campagnoli et al., 2001; da Silva Meirelles et 
al., 2006; De Bari et al., 2001; Gronthos et al., 2002; Romanov et al., 2003; 
Salingcarnboriboon et al., 2003; Seo et al., 2004; Shi and Gronthos, 2003; Toma et 
al., 2005; Villaron et al., 2004; Zuk et al., 2002; Zuk et al., 2001). (The characterization 
of MSCs derived from various tissues are summarised in Table 1-2.)  
Since the discovery of BMMSCs and later MSCs originating from tissues all over the 
body, MSCs have been widely used in translational researches, such as orthopaedic 
reconstruction, which has promising clinical potential. Some clinical trials have taken 
advantage of the benefits of the immune regulatory function of MSCs and have shown 
promising and reproducible results in immune disorders such as multiple sclerosis, 
graft-versus-host disease and Crohn’s disease (Prockop and Olson, 2007; Uccelli et 
al., 2008). Clinical benefits have also been achieved in other areas such as 
cardiovascular diseases (myocardial infarction and ischemia), pulmonary and 
neurological diseases. However, some of the results are anecdotal and not 
reproducible due to the lack of homogeneity, poor understanding of in vivo identity of 
MSCs and the lack of standard culture conditions. The promising therapeutic 
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application of MSCs in translational researches urges further efforts to be invested in 
elucidating the in vivo identity and biological function of these cells.  
Umbilical cord-derived mesenchymal stem cells (UCMSCs) 
UCMSCs have similar immunophenotypic characteristics and functional properties 
with MSCs derived from other tissues. However, source-dependent differences exist. 
Compared to MSCs derived from other tissues, UCMSCs display higher proliferation 
capacity which is a significant advantage with regard to their application potential in 
tissue engineering (Abu Kasim et al., 2012; Hsieh et al., 2010; Lu et al., 2006; Yu et 
al., 2013). UCMSCs grow faster than BMMSCs at early passages with a cell 
population doubling time of 24 hours over 40 hours of BMMSCs (Abu Kasim et al., 
2012). Furthermore, UCMSCs demonstrate better ability to form colony forming units 
in vitro which is also a proof of their relatively better proliferation capacity compared 
to bone marrow nucleated cells (Lu et al., 2006). 
Regarding the transcriptomic profile of UCMSCs and BMMSCs, most of the surface 
markers they express are common mesenchymal markers. However, unlike in 
BMMSCs, HLA-ABC is weakly expressed in UCMSCs, indicating that these cells 
might be less immunogenic than BMMSCs (El Omar et al., 2014). This immune 
privilege makes UCMSCs a good candidate for tissue engineering of vascular grafts, 
which will be grafted in vivo in the end.  
Adipose tissue-derived mesenchymal stem cells (ADSCs) 
The harvesting method of BMMSCs is invasive with a relatively low yield. ADSCs 
present similar properties with MSCs derived from other tissues including BMMSCs 
(da Silva Meirelles et al., 2006). The main advantage of ADSCs over BMMSCs is 
perhaps the abundance of adipose tissue which makes ADSCs readily available. 
Arguably, ADSCs are among the most promising MSCs for stem cell based cell 




Table 1-2 Characterisation of MSCs derived from various sources 




Zuk PA, 2002  FVIII 24.9%, α SMA 29.2% (ECs, SMCs, 
pericytes), ASO2 85.0%, vimentin 63.2% 
(mesenchymal markers) 
(IF) Positive: CD29, CD44, CD71, CD90, CD105, 

























(IF) Stro-1, CD146 Cementoblast-
like cells 
Adipogenic, 







Skin Toma JG, 
2005  
(IF) fibronection, vimentin, nestin Neurons  
Glias 
SMCs 
Cartilage Alsolameh S, 
2004  



















(FACS) CD29+, CD44+, CD117-, CD49e, 
CD90.2: expression varies; Sca-1, CD34: 





Blood Villaron EM, 
2004  
(FACS) Positive: CD90, CD106, CD54, CD49b; 
Negative: CD105, CD56, CD34, CD133, CD104, 
CD62L, HLA-DR 
 
Cord blood Campagnoli 
C, 2001  
(FACS) Positive: CD29, CD44, CD105, SH3, 





1.1.4. The minimal criteria of mesenchymal stem cells 
Since 2000, there has been an explosion in the number of studies about 
mesenchymal stem cells. However, without standard characterisation method, 
obvious discrepancy across different labs existed, which made it difficult to interpret 
the results accurately. To solve this problem, International Society for Cellular 
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Therapy (ISCT) published a position statement of the minimal criteria to define 
multipotent mesenchymal stromal cells cultured from human tissues (Dominici et al., 
2006). In this position paper, mesenchymal stem cells are defined as being adherent 
to the plastic surface when cultured under standard conditions. They acquire a 
specific phenotype and display multipotent differentiation capacity in vitro. (The 
minimal criteria of human MSCs are summarised in Table 1-3.) Concerning negative 
surface markers of the phenotype, CD45 (cluster of differentiation 45), CD34, CD14 
or CD11b, CD79α or CD19 are used to exclude contamination of pan-leukocyte, 
primitive haematopoietic progenitors, monocytes/macrophages and B cells 
respectively in the culture. Positive expression of the surface markers merits further 
exploration because none of the markers are specific to mesenchymal stem cells and 
more markers should be explored to distinguish mesenchymal stem cells between 
their differentiated state and undifferentiated state.  
Though the ISCT position managed to define MSCs with phenotypic markers and 
avoided contamination of other cell population, these criteria still could not uniquely 
identify all MSCs (Sabatini et al., 2005). Sabatini identified human bronchial 
fibroblasts exhibiting a mesenchymal stem cell phenotype and multilineage 
differentiation potentials in 2005. Furthermore, though these markers are used to 
identify mesenchymal stem cells in vitro, it is hard to search for mesenchymal stem 
cells in situ in tissue sections with multi-staining of them even with the most advanced 
multicolour fluorescence microscopes due to the in vitro culture artifacts and the lack 
of knowledge about the differences between MSCs in vivo and in vitro. 
Table 1-3 The minimal criteria to characterise human MSCs 
1. Adherence to the plastic surface in standard culture conditions 
2. Phenotype:  
Positive (≥95%+): CD73, CD90, CD105; Negative (≤2%+): CD45, CD34, CD14 or 
CD11b, CD79αor CD19, HLA-DR 
3. In vitro differentiation capacities: osteoblasts, adipocytes, chondrocytes 




Other markers used for mesenchymal stem cell characterisation include Stro-1 
(Simmons and Torok-Storb, 1991), which can enrich CFU-Fs (colony forming unit 
fibroblasts) by approximately 100-fold in human MSCs, when combined with 
glycophorin A negative phenotype (to exclude erythroid progenitors). However, Stro-
1 is only expressed in human tissues and there is no corresponding marker in other 
species. Recent findings showed that Stro-1 is expressed in the endothelium rather 
than in mesenchymal tissue in vivo, and it was induced under mesenchymal stem cell 
culture conditions in vitro (Ning et al., 2011). Additionally, it is well documented that 
difference exists across tissue origins and between species (Sacchetti et al., 2016). 
This implies the necessity of future work to discover true markers of mesenchymal 
stem cells and minimise artifacts of in vitro culture. 
1.1.5. In vivo identity and function of mesenchymal stem cells 
MSCs are a heterogeneous population reflected in the colonies they form in vitro 
which have different growth rates and morphologies ranging from fibroblast like 
spindle shaped cells to large spread cells. Furthermore, if the colonies are allowed to 
grow for a long period, heterogeneity in the colonies could be observed as well, with 
some of the colonies alkaline phosphate positive, some of them negative and some 
others positive in the centre and negative in the periphery region (Friedenstein et al., 
1982). This heterogeneity might be explained by the tissues themselves which consist 
of numerous different cell types and therefore have diverse precursor types and are 
heterogeneous in nature and origin. However, in vitro culture of these cells seems to 
be at least similar concerning the phenotype and multilineage differentiation potential.  
To minimise the discrepancy of reported properties of mesenchymal stem cells and 
increase the consistency of molecular studies and preclinical trials across different 
labs, characterisation of in situ/native mesenchymal stem cells is a prerequisite and 
could allow for purification of these cells which could facilitate the researches in tissue 
engineering applications. Approaches in searching for the in vivo nature, localisation 
and identity of mesenchymal stem cells so far include seeking for the in vivo MSCs 
with in vitro expressed surface markers, infusion of marked MSCs in vivo to track their 
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homing and distribution, and systemic isolation of MSCs from various tissues to 
evaluate their characterisation. 
As discussed earlier, Stro-1 is strongly expressed in stromal cells which are 
clonogenic in in vitro cultured cells (Gronthos et al., 1994). Theoretically, the same 
reagent used in in vivo sections could establish the in vitro and in vivo relationship of 
mesenchymal stem cells, providing evidence of micro-anatomical niches or identity 
of the clonogenic cells (Bianco et al., 2001). In frozen sections stained with Stro-1, it 
was shown that the wall of vasculature was the main location of Stro-1 positive cells. 
However, the major obstacle is that most surface markers of in vitro cultured 
mesenchymal stem cell do not uniquely identify these cells, and they are still 
expressed in other cell types. For example, CD105 is also expressed in ECs and 
CD44 is also expressed in SMCs. Nonetheless, the phenotype of MSCs changes 
once they are cultured in vitro and heterogeneity of MSCs indicates that even we 
could characterise cells with some specific markers; it does not necessarily mean that 
these are all the cells that have clonogenic potential in vitro. As a result, 
characterisation of MSCs in vivo of their phenotypic feature closely mimics  shooting 
a moving target in that the phenotypic print of MSCs constantly changes in response 
to their in vitro and in vivo microenvironment (Bianco et al., 2001). 
Another strategy is to infuse MSCs in vivo to track the engraftment and homing of 
them to specific tissues. After transducing murine BMMSCs with eGFP, tagged cells 
were systemically injected into minimally injured mice and tissue specific 
differentiation of these cells was determined by RT-PCR and immunohistochemistry 
(Anjos-Afonso et al., 2004). The contribution of donor derived eGFP-MSCs to 
different cell types including hepatocytes, lung epithelial cells, myofibroblasts, and 
renal tubular cells was confirmed.  Although this approach could provide functional 
information about mesenchymal stem cells in tissue regeneration, utilising it as a 
proof of the in vivo natural localisation of MSCs is inappropriate, as non-specific 
binding of MSCs in various tissues could not be excluded. Furthermore, there is 
evidence showing that MSCs are short-lived when injected intravenously into the 
circulation and do not pass the lungs  (Eggenhofer et al., 2012).  
29 
 
Systemic isolation and evaluation of MSCs from different tissues represents an 
alternative approach (da Silva Meirelles et al., 2006). It was reported in many studies 
that MSCs with similar in vitro characterisation can be cultured from various tissues 
like adipose tissue, umbilical cord, tendon, synovial membrane and others. Isolation 
of MSCs from tissues all over the body (brain, kidney, liver, lung, spleen, bone marrow, 
vena cava and aorta) provides an opportunity to consistently visualise the distribution 
of MSCs in vivo (da Silva Meirelles et al., 2006). The similar but not identical 
phenotype of mesenchymal stem cells originating from different tissues reflects the 
similar origins but influences of different microenvironments. The proposed 
hypothesis that MSCs are tissue resident stem cells led to further investigations of 
their perivascular origin (Crisan et al., 2008), and this has been suggested by other 
studies as well (Bianco et al., 2001; Farrington-Rock et al., 2004; Shi and Gronthos, 
2003). Despite the accumulating evidence indicating a perivascular origin of MSCs, 
disputes have also arisen, most of which lie in the use of CD146 as a perivascular 
surface marker and the lack of biological relevance of CD146 expression and MSC 
function. In addition, it is demonstrated recently that MSCs might actually contain 
tissue specific progenitors from different mesoderm derivatives (Sacchetti et al., 
2016).   
As none of the approaches provides a definite answer to the question of the in vivo 
identity of MSCs, more studies should be done to track the development origin and 
elucidate the in vivo function of MSCs. 
 
1.2. Differentiation of stem cells towards smooth muscle 
lineage 
1.2.1. SMC differentiation from embryonic stem cells 
Developmentally, vascular SMCs originate from different embryonic stages, and form 
different vessels or different sections of one vessel with sharp boundaries (Majesky, 
2007; Yoshida and Owens, 2005).  Utilising stem cells at different embryonic stages, 
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in vitro systems of SMCs differentiation have been established (Xie et al., 2011b), 
applying treatment with all-trans retinoic acid (at-RA), TGFβ, PDGF-BB, and collagen 
IV coating, either alone or  combined.  These systems, including the cell origin, 
treatment, the extent of differentiation marked by SMC marker expression, and 
functional contractility of differentiated cells, are summarised in Table 1-4.  
It is worth mentioning that each differentiation system has its own pros and cons. For 
example, Kamaritini E (Karamariti et al., 2013a) demonstrated that reprogrammed 
lung fibroblasts had the ability to differentiate into functional and contractile SMCs 
when treated with PDGF-BB on collagen IV coated flasks. When derived SMCs were 
seeded on decellularised aortic scaffold from mouse in combination with ECs, 
functional vessels could be formed when transplanted in vivo. However, it needs to 
be considered that the cells they use are reprogrammed embryonic lung fibroblasts 
transfected with the Yamanaka factors (Oct4, Sox2, Klf4 and cMyc), which could form 
teratomas in immunodificient mice. Pros and cons of each differentiation system 
should be taken into consideration and weighed carefully before choosing specific 
system. What is more, all these systems utilise in vitro culture of cells which is the 
intrinsic limitation, which should not be ignored when interpreting experiment results; 
because it is unknown to what extent these in vitro systems could recapitulate SMCs 




Table 1-4 In vitro SMC differentiation models from embryonic stem cells (Modified from 
Xie C, 2011)  
Cells Cell origin Treatment  SMC 
markers 
Pros Cons Reference 
A404 Mouse P19-






atRA 10-6mol/L, 2 
d; puromycin 0.5 














cells grown in 
vitro  
AtRA 10-8 mol/L, 
dibutyryl-cAMP 
0.5x10-3 mol/L,  
6 d 















overnight or for 3 
days 
αSMA Potent Risk of 
teratomas 























ESC Mouse, human atRA 10-6 mol/L, 
10 d 
αSMA  Potent  Huang H, 
2006  
ESC  Mouse  αMEM + 10% FBS 















αMEM + 10% FBS 
+ PDGF-BB 10 
ng/ml, in collagen 































neural crest cell 
line 
 TGFβ1 5 ng/ml,  
3 d 







neural crest cell 
line 













1.2.2. SMC differentiation from adult stem cells 
Vascular SMCs are a major cell type in the vascular wall constituting the media layer 
in relatively large vessels. In various cardiovascular diseases such as coronary artery 
disease, SMCs play an essential role. For example, SMC accumulation is a major 
event during the development of atherosclerosis. Unravelling the origin of these cells 
prove to be an important building block in deciphering the mechanism of 
cardiovascular diseases for subsequent therapeutic exploration. However, conflicting 
data exist, with some of the reports describing the importance of adult stem cells and 
some others reporting importance of existing SMC.  
The adult stem cell pool includes the bone marrow-derived stem cells 
(haematopoietic stem cells and mesenchymal stem cells) which can be mobilised to 
circulation, and tissue resident stem cells (vascular progenitor cells and stem cells 
from tissues all around the body).   
It is now recognised that these SMCs might originate from transdifferentiation of other 
cell types such as ECs (DeRuiter et al., 1997) and fibroblasts, through phenotypic 
switching from SMCs in the media or differentiation from either resident stem cells or 
those mobilised from other tissues such as bone marrow. Transdifferentiation and the 
phenotypic switching will be discussed later. The evidence is also accumulating that 
adult stem/progenitor cells differentiate into SMCs in a variety of cardiovascular 
diseases, including atherosclerosis and intra vascular stent restenosis.  A set of in 
vivo studies have provided evidence of the origin of tissue resident stem cells that 
give rise to neointimal SMCs which may contribute to atherosclerosis and restenosis.  
In 2001, Han and colleagues (Han et al., 2001) confirmed that bone marrow-derived 
cells could contribute to SMCs in vascular healing by providing an alternative source 
of smooth muscle-like cells when the media was severely damaged. However, they 
did not elucidate whether it was the haematopoietic stem cell or the mesenchymal 
stem cell within the bone marrow that was responsible for the effect. Later, Shimizu 
(Shimizu et al., 2001) confirmed the finding of Han by transplantation of bone marrow 
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galactosidase-expressing cells. Sata (Sata et al., 2002) took the study one step 
further. They injected purified haematopoietic stem cells into mouse circulation and 
observed that injected cells could participate in the pathogenesis of atherosclerosis. 
Although they confirmed that haematopoietic stem cells had potential to differentiate 
into SMCs both in vivo and in vitro, they did not exclude the possibility that 
mesenchymal stem cells within the bone marrow could be mobilised in terms of 
vascular injury and take part in atherosclerosis. 
However, conflicting data exist as to whether bone marrow is a source for neointimal 
SMCs. Bone marrow transplantation of SM-LacZ β-gal expressing cells into mice 
suggested that bone marrow progenitor cells did not serve as a source of SMCs (Hu 
et al., 2002). And later on, the same group identified a type of Sca-1(+) cells within 
the adventitia of aortic root and confirmed that after seeding these Sca-1(+) positive 
cells cultured in vitro onto the adventitia side of the vascular injury, the cells migrated 
into the media and intima and participated in atherosclerotic lesion formation and 
vascular repair (Hu et al., 2004).  
These studies are summarised in Table 1-5. An explanation of the conflicting data is 
that αSMA is more sensitive than SM22 as a marker for SMC identification. Thus, the 
use of different markers for SMCs (αSMA, SM22 or SMMHC) in different reports 
made the conclusion ambiguous and the question of whether bone marrow-derived 
stem cells could contribute to SMC differentiation requires further investigation.  
As stated earlier, several processes may contribute to SMCs presence in 
atherosclerotic lesions, and it remains unclear to what extent stem cells could give 
rise to SMCs in pathogenesis. What is now widely accepted is that the origin and 
residency of these stem cells requires further exploration. Using the models 
summarised in Table 1-5, it may be possible to elucidate detailed mechanisms of 
SMCs differentiation. New light might be shed on the pathological reasons behind 
differentiation of vascular resident stem cells into SMCs, thus providing more 




Table 1-5 Studies of adult stem cell differentiation into SMCs in vivo and their 
pathological meaning 





Han CI, 2001 Staining of  
αSMA 
Bone marrow-derived cells are recruited 
in vascular healing as a complementary 
source of smooth muscle-like cells when 
the media is severely damaged and few 








Staining of  
αSMA 
Host bone-marrow cells are a source of 
donor intimal smooth-muscle–like cells in 







Staining of  
αSMA 
Haematopoietic stem cells differentiate 
into vascular cells that  participate in the 





Hu Y, 2002  SM22-LacZ SMCs in transplant atherosclerotic 
lesions are originated from recipients, but 
not bone marrow progenitor cells 
Sca-1 (+) adventitia 
cells  
Hu Y,2004  SM22-LacZ When Sca-1(+) cells carrying the LacZ 
gene were transferred to the adventitial 
side of vein grafts in ApoE-deficient mice, 
β -gal(+) cells were found in 
atherosclerotic lesions of the intima, and 
these cells enhanced the development of 
the lesions 
Adventitia fibroblast Li G, 2001  __ Adventitial fibroblasts seeded on the 
adventitia side of vascular balloon injury 
would migrate to neointimal site and take 
part in neointimal formation 
1.2.3. Phenotypic switching/plasticity of SMCs 
Vascular SMCs in normal vessel walls are highly specialised cells whose contractile 
function controls the blood vessel tone. In physiological conditions, vascular SMCs 
display a contractile phenotype, remain quiescent, exhibit a low proliferation rate and 
synthesise minimal extracellular matrix (Owens, 1995). However, unlike skeletal or 
cardiac myocytes which are terminally differentiated, vascular SMCs retain the ability 
to undergo profound and remarkable phenotypic switching, changing from the 
functional contractile phenotype into the synthetic phenotype in response to 
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environmental cues (Ammit and Panettieri, 2001). The comparison of these two 
phenotypes is described in detail in Table 1-6. Briefly, SMCs exhibiting a contractile 
phenotype express more contractile proteins such as SM22, αSMA, Calponin and 
SMMHC, while synthetic SMCs express more extracellular matrix proteins and are 
more proliferative and migratory.  
Developmentally, vascular SMCs plasticity plays a key role in the morphogenesis of 
blood vessels, in which, they exhibit a high rate of proliferation, migration, and 
production of extracellular matrix components but at the same time they still acquire 
contractile capabilities. Physiologically, SMC phenotypic switching represents an 
important capability of vascular repair, in which SMCs change from a contractile 
phenotype to a synthetic phenotype, migrate to the sites of vascular injury and restore 
vessel function.  
However, when this repairing system goes too far, it may contribute to the 
development and progression of vascular diseases including atherosclerosis and 
post implantation in-stent restenosis. In atherosclerosis, vascular SMCs migrate into 
subintimal space and contribute to fibrous cap formation over the atherosclerotic 
plaques. Although SMCs could synthesise collagen to promote stabilisation of the 
fibrous cap, they could also release matrix metalloproteinases which might contribute 
to the disruption of the fibrous cap and cause subsequent arterial thrombosis. 
Extracellular matrixes released by SMCs located in the subintimal space could cause 
hyperplasia of the intima, restenosis and eventually lead to failure of the vascular 
intervention or reconstruction. 
Before the recognition of the contribution of adult stem cells to SMCs presence in 
atherosclerotic lesions or at other vascular injury sites, media of the vessel was widely 
thought to be the major source of synthetic SMCs, which were contractile SMCs in 
the dedifferentiated phase (Ross and Glomset, 1976). However, it is hard to quantify 
which proportion of SMCs in the intima are derived from media SMCs, due to the 
downregulation of the specific SMC markers in the intimal SMCs and the use of αSMA 
staining which was not specific to identify SMCs in the lesion site (Owens et al., 2004). 
36 
 
Overall, the origins of intimal SMCs in atherosclerotic lesions, restenosis and other 
vascular injuries as well as the control of the phenotypic switching and differentiation 
process are very complex and further exploration is needed.  
1.2.4. Transdifferentiation of SMC from other cell types 
Apart from phenotypic switching and differentiation, there is also evidence that other 
cell sources including ECs (Arciniegas et al., 2000; Clowes et al., 1983) and adventitia 
fibroblasts (Sartore et al., 2001; Stenmark et al., 2000) can be transdifferentiated and 
act as alternative origins of SMCs. 
Table 1-6 The comparison between contractile phenotype and synthetic phenotype of 
SMCs (Modified from Rzucidlo EM, 2007)  
Difference Contractile phenotype Synthetic phenotype 
Cell size and 
shape 
Spindle elongated shape Hypertrophic spread shape  
ECM (extracellular 
matrix) production 
Decreased ECM production: 
predominance collagen IV, 
laminin 
Increased ECM production: 
Predominance collagen III, fibronection 
Contractile protein 
expression 
Increased contractile protein 
expression: 
 SMMHC2, Calponin, αSMA 
Decreased contractile protein 
expression; 
increased expression of osteopontin 
Migration Decreased migration: 
decreased MMPs, increased 
TIMPs 
Increased migration: Increased MMP-1 
and MMP3 
1.3. Mechanism of smooth muscle differentiation 
1.3.1. Signalling pathways 
1.3.1.1. SRF – CArG-dependent regulation of SMC differentiation  
Serum response factor is a MADS (MCM1, agamous, deficiens, serum response 
factor) box transcription factor, which binds to the highly conserved CArG cis-
elements (CC(A/T)6GG) that is present within virtually all promotor or intronic 
sequences of SMC marker genes, including αSMA, SM22, Calponin, SMMHC, and 
desmin. SRF binds with CArG elements as dimers and interacts with other co-factors 
such as Myocardin, the Myocardin-related transcription factors (MRTFs), and some 
Nkx and Gata family members. The complex has the capability to regulate the 
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expression of SMC markers (Figure 1-2). SRF is a ubiquitously expressed protein 
which also regulates cardiac and skeletal muscle gene expression, as well as some 
early response and structural genes (Sun et al., 2006). Although expressed widely in 
many cell types, the relatively higher level of SRF within SMCs (and other muscle cell 
types) partly explains the specific regulation muscle cell specific genes (Belaguli et 
al., 1997; Croissant et al., 1996). The ability of SRF to bind to CArG regions of SMC 
genes proves to be the rate limiting factor in SMC differentiation (Manabe and Owens, 
2001).  
Other than Myocardin and the Myocardin-related family, the homeodomain proteins 
(Hox, Nkx3.1, Prx-1 and Barx2b) could also enhance SRF binding ability, while the 
HERP1/HEY2 (Doi et al., 2005) (a target of the Notch signalling pathway), 
homeodomain-only protein (HOP) and YY1 possesses the ability to inhibit it 
(Hautmann et al., 1997; Herring et al., 2001; Yoshida et al., 2004).  
Post translationally, modification of SRF by phosphorylation changes the binding 
affinity of SRF with transcription factors. Arginine vasopressin increased αSMA 
promotor activity by phosphorylation of SRF at Ser103 by Jun amino-terminal kinases 
(JNKs) and p38 mitogen-activated protein kinase (MAPKs) (Garat et al., 2000).  
Phosphorylation at Ser162 by protein kinase Cα and at Thr159 by protein kinase A 
decreased αSMA promotor activity (Blaker et al., 2009; Iyer et al., 2006). Interestingly, 
CArG elements control the promotor activity of SRF (Belaguli et al., 1997), suggesting 
a positive feedback loop of the control system (Spencer and Misra, 1996). It is 
noteworthy that SRF-CArG regulation needs other complementary signalling 
mechanisms which control chromatin structure and transcription factor access to SRF 
and this will be discussed later.  
Furthermore, the SRF-CArG regulating pathway is not sufficient for SMC specific 
gene expression, other cis elements and trans-binding factors also play a very 
important role in the regulation of SMC differentiation, including TGFβ control element 
(TCE), E box elements (CANNTG motifs) and a cis element referred to as a G/C 
repressor (Liu et al., 2003; Madsen et al., 1997; Shimizu et al., 1995). Mutation of 
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TCE and E box elements, which are non-CArG elements, eliminated the expression 
of SMC specific genes in transgenic mice (Kumar et al., 2003; Liu et al., 2003). 
In summary, SMC differentiation depends on the integration of multiple regulatory 
pathways in which SRF-CArG cis elements regulation plays a critical but not exclusive 
role. 
 
Figure 1-2 The interaction of Myocardin, SRF and the CArG elements at SMC 
contractile gene promotors regulates the contractile gene expression in SMCs 
Myocardin and SRF binds to the highly conserved CArG cis-elements (CC(A/T)6GG) that are 
present within virtually all promotor or intronic sequences of SMC marker genes, including 
αSMA, SM22, Calponin, SMMHC, and desmin.  
 
1.3.1.2. Myocardin-related regulation  
Myocardin (935 aa) is expressed in the heart and most SMC containing tissues, and 
is located predominantly in the nucleus (Chen et al., 2002; Wang et al., 2002), 
whereas its two family members Myocardin-related transcription factor A (MRTF-A) 
and Myocardin-related transcription factor B (MRTF-B) are ubiquitously expressed 
and located in the cytosol due to the structural difference (RPEL motif) they possess 
from Myocardin (Guettler et al., 2008). SMCs with Myocardin knocked out can still 
differentiate (Pipes et al., 2005). Myocardin is dispensable for vascular development, 
but not visceral development.  Mice with a homozygous null mutation of Myocardin 
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could not survive and died at embryonic day 10.5 (Li et al., 2003), and the death was 
caused by the loss of Myocardin in vascular SMCs. 
Other than SMC contractile markers which are controlled by the Myocardin-SRF-
CArG regulatory system, what is also induced by this system is a set of micro-RNAs, 
such as miR-1 (Chen et al., 2011) and miR-143/145 (Boettger et al., 2009; Cheng et 
al., 2009; Cordes et al., 2009; Xin et al., 2009), which play a role in the negative 
feedback loop (Jiang et al., 2010) or the positive feedback loop in the complex and 
integrated SMC differentiation mechanism. 
Regulated Myocardin level 
It has been shown that Myocardin expression in cardiac and SMCs is regulated by 
the Myocardin enhancer through scanning the genomic DNA for cis-regulatory 
elements capable of directing Myocardin transcription in vivo. As a direct target of 
Myocardin enhancer factor 2 (MEF2), Foxo and Tead factors, Myocardin enhancer 
could be activated with the combination of these factors and display increased 
Myocardin expression independent of the SRF-CArG regulatory system (Creemers 
et al., 2006) (Figure 1-3). In comparison with the SRF-CArG independent regulation, 
other studies showed that CArG cis elements were also present upstream of the 
Myocardin gene (Miano, 2003), and cofactors such as Nkx2.5, p49/STRAP (SRF-
dependent transcription regulation associated protein) and Myocardin itself could 




Figure 1-3 The combination of Foxo, MEF2 and Tead at Myocardin enhancer could 
activate Myocardin expression independent of SRF-CArG element 
This figure is reproduced from (Creemers et al., 2006). 
 
Environmental cues which can stimulate the expression of Myocardin include TGFβ1 
(Shi and Chen, 2013), angiotensin II (AngII) (Yoshida et al., 2004), increased calcium 
influx, insulin-like growth factor (IGF) and hypoxia (Jie et al., 2010), and the 
modulation mainly influences the interaction of SRF cofactors (Nkx2.5 (Shi and Chen, 
2013) and Prx1 (Yoshida et al., 2004)) with SRF.  
PDGF-BB inhibits the expression of Myocardin and this is probably through the SRF-
CArG-dependent pathway in cultured SMCs (Yoshida et al., 2007). Atorvastatin, a 
widely used lipid lowering drug, inhibits the expression of Myocardin in vivo and in 
vitro through the RhoA-Rho-associated kinases pathway (Li et al., 2012). BMP2 was 
shown in cardiac myocytes to inhibit the expression of Myocardin (Callis et al., 2005), 
but not in SMCs (Hayashi et al., 2006), reflecting a differential response governed by 
cell types. 
Posttranslational modification including acetylation, phosphorylation, sumoylation 
and ubiquitination can also influence the activity of Myocardin. Chromatin-modifying 
enzyme p300 acetylates lysine residues at the N terminus of the Myocardin protein 
and promotes its interaction with SRF and the formation of Myocardin-SRF-CArG box 
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ternary complex (Cao et al., 2012). Phosphorylation of Myocardin by ERK1/2 at four 
sites (Ser812, Ser859, Ser866, and Thr893) is required for its interaction with 
acetyltransferase (Taurin et al., 2009). Ubiquitination of Myocardin directs its 
degradation, resulting in altered activity of Myocardin. Evidence suggests that 
degradation of ubiquitinated Myocardin by proteasomes can activate Myocardin 
activity and that accumulations of Myocardin due to dysfunction of ubiquitination were 
unable to activate its target genes, probably because of its inability to recruit RNA 
polymerase II to the Myocardin-SRF-CArG complex (Sandbo et al., 2005; Yin et al., 
2011). In vivo study of a canine carotid model showed that the downregulation of 
ubiquitin, E2, E3 and proteasome subunits in anastomotic intimal hyperplasia 
indirectly supported this degradation-induced transactivation model of Myocardin 
(Stone et al., 2001).  
Regulated Myocardin activity 
Interaction of Myocardin with other proteins reduces the accessibility of Myocardin to 
SRF, thus inhibiting its transcriptional activity. FOXO4, which is a forkhead 
transcription factor, can repress the expression of SMC specific genes through 
interaction with Myocardin. IGF can induce SMC phenotypic switching from a 
synthetic and proliferative phenotype to a contractile and differentiated phenotype 
through phosphorylation of FOXO4 by activation of the phosphoinositide-3-kinase 
(PI3K)-Akt signalling pathway and translocating phosphorylated FOXO4 from the 
nucleus to cytoplasm, thus releasing Myocardin from the interaction and promoting 





Figure 1-4 IGF induces contractile gene expression in SMCs through PI3K-Akt pathway 
Phosphorylated FOXO4 is translocated from the nucleus to the cytoplasm thus releasing 
Myocardin. Myocardin binds to SRF and then promotes the differentiation of SMCs. 
 
Other factors that can interact with Myocardin and inhibit Myocardin activity include 
SOX9 (Xu et al., 2012b), which is a master regulator of chondrogenesis, and Msx1 
and Msx2 (Hayashi et al., 2006), which are induced by bone morphogenetic proteins 
(BMPs). Nuclear uPAR (Urokinase-type plasminogen activator receptor) has been 
shown to associate with Myocardin and recruit it from the promoters of serum 
response factor target genes, resulting in Myocardin degradation by the proteasomes 
(Kiyan et al., 2012). Apart from abrogating Myocardin function through disrupting its 
binding with SRF, high mobility group 2 like 1 (HMG2L1) abolished the SRF-
Myocardin complex binding to CArG elements of SMC specific genes (Zhou et al., 
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2010). (The factors that could inhibit the interaction of Myocardin and SRF are 
summarised in Figure 1-5.) 
 
 
Figure 1-5 Factors that could inhibit the interaction of Myocardin and SRF 
Myocardin binds to SRF dimers and forms and complex which could bind the CArG element 
at the promoter region of target genes. Transcription factors such as FOXO4, SOX9, Msx1, 
Msx2 and uPAR could interact with Myocardin and prevent it from binding to SRF dimers. 
HMG2L1 could prevent the Myocardin-SRF dimer complex from binding to the CArG element. 
In both ways, the downstream target gene expression would be inhibited.  
 
1.3.1.3. RhoA regulated signalling pathway 
It was discussed in the part of “SRF – CArG-dependent regulation of SMC 
differentiation” that SRF dimers bind to CArG elements of SMC specific genes and 
stimulate expression of these genes with the help of Myocardin or MRTFs, thus 
promoting SMC differentiation or phenotypic switching from synthetic phenotype to 
contractile phenotype. Due to the structural difference between Myocardin and 
MRTFs (MRTF-A and MRTF-B), Myocardin constitutively exists in the nucleus, while 
MRTFs are mainly located in the cytoplasm.  
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RhoA was proved to influence SMC differentiation in a variety of studies (Lu et al., 
2001; Wamhoff et al., 2004), and RhoA kinases were important RhoA effectors. 
Various environmental cues can promote SMC differentiation through the 
RhoA/ROCK pathway including thrombin (Martin et al., 2009), TGFβ (Chen et al., 
2006; Deaton et al., 2005), sphingosine-1-phosphate (S1P) (Lockman et al., 2004), 
BMP (Lagna et al., 2007) and cell stretch (Zeidan et al., 2003). These agonists 
activated the transmembrane G protein coupled receptors (GPCRs) and then with the 
facilitation of guanine exchange factors (GEFs) which exchange GDP for GTP, RhoA 
was activated (Heasman and Ridley, 2008). Details about the GPCRs types and 
GEFs that respond to each agonist are reviewed elsewhere (Mack, 2011).  
Before RhoA activation, MRTFs bind to G-actin and remain in the cytoplasm. After 
RhoA-ROCK (RhoA kinases) pathway activation, however, G-actin in the cytoplasm 
forms F-actin and dissociates with MRTFs, releasing MRTFs and promoting the 
translocation of them from the cytoplasm to the nucleus. Increased MRTFs in the 
nucleus interact with SRF and enhance SMC specific gene expression (Miralles et 
al., 2003). Direct evidence of this nuclear translocation pattern was observed using 
enhanced GFP fusion protein (Hinson et al., 2007). (The RhoA regulated signalling 




Figure 1-6 RhoA pathway regulates SMC differentiation in response to various 
environmental cues 
Thrombin, TGFβ, S1P, and BMP bind to G protein coupled receptors (GPCRs) and signals 
through the RhoA-ROCK pathway, which results in polymerisation of G-actin. MRTFs then 
dissociate with G-actin and are translocated to the nucleus, thus activating SMC gene 
expression by binding the SRF-CArG elements. 
 
1.3.2. Epigenetic modulation 
1.3.2.1. Chromatin modification 
Genomic DNA is wrapped in a compact structure known as chromatin, which is 
composed of nucleosomes and linked by a linker chromatin. Histones (2x H2A, 2x 
H2B, 2x H3, 2x H4) and a 146 base pair long genomic DNA form the basic unit of a 
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nucleosome. The linker chromatin is formed by DNA of variable lengths and histone 
H1. The N terminal tail of histones are freely exposed to the environment and are 
prone to modifications including methylation, acetylation, phosphorylation, 
ubiquitination and ADP-ribosylation (Cheung et al., 2000). Modification of histones or 
interaction of histones with other binding proteins could then change the protein 
conformational structure and the accessibility of DNA within the chromatin to 
transcription factors (Figure 1-7).   
 
Figure 1-7 Structure and modification of chromatin 
(A) Naked DNA binds to histones to form a spatial configuration. (B) Modification and 
interaction of chromatin with other proteins could regulate chromatin configuration and 
function.  
 
The first evidence that certain chromatin modification promoted smooth muscle 
differentiation was presented by Manabe and his colleagues in 2001 (Manabe and 
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Owens, 2001). It was found that in the undifferentiated state of A404 cell line (derived 
from P19 embryonal carcinoma stem cells), although Myocardin and SRF were highly 
expressed, they could not bind to the CArG containing regions of the promoters of 
SMC specific genes. Upon retinoic acid treatment, however, binding was promoted, 
followed by the stimulation of SMC specific gene expression. Hyperacetylation of H3 
and H4 through histone acetyltransferase (HAT) proved to be critical to this process 
and histone deacetylase (HDAC) inhibitors could have the same effect. Other studies 
later confirmed their results. Cao and colleagues showed that p300, a histone 
acetyltransferase associated with the Myocardin transcription activation site induced 
the acetylation of histones surrounding SRF binding site in the promotor region of 
SMC specific genes (Cao et al., 2005). HDAC7 underwent alternative splicing in 
collagen IV-induced SMC differentiation from embryonic stem cell through modulation 
of the SRF-Myocardin complex (Margariti et al., 2009).  Recruitment of HDAC2 and 
HDAC5 by Krüppel-like factor 4 (Klf4) and pElk at the αSMA promotor region resulted 
in hypoacetylation of histone 4, thus inhibiting the gene expression (Yoshida et al., 
2008).  
Other than acetylation, methylation also proved to be of major importance in the 
regulation. H3K4 methylation increased the binding of SRF with CArG regions in the 
activation of SMC specific genes (Yoshida et al., 2008). 
A specific modification pattern was identified which was termed “bivalent domains” by 
screening embryonic stem cells for specific histone methylation patterns (Azuara et 
al., 2006; Bernstein et al., 2006). H3 lysine 27 methylation and H3 lysine 4 
methylation coincide with transcription factors expressed at low levels in embryonic 
stem cells, keeping the developmental gene/lineage specific genes silent while in the 
meantime, keep them poised for activation (Azuara et al., 2006; Bernstein et al., 
2006). It is easy to reason that this silencing pattern should be eliminated when 
inducing lineage specific gene expression.  
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In summary, epigenetic modification plays a critical role in initiating SMC 
differentiation from a stem cell state and requires the integration and cooperation of 
other signalling pathways to promote and determine SMC fate. 
1.3.2.2. MicroRNAs 
MicroRNAs are necessary for the differentiation of SMCs as demonstrated by the 
study of Dicer deletion experiments which resulted in the failure of microRNA 
maturation (Albinsson et al., 2010; Pan et al., 2011). Dicer deletion in vascular SMCs 
caused embryonic lethality at day 16 to 17, with extensive internal haemorrhage 
generated by reduction of SMC proliferation and impaired contractility which could be 
partly rescued by overexpression of miR-145 (Albinsson et al., 2010). 
1.3.2.2.1. MiR-143/145  
Both in vitro and in vivo loss-of-function studies have shown that miR-143/145 is 
important for SMC differentiation (Boettger et al., 2009; Elia et al., 2009). Through the 
repression of antagonistic factor (Klf4, Klf5, Elk1, versican and angiotensin converting 
enzyme) gene expression in the SMC differentiation process, miR-143/145 facilitates 
expression of SMC specific genes (Cordes et al., 2009; Davis-Dusenbery et al., 2011; 
Long and Miano, 2011; Rangrez et al., 2011; Xin et al., 2009). MiR-143 and miR-145 
are expressed in proximity in chromosome 5 and share the same promotor which 
contains CArG elements, as with most contractile SMC specific genes. Thus miR-
143/145 is regulated in an SRF-CArG-dependent pathway. Briefly, for the induction 
of miR-143/145, TGFβ signals through the Smad2/3 pathway and Myocardin is 
required to promote binding of SRF to the CArG element, and BMP4 signals through 
RhoA pathway and MRTF-A translocation to the nucleus is required (Davis-
Dusenbery et al., 2011). PDGF-BB, which is known as a synthetic SMC phenotype 
inducer, activates Src through PDGF receptor and as a result, p53 (Suzuki et al., 
2009), which is an inducer of miR-143/145 is repressed (Quintavalle et al., 2010). In 




MiR-1 was observed to be steadily increased in the differentiation process from 
embryonic stem cells to SMCs and loss-of-function study showed that miR-1 was 
essential to the process. MiR-1 induces SMC differentiation through the repression 
of Klf4 (Xie et al., 2011a) and Pim-1 (a serine/threonine kinase) (Chen et al., 2011) 
which also serves as a negative regulator of SMC differentiation. Upstream regulators 
include Myocardin, whose overexpression resulted in significant induction of miR-1 
(Chen et al., 2011). However, contradictory data was also observed which 
demonstrated that exogenous miR-1 inhibited contractility of SMCs and repressed 
the expression of contractile proteins (Jiang et al., 2010). Further studies are needed 
for the elucidation of miR-1 function in SMC differentiation. 
1.3.2.2.3. MiR-21 
MiR-21 was also involved in TGFβ- and BMP4-induced SMC differentiation by 
downregulating programmed cell death 4 (PDCD4), which is a repressor of SMC 
contractile genes (Davis et al., 2008). Dedicator of cytokinesis (DOCK) protein 
superfamily was also identified as the targets of miR-21, whose downregulation 
inhibited cell migration (Kang et al., 2012). Mature miR-21 could be increased by the 
recruitment of TGFβ and BMP4 specific SMAD signal transducers to the DROSHA 
complex which facilitated the processing of pri-miR-21 to precursor miR-21 (Davis et 
al., 2008). However there was still evidence that miR-21 could be repressed by 
increased miR-143 through repression of fos-related antigen 1 (FRA-1) in SMC 
differentiation (Horita et al., 2011) suggesting the complex regulatory role of miR-21. 
MiR-21 has also been investigated in many tissues outside of the vasculature and its 
function is suggested to be highly context-dependent (Lin et al., 2009). 
1.3.2.2.4. MiR-10a 
Retinoic acid induces SMC differentiation from embryonic stem cells during which 
process miR-10a was increased (Huang et al., 2010). This increase is the direct result 
of retinoic acid-induced nuclear translocation of NF- κB. Upregulated miR-10a binds 
to the 3’-UTR of HDAC4 which is a negative regulator of SMC differentiation (Huang 
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et al., 2010). The regulatory function of microRNAs in SMC differentiation is 
summarised in Figure 1-8. 
1.3.2.2.5. Others 
Other microRNAs that contribute to SMC differentiation, proliferation and migration 
include miR-100 (Grundmann et al., 2011) and miR-125b (Goettsch et al., 2011; 
Mizuno et al., 2008). Furthermore, various microRNAs are involved in the promotion 
of a synthetic phenotype of SMCs, such as miR-24(Chan et al., 2010b), miR-26a 
(Leeper et al., 2011), miR-31 (Liu et al., 2011), miR-146a (Sun et al., 2011), miR-204 
(Morrell et al., 2001), miR-208 (Zhang et al., 2011) and miR-221 (Liu et al., 2009).  
In summary, microRNAs play a critical role in SMC differentiation, and represent an 
important therapeutic choice for cardiovascular diseases (Scalbert and Bril, 2008). 
 
Figure 1-8 MicroRNAs that could induce SMC differentiation 
MicroRNAs induce SMC differentiation by repressing the expression of proteins that inhibit 




1.3.3. TGFβ1-induced SMC differentiation 
TGFβ is a multi-functional regulator in vascular development and maintenance, by 
controlling the proliferation, differentiation and other properties of SMCs. It was 
described earlier in the report that TGFβ could induce SMC differentiation by 
dissociating MRTF-A from G-actin through the RhoA-ROCK pathway and 
translocating it to the SRF-CArG complex at the SMC specific gene promotors in the 
nucleus, thus inducing SMC differentiation. 
Moreover, TGFβ could also induce the expression of SMC specific genes through 
putative Smad binding elements other than the SRF-CArG regulating system (Hu et 
al., 2003; Qiu et al., 2003; Qiu et al., 2005). Independent of CArG elements, Smad3 
was induced by TGFβ and could bind to the Smad binding element of SMC specific 
gene promotor and induce SMC differentiation. In addition, this process was 
enhanced by Myocardin (Qiu et al., 2005).  
Moreover, it is worth mentioning again that miR-143/145 is also upregulated upon 
TGFβ treatment through the RhoA-ROCK/MRTF-A/SRF-CArG system as stated 
earlier. MiR-143/145 is known as positive regulators of SMC differentiation and the 
detailed mechanism is explained in the last part of the report. 
It was displayed earlier in the report that IGF signals through the PI3K-Akt-FOXO 
pathway and translocated phosphorylated FOXO from the nucleus to the cytoplasm 
thus inhibiting the repressive function of nuclear FOXO on the Myocardin-SRF-CArG  
system and SMC specific gene expression (Qureshi et al., 2007). 
Moreover, TGFβ1 in vivo stimulates the expression of NADPH oxidase 4 (Nox4) in 
the media of the vessel wall (Clempus and Griendling, 2006; Clempus et al., 2007), 
which constitutively produces large amounts of H2O2. Xiao and colleagues showed 
that Nox4 was crucial for SMC differentiation by the generation of H2O2, translocation 
of phosphorylated SRF to the nucleus and subsequent induction of SMC 
differentiation (Xiao et al., 2009). It was displayed that Nox4 could also produce O2- 
and stimulate SMC differentiation through the p38-MAPK pathway (Su et al., 2001). 
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As a result, Nox4, as well as reactive oxygen species, is an important signalling 
pathway for TGFβ-induced SMC differentiation. 
 
1.4. Recognition of small regulatory miRNAs  
1.4.1. Recognition of small regulatory RNAs 
In the human genome, only 1-2% of the genes code for proteins. However, with recent 
next-generation deep sequencing technologies, it is revealed that most of the genome 
is transcribed to RNAs. Apart from the mRNAs which would be translated to proteins, 
there is also a vast number of RNAs which were not thought to be functional, i.e. 
noncoding RNAs. Recent studies have established a significant regulatory role of 
these non-coding RNAs in various molecular mechanisms (Beermann et al., 2016). 
Non-coding RNAs could be divided into two groups: the constitutive non-coding RNAs 
and regulatory ones. Like the housekeeping genes, constitutive non-coding RNAs are 
stably transcribed in the cells and the transcription is not generally affected by the cell 
state. Ribosomal RNAs, transfer RNAs, small nuclear RNAs and small nucleolar 
RNAs are included in the constitutive non-coding RNA category. According to the size, 
regulatory non-coding RNAs could be sub-grouped into short non-coding RNAs and 
long non-coding RNAs. Short non-coding RNAs are defined to be RNAs less than 
200 nucleotides long and include endogenous short interfering RNAs (siRNAs), 
microRNAs (miRNAs) and others such as piwi-associated RNAs (Hombach and Kretz, 
2016). Among the short non-coding RNAs, miRNAs are the most extensively studied 
and have been proved to play important roles in diverse regulatory pathways and 
numerous disease contexts. The size of long non-coding RNAs ranges from 200 
nucleotides to several kilobases. The mechanism through which they function is not 
fully understood. Continuous efforts have been invested to develop standard 
characterisation methods of long non-coding RNAs such as ribosome profiling and 
genome engineering with clustered regularly interspaced short palindromic repeats 
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(CRISPR). The focus will be placed on the discovery, biogenesis, and current 
research trends on miRNAs in this thesis introduction. 
1.4.2. Discovery and history of miRNAs 
Though it seems easy for us to accept the concept of regulatory RNAs which is not 
included in the central dogma now, it takes the scientists several decades from the 
description of the first regulatory miRNA to subsequent establishment of various 
miRNAs along with their involvement in numerous physiological and 
pathophysiological processes. Reviewing the discovery of miRNA and the associated 
establishment of concept-changing scientific discoveries would give us some 
implications about future research that could push the present scientific boundaries. 
The first miRNA and its inhibitory effect through binding to 3’-UTR region of target 
mRNA was depicted in nematode Caenorhabditis elegans (C. elegans) in which cell 
lineages were fully understood. In 1981, it was reported that mutation of gene lin-4 
resulted in reiterative cell lineages in C. elegans (Chalfie et al., 1981). Later in 1989, 
lin-4 was proved to be a negative regulator of lin-14 as suggested by the almost 
identical defect induced by lin-4 loss-of-function mutation e912 and lin-14 gain-of-
function mutation n536 and n355 (Ambros, 1989). Two years after that, two mutations 
in lin-14 gene that caused the deletion of its 3’-UTR region led to the inappropriate 
accumulation of lin-14 proteins within the nucleus and helped to identify the 3’-UTR 
region as a negative regulatory element (Wightman et al., 1991). With these results 
combined, researchers continued to examine whether the negative regulatory effect 
of lin-4 on lin-14 was exerted through the 3’-UTR region of lin-14.  
In 1993, two studies published in Cell worked in line to further confirm and add details 
to the hypothesis (Lee et al., 1993; Wightman et al., 1993). Wightman et al. described 
the necessity and sufficiency of lin-14 3’-UTR existence in the exertion of lin-4 
negative regulatory effect on lin-14 protein (Wightman et al., 1993). Conservation of 
lin-14 3’-UTR across several different species acted as another evidence of its 
participation in the regulating process. Whereas Wightman et al. invested their main 
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efforts in deciphering the role of lin-14 3’-UTR in mediating the inhibitory effect of lin-
4 on lin-14 protein level, Lee et al. focused mainly on characterising the lin-4 gene 
(Lee et al., 1993). By introducing frameshift mutation as well as point mutation of the 
putative open reading frame of lin-4 gene, Lee and co-workers first managed to rule 
out the possibility that lin-4 gene could code for any proteins because the introduction 
of mutation did not affect the function of lin-4. Afterwards, in Northern blots and 
RNAase protection experiments, they detected two small RNA transcripts (lin-4S and 
lin-4L) with lin-4 gene probe which rescued the lin-4 loss-of-function mutation e912. 
Furthermore, these two small RNAs were found partially complementary to the 3’-
UTR region of lin-14 gene (Lee et al., 1993).  
Until then, sufficient experimental evidence was gathered about the first miRNA lin-4. 
Firstly, it is a non-protein-coding gene which gives rise to miRNA transcript lin-4. 
Secondly, miRNA lin-4 functions through partially binding to the 3’-UTR region of 
target lin-14 mRNA and induces translational inhibition of lin-14. This serves as the 
prototype of miRNA functioning mode for later research. However, before moving 
forward to set miRNA as a general and universal regulatory element, more miRNAs 
have to be described other than this isolated report of lin-4.  
In the following years, more reports have been published to prove involvement of 
miRNA lin-4 in inhibiting the translation of lin-14 mRNA through targeting its 3’-UTR 
region (Ha et al., 1996; Olsen and Ambros, 1999). It was not until 2000 that the report 
of the second miRNA let-7 was documented. Reinhart et al. described the 
transcription of the 21 nucleotides long let-7 RNA and its inhibitory regulation of lin-
41 and other genes by binding to their 3’-UTR region (Reinhart et al., 2000). 
Pasquinelli et al. in the same year analysed the conservation of let-7 RNA across 
various species and managed to detect it in species ranging from vertebrate, 
hemichordate, mollusc and others (Pasquinelli et al., 2000). Different tissues from 
Homo sapiens were also found to express let-7 RNA including the brain, kidney, lung, 
spleen and stomach (Pasquinelli et al., 2000). These two reports serve more 
important roles than being the second report of small RNA regulating translation 
through complimentary binding to 3’-UTR region of target mRNA. If these two reports 
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were examined more pervasively, the information suggested was that the concept of 
regulatory non-coding small RNAs could move beyond nematodes to invertebrates 
and vertebrates. This valuable piece of information, however, could not be achieved 
from the examination of the first miRNA lin-4, since its expression seemed to be 
restricted to Caenorhabditis or nematode species as shown by database search and 
Northern blot experiments (Pasquinelli et al., 2000).  
After the recognition of the second miRNA and its existence in Homo sapiens, the 
concept of regulatory small non-coding RNAs started to be shaped. Extensive efforts 
were then invested to characterise more miRNAs in various species including C. 
elegans and humans. Only one year after the description of miRNA let-7, abundant 
miRNAs were detected in different species which unveiled the curtain of this essential 
regulatory RNA group that were previously shaded by the dominant central dogma 
(Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001).  
Since the genes coding from miRNA transcripts do not normally contain open reading 
frames and other features recognised by then, most of the miRNAs were not identified. 
For this reason, Lau et al. went on to directly clone RNA transcripts from total RNAs 
isolated from C. elegans. The standards they set for miRNAs while they were 
exploring miRNA pool in the cells include the following. Firstly, it should be around 22 
nucleotides long. Secondly, it should contain a 5’-terminal monophosphate and a 3’-
terminal hydroxyl group. Thirdly, the longer transcript from which it was processed 
should form a “stem-loop” structure (Lau et al., 2001). With these standards to 
develop a protocol to clone miRNAs, they first found 330 clones that match the 
genomic sequence of C. elegans; out of these clones, 300 contain the capacity to 
form fold-back structures and they represent 54 miRNA transcript sequences. What 
is assuring is that, lin-4 and let-7 were among the abundant miRNAs characterised 
with this approach. Northern blot analysis later confirmed the existence of some of 
the miRNAs identified (Lau et al., 2001). Moreover, it was found that a large fraction 
of these miRNAs could also be found in C. briggsae (Lau et al., 2001). 
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In the same year, Lee et al. published in the same issue of Science reporting similar 
results about the characterisation of miRNAs in C. elegans (Lee and Ambros, 2001). 
It is of more significant meaning that apart from the elucidation of miRNA pool in 
nematodes, Lagos-Quintana et al. managed to characterise and clone 21 novel 
miRNAs from Hela cell, a human cervical cancer cell line (Lagos-Quintana et al., 
2001). The recognition of abundant miRNA existence in various species especially in 
human has led the research to a new era focusing on regulatory noncoding miRNAs. 
Till now, the miRNA-related research is still on-going and numerous challenges 
remain such as the involvement of miRNAs in specific diseases, miRNAs as 
diagnostic biomarkers and miRNAs as therapeutic targets in the clinics. Further and 
more extensive studies are required. 
1.4.3.  Biogenesis of miRNAs 
MicroRNA biogenesis is a multistep process, beginning from the initial transcription 
of primary miRNA, which has a hairpin/stem-loop structure. After being transcribed 
with RNA polymerase II or RNA polymerase III, primary miRNAs were first processed 
in the nucleus through Drosha/DGCR8 microprocessor complex in a sequence 
independent but structural-dependent manner to form the precursor miRNA around 
60 to 80 nucleotides long. Afterwards, precursor miRNAs were actively exported to 
the cytoplasm with Exportin-5 in a Ran-GTP-dependent manner. In the cytoplasm, 
the transition of GTP to GDP helped to release the precursor miRNAs from Exportin-
5. Dicer later works cooperatively with TRBP to cleave the precursor miRNA and 
generate mature miRNAs which would be incorporated into the RISC complex and 
then bind to the 3’-untranslated region (3’-UTR) of the target sequence in a 
complementary manner to induce target mRNA degradation or translation inhibition. 





Figure 1-9 The synthesis and maturation process of microRNAs  
The microRNA gene was transcribed to be pri-microRNA. With the facilitation of enzymes 
later, it was processed to pre-microRNA and then microRNA duplex. One strand of the duplex 
is later degraded and the other strand, which is the mature microRNA, binds to RISC and 3’-




1.4.4. Database of miRNAs: annotation and target prediction  
1.4.4.1. Criteria for miRNA annotation  
After the identification and characterisation of multiple miRNAs from C. elegans, 
insects, mammals and human cells, regulatory miRNAs emerge to be a new focus in 
research and exhibit potentials to unveil a previously hidden regulatory layer of 
various physiological and pathophysiological processes (Lagos-Quintana et al., 2001; 
Lau et al., 2001; Lee and Ambros, 2001). The first challenge that had to be overcome 
in laying a solid foundation of miRNA research and move from single/isolated reports 
of one miRNA and its function to large scale miRNA-related processes was to define 
the features of miRNAs and standardise the annotation. As shown by previous 
studies on several miRNAs such as let-7 and lin-4, miRNAs exert nice conservation 
among different species. Consistent annotation of these miRNAs is necessary. 
Furthermore, there are other small RNAs in the cells, such as fragments of larger 
noncoding RNAs including ribosomal RNAs, small nuclear RNAs and siRNAs. 
Standard annotation is a pre-requisite for differentiation of miRNAs with these small 
RNAs. 
Among these RNAs, siRNAs bear the biggest similarity to miRNAs. They were both 
small and shared a similar structure. They could both function in a complementary 
binding manner with target mRNAs and exhibit the inhibitory effect. Although siRNAs 
normally bind to target mRNAs with strict and complete complementarity which is 
different from the generally accepted partial binding mode of miRNAs to target 
mRNAs, there are also miRNAs that could function with a complete complementary 
binding mode (Hutvagner and Zamore, 2002). The more distinguishable difference 
between siRNAs and miRNAs may lie in their biogenesis process. SiRNAs are 
processed from long double-stranded RNAs and could be generated from both 
strands, whereas miRNAs are generated from primary and precursor hairpin/stem-
loop miRNAs and the mature form originates normally from one strand. 
Given the necessity for standard characterisation and annotation to ensure that it is 
the miRNA that we are working with and experiment results about the same miRNA 
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across different species and different research groups could be referred to, criteria to 
define and name the miRNAs were proposed by Ambros et al in 2003. It was required 
that the small single-stranded RNA around 22 nucleotides needed to be detected 
both by specific primers and in the cDNA library prepared from size fractionated RNA. 
Furthermore, at the biogenesis level, it was required that the precursor miRNAs from 
which they were processed should have a hairpin structure and Dicer should be 
confirmed to be the enzyme mediating that process (Ambros et al., 2003).  
The database was updated every several years to include more newly annotated 
miRNAs and the criteria were proved to be capable of keeping a clean database of 
miRNAs. This database of miRNAs provided consistent annotation scheme and 
served as a repository of miRNAs over the years for reference of researchers 
(Griffiths-Jones, 2010; Griffiths-Jones et al., 2006). 
Later on, with the development of new RNA sequencing technologies, deep 
sequencing data were integrated to the database to further facilitate the error 
correction of miRNA sequences and provide a whole picture of miRNA expression 
mode in different contexts (Kozomara and Griffiths-Jones, 2011, 2014). With data 
utilisation from published articles that reported novel miRNAs, the sequence reads 
and counts were extracted and compared against those already reserved in the 
miRBase. Data acquired from different tissues, species and with different methods 
were pooled together with the inclusion of published RNA deep sequencing data. It 
gradually provided an outlook for researchers about the distribution and level of 
various miRNAs. Furthermore, the comparison of sequence data with known 
sequences from the miRBase enables the error correction of the reserved database 
(Kozomara and Griffiths-Jones, 2011). For example, for dme-miR-317, it was 
revealed by the sequencing data that it was actually 21 nucleotides long whereas it 
was 24 nucleotides as recorded by the database before. The addition of certain 
miRNA isoforms suggested by the sequencing data was possible as well (Kozomara 
and Griffiths-Jones, 2011). Moreover, deep sequencing data could also demonstrate 




1.4.4.2. Principles of target recognition by miRNAs and databases of miRNAs 
1.4.4.2.1. Canonical sites and marginal sites 
With the characterisation of a high number of miRNAs across different species, 
understanding the mechanism through which miRNAs exert their inhibitory functions 
becomes a hurdle to be crossed. The brief conclusion was drawn from the several 
firstly discovered miRNAs that complementary binding of miRNA and target mRNA is 
necessary for mediating the effect. In 2003, Lewis et al. firstly described a 
computational tool with algorithms to predict targets of miRNA, which was the first 
version of the web based TargetScan software that is still widely used now in miRNA 
research field. This study was a hallmark of miRNA researches as it identified the 
“seed site” which was the 7 nucleotides (2-8 from the 5’ end of miRNA) at the 5’ end 
of miRNA and was the major location of Watson-Crick pairing site to bind to target 
mRNAs (Lewis et al., 2003). Although the “seed site” was later modified by the same 
group to be the 6 nucleotides from the second to the seventh at the 5’ end of miRNA, 
the basic principle remained the same (Lewis et al., 2005).  
It was determined that the 5’ end of miRNA was more conserved than the 3’ end and 
this conservation significantly contributed to better target prediction. Further 
sequence alignment across different species showed a frequently conserved A in the 
target mRNA 3’-UTR immediately downstream of the sequence that was 
complimentary to the seed site (Lewis et al., 2005). This conserved A was named A1. 
Since the nucleotide A could not always bind to the first nucleotide of miRNA in a 
Watson-Crick base pair matched manner, it was proposed that this conserved 
nucleotide A could be recognised by proteins in the RISC. Conservation at the 8th 
nucleotide from the 5’ end of the miRNA was also revealed and named m8. Thus in 
the article, three kinds of canonical target sites centred on the seed site was 
uncovered to be of great predicative value, i.e. central seed site (2-7) with A1 and m8 
(8mer), central seed site with only A1 (7mer-A1) as well as central seed site with only 
m8 (7mer-m8) (Lewis et al., 2005). Conservation analysis showed that miRNA 
sequence other than the 8 nucleotides containing the seed site at the 5’ end was often 
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not conserved. It further supported the exclusion of those sequences when predicting 
miRNA targets.  
1.4.4.2.2. 3’ complimentary sites and 3’ supplementary sites 
Krek et al. in 2005, the same year when Lewis described the seed site concept, 
published an article utilizing a similar computational method to identify potential target 
site for miRNAs (Krek et al., 2005). Apart from the conservation analysis of miRNAs 
across species, they also applied thermodynamic parameters in determining a fine 
miRNA:mRNA base pairing duplex which required a low free energy as shown by 
software predicted RNA secondary structures (Krek et al., 2005).  Their validation of 
target sites also mainly emphasised the importance of seed sites at the 5’ end of 
miRNAs. In addition, they found that if imperfect seed site was present bearing 
mismatches, bulges, or G:U wobbles, compensatory base pairing at the 3’ end of 
miRNAs would help to strengthen the miRNA:RNA duplex formation. This could be 
called 3’ end compensatory site (Krek et al., 2005). If 3’ end base pairing exists even 
if there is perfect seed site base pairing at the 5’ end of the miRNA, this 3’ end base 
pairing could be called 3’ complimentary site and could literally compliment the effect 
of seed site binding. This formed the basis of another web based software PicTar and 
softwares using similar algorithms to powerfully predict miRNA targets (Krek et al., 
2005). In that same year, Brennecke et al. validated consistent findings as 
demonstrated by Krek et al. with an in vivo assay (Brennecke et al., 2005). After 
expressing the enhanced green fluorescent protein (eGFP) ubiquitously, they 
transfected the cells with a miRNA in a specific region of Drosophila and examined 
their inhibition of eGFP with different modifications of the 3’-UTR, which yielded 
similar results (Brennecke et al., 2005). Furthermore, they explored the 6mer site 
(seed pairing at the seed site only with Watson-Crick base pairing at position 2-7 from 
5’ end of miRNA) effect and revealed their minimal contribution to target inhibition 
(Brennecke et al., 2005). 
In comparison to TargetScan, Pictar based target prediction algorithm did not include 
a conserved A immediately downstream the seed pairing at the 3’-UTR of target 
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mRNAs. Later large scale proteomic experiments checking the effect of miRNAs on 
a wide range of targets at the protein level showed that the 7mer-A1 target site 
characterised by TargetScan with the conserved A outperformed the kind of base 
pairing described by Pictar at the first 7 nucleotides of 5’ end miRNA. This implies 
that perfect base pairing might not be the only determinant factor in identifying 
potential targets, more factors such as the structural interaction of miRNAs with 
mRNAs as well as proteins also need to considered (Baek et al., 2008).  
Collectively, the target sites described could be separated into 2 groups according to 
their location on miRNAs. The first group mainly includes the seed site centred ones 
located at the 5’ end of miRNAs: 8mer site, 7mer-A1 site, 7mer-m8 site and 7mer site, 
which could be called canonical sites of miRNAs for target prediction. Efforts have 
also been invested to identify 6mer and offset 6mer sites (Friedman et al., 2009). The 
second group was 3’ supplementary site and 3’ compensatory site, which, as 
suggested by the nomenclature, locates at the 3’ end of miRNAs. 3’ supplementary 
site serves a supplementary role for miRNA:mRNA binding when there is perfect base 
pairing at the seed site, whereas 3’ compensatory site compensates for the imperfect 
5’ end base pairing. They are non-canonical or atypical sites. 
The involvement of canonical sites has been confirmed by high throughput 
transcriptomic or proteomic studies (Baek et al., 2008; Grimson et al., 2007; Selbach 
et al., 2008). However, in these high throughput studies, canonical target site are 
endogenously more prevalent, with the non-canonical sites taking a smaller fraction 
and might not be granted sufficient data acquisition, attention or efforts in the 
identification (Helwak et al., 2013). Furthermore, the target prediction by different 
algorithms largely depends on sequence conservation across species. A 
presupposition of these computational methods is that the target site lies within the 
3’-UTR of target mRNAs. This further restricts the view in a limited segment of the 
mRNA, whereas other parts of mRNA might also be targeted, even the protein coding 
region. False positive prediction always exists. Moreover, in some cases, even 
perfect pairing at the seed site or canonical site sometimes is not sufficient in 
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predicting the miRNA and mRNA interaction (Didiano and Hobert, 2006; Vella et al., 
2004a).  
1.4.4.2.3. Other target sites 
Under this circumstance, to obtain an unbiased analysis of miRNA:RNA interaction, 
or prediction of target binding site, high throughput sequencing of RNAs isolated by 
crosslinked immunoprecipitation (Argonaute HITS-CLIP) method was utilised to study 
the miRNA/RNA and Argonaute protein interaction (Chi et al., 2009). Argonaute 
proteins, mainly Argonaute 2, was an indispensable composition of RISC in vivo, 
being the catalytic centre of it. However, Argonaute proteins from the same family 
such as Argonaute 1, 3 and 4 also exhibit cleavage activity when they are loaded with 
mRNAs in vitro, but the only Argonaute protein recognised to be active in vivo is 
Argonaute 2. Data gathered about miRNA/Argonaute interaction site as well as 
mRNA/Argonaute interaction site could be combined with bioinformatic methods, 
which could provide valuable information for site characteristics both within miRNAs 
and within mRNAs. The predominant advantage of this experiment based analysis 
about interaction sites is that all identified interaction sites would be characterised 
without any pre-exclusion of either the 3’ end of miRNA or mRNA segments outside 
the 3’-UTR region (Chi et al., 2009). The importance of this unbiased view lies in the 
possibility it could provide for further identification of non-canonical sites. It even 
provides a chance to study interactions of miRNA and mRNA without any binding site. 
The main disadvantage, however, is that physical interaction of miRNA/mRNA with 
Argonaute protein does not necessarily guarantee downstream functional inhibitory 
effect of miRNAs.  
Most studies utilising Argonaute HITS-CLIP method firstly confirmed the already 
established canonical sites on miRNAs, further proving their importance for miRNAs 
to exert effect (Easow et al., 2007; Hendrickson et al., 2008; Karginov et al., 2007; 
Konig et al., 2012). On top of that, more efforts have been invested in determining 
non-canonical sites. With Argonaute HITS-CLIP method, miR-124 interaction site 
with mRNA in the brain in vivo was analysed, and focus was mainly placed on the 
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non-canonical ones (Chi et al., 2012). A new class of sites were identified. This G-
bulge site was described to be the existence of a G nucleotide on mRNA which 
rendered the skipped base pairing at miRNA position 5 or 6. Nice conservation of this 
G-bulge site was found to be present in almost all miRNAs and it was also widespread, 
compromising nearly a similar fraction as the canonical seed site (Chi et al., 2012). 
The concept of bulged site was already demonstrated in several isolated miRNAs 
before the general description in this report. It was found in 1996 in the first ever 
reported miRNA lin-4 that bulged site was present and sufficient in inducing the 
inhibitory effect of lin-4 (Ha et al., 1996). In addition, it was shown in 2008 by Didiano 
et al. that for miRNA lys-6 and its target mRNA cog1, perfect base pairing in the target 
site exerts no inhibitory regulation, whereas a bulged site was required for effective 
down regulation (Didiano and Hobert, 2008). 
Non canonical G:U wobbles were also found to be functional. For miRNA let-7 and 
its target lin-41 mRNA as well as miR-196 and its target HoxB8 mRNA, wobble G:U 
base pairing was found and proved to display inhibitory function (Vella et al., 2004b). 
However, in the algorithm utilised by the computational prediction of miRNA targets 
software TargetScan and PicTar, G:U wobbles was not tolerated even though the 
established G:U wobble functional effect was already described since the tolerance 
would significantly decrease signal:noise ratio in the bioinformatic prediction 
(Brennecke et al., 2005; Lewis et al., 2005; Lewis et al., 2003). Mutation study in 2008 
by Didiano et al. showed that G:U wobble in the binding site could not achieve 
equivalent inhibition as demonstrated by site with Watson-Crick base pairing at the 
same position, however, the inhibitory function was not abrogated and should not 
thus be eliminated in target prediction (Didiano and Hobert, 2008). 
Other atypical target sites have been identified as well. Centred site, which means 
the 11-12 perfect base-pairing on the miRNA from position 4-15, was demonstrated 
in miRNAs lacking both the seed sites and 3’ compensatory sites. The method the 
authors used was the cleavage assay rather than previously established computation 
methods, which might be the reason why the authors managed to characterise this 
kind of site (Shin et al., 2010). They also claimed conservation to some extent about 
65 
 
this centred site in various miRNAs (Shin et al., 2010). They only constitute a small 
proportion of the predicted sites, which is similar to the fraction of 3’ compensatory 
sites (Shin et al., 2010).   
Crosslinking, ligation and sequencing of RNA-RNA interaction hybrids (CLASH) 
method allowed the analysis of a direct interaction between miRNAs and mRNAs, 
which is a significant progress after the utilisation of Argonaute HITS-CLIP method to 
study RNA protein interaction (Kudla et al., 2011). In addition to the sites described 
by other studies, they also identified the miRNA and mRNA interaction at more 
atypical sites. Though miRNA binds predominantly to mRNA 3’-UTRs, direct 
interaction between miRNA with other parts of mRNA such as the coding region and 
the 5’-UTRs have also been observed (Helwak et al., 2013). This is consistent with 
previous isolated reports (Brodersen and Voinnet, 2009; Grey et al., 2010; Ørom et 
al., 2008; Tay et al., 2008). More interestingly, the direct interaction between miRNAs 
and noncoding RNAs have also been uncovered with CLASH experiments, adding a 
new class of potential target types to the already complicated miRNA regulation 
network (Helwak et al., 2013). 
Apart from all kinds of sites on miRNAs, including the canonical ones and the non-
canonical ones (Illustration of different target sites are shown in Figure 1-10), 
“seedless” inhibition of miRNA on mRNA was also observed, implying that the whole 
system of miRNA regulation mechanism might be more complex than we have 
already described. E2F2 gene could be directly inhibited by miR-24 through seedless 
3’-UTRs (Lal et al., 2009). Additionally, as introduced earlier, perfect canonical seed 
sites were not sufficient to predict the functional interaction between miRNA and its 
target mRNAs. The possible explanation behind it is that there are other factors 
influencing the interaction process. Argonaute 2 protein is an important component 
of the RISC complex. It was demonstrated by structural studies that it displayed a 
flexible structure which could be stabilised by miRNAs binding to it (Elkayam et al., 
2012). Another element that influences the interaction process is the mRNA 
accessibility to binding sites (Brodersen and Voinnet, 2009). Binding of the target site 
on mRNAs with RNA binding protein (RBP) or the inclusion of target site within the 
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stem loop structures of mRNA itself would prevent the target site from being 
accessible to miRNAs. Whereas other factors that promote the release of RBP from 
binding to complimentary sequences which could form the stem loop structure with 
the target sites would increase the accessibility of mRNA target site. The better 
binding affinity of RISC with target site that could help release other translational 
repressors from the target site would increase the accessibility as well (Brodersen 
and Voinnet, 2009). 
 
 
Figure 1-10 Illustration of different miRNA target sites  
The different types of miRNA target sites depicting the binding mode of target mRNA and 
miRNA including canonical sites (A-C), marginal sites (D, E) and atypical sites (F, G) are 





1.5. Vascular tissue engineering 
1.5.1.  Introduction of tissue engineered vascular grafts 
Cardiovascular diseases are the leading medical problems which often require 
surgical bypass intervention. Saphenous vein and internal mammary arteries as well 
as the radial arteries are typical vascular graft choices (Writing Group et al., 2016). 
The saphenous veins are the most commonly used graft choices owing to their ease 
of availability (Desai et al., 2004). However, compared to internal mammary arteries 
or radial arteries, the saphenous vein grafts display not as good long term patency 
rate since they are more prone to develop graft body diseases including aneurysm 
formation at the anastomotic site, intimal hyperplasia and atherosclerosis, which are 
the main causes for graft failures in the long run (Hess et al., 2014; Sabik et al., 2005; 
Yamasaki et al., 2016). These side effects are conceivable because of the 
mechanical mismatch and structural difference between veins and arteries. However, 
artery bypass graft harvesting sometimes may lead to severe side effects such as 
limb oedema. Moreover, precedent disease conditions such as atherosclerosis in the 
patients may involve the autologous artery bypass choices as well rendering them to 
be not as effective as what is expected. In patients who have undergone graft failures 
of previous coronary artery bypasses surgeries, the bypass choices would be more 
limited. Given these circumstances, it is imperative that novel choices of bypass grafts 
be explored. Tissue engineered vascular bypass emerge in the last 50 years as a 
promising alternative for the replacement of disease-involved and symptom-causing 
coronary arteries as well as peripheral arteries.  
 
1.5.2.  Scaffold-based vascular tissue engineering 




As early as 1952, it was reported that Vinyon “N” cloth, a synthetic fibre made from 
polyvinyl chloride and invented in 1939, could be constructed as a tubular mesh 
structure and transplanted in vivo as an arterial bridge. Exposure of this arterial 
prostheses to arterial blood flow would result in fibrin formation in the mesh holes and 
lead to integral prostheses wall, thus preventing the high speed arterial flow from 
leaking into adjacent tissue space (Voorhees et al., 1952). The thought of utilising 
Vinyon “N” mesh to serve as an arterial bypass originated from previous experimental 
observation. When Vinyon “N” was sutured in the cardiac wall, a new layer of the film 
could form throughout its length. The implication of this experiment was that the 
presentation of Vinyon “N” in vivo could result in an appropriate level of healing 
reaction without intensive foreign body immuno-rejection (Voorhees et al., 1952). Out 
of the 15 dogs which have undergone a segment of abdominal artery replacement 
with Vinyon “N” mesh, 11 got autopsy examination upon the sacrifice, and 8 arterial 
prostheses among these remained patent. In the remaining 4 live dogs, nice patency 
was also demonstrated by the pulsation of the femoral artery (Voorhees et al., 1952). 
Encouraged by the promising patency rate in canine experiments, the group went on 
with a larger scale of canine abdominal arterial replacement experiments and yielded 
similarly promising results (Blakemore and Voorhees, 1954). Later clinical efficacy 
examination of the Vinyon “N” mesh in 18 patients exhibited to some extent gratifying 
results with a recovery of the 10 patients previously suffering from the abdominal 
aneurysm. However, the other 8 patients died from direct or indirect reasons related 
to the difficulty of handling vascular walls that had degenerated (Blakemore and 
Voorhees, 1954).   
It was found later that vascular grafts with synthetic materials, in general, displayed 
poorer patency rate when used to replace small diameter vessels (<6 mm) compared 
to the utilisation of them in replacing larger diameter vessels as the velocity of blood 
flow was significantly lower. Reduced blood flow velocity leads to higher thrombosis 
rate and a low degree of intimal hyperplasia might result in extensive occlusion of the 
vessel, and thus graft failure (Bennion et al., 1985). Indeed, the engineering of small 
diameter blood vessels presents as a long existing challenge since the recognition of 
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its importance in the clinics especially in the treatment of coronary artery diseases. 
Continuous and intensive efforts are invested in improving the performance of 
synthetic grafts as they are easily manufactured and could be tailor made according 
to patients’ need and parameters of the diseased vessel. Many other synthetic and 
non-degradable materials have demonstrated potential in vascular tissue engineering 
such as expanded polytetrafluoroethylene (ePTFE), polyethylene terephthalate 
(PET), polyurethane (PU) and polyhedral oligomeric silsesquioxane poly(carbonate-
urea) urethane(POSS-PCU) (G et al., 2015).  
1.5.2.2. First report of degradable synthetic scaffold in 1999 and later 
development 
In 1999, Niklason and his group firstly utilised the polyglycolic acid polymer (PGA) 
which was a biodegradable material to generate small vascular grafts. Combined with 
the mechanical stimuli provided by the bioreactor system which was also firstly used 
by their group, grafts with satisfactory mechanical strength was constructed with a 
burst pressure of more than 2000 mmHg (Niklason et al., 1999). Compared to the 
non-degradable scaffolds, degradable scaffolds could be gradually degraded and 
absorbed. The rate of degradation should be delicately designed so that it matches 
the rate of in vivo integration. Too fast degradation rate would lead to compromised 
mechanical feature and hence aneurysm formation or graft rupture; whereas when 
degradation rate is too slow, the unintended immunogenic response could persist. 
Degradation process of the graft may also yield PH change which could affect the 
proliferation and differentiation of SMCs seeded on the graft (Higgins et al., 2003). 
Apart from polyglycolic acid based material, other degradable materials have also 
been explored in vascular tissue engineering including polylactic acid (PLA), poly e-
caprolactone (PCL), poly(l-lactide-co-e-caprolactone)(PLCL), and polyglycerol 
sebacate (PGS) (G et al., 2015).    
One crucial drawback of the synthetic graft lies in their poor biocompatibility which 
often leads to native immune response and thrombosis within a short term of 
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transplantation. The mechanical strength of the synthetic grafts also needs further 
improvement to match the requirement and meet in vivo haemodynamic environment.  
To overcome these drawbacks and take full advantage of the synthetic materials, 
numerous approaches were attempted in the last 50 years or so to achieve satisfying 
results. Firstly, different modifications of these synthetic grafts including molecular 
level modifications are examined. Various peptides have shown anti-thrombogenic 
potentials (Ren et al., 2015). It was shown on chitosan hydrogel/poly(ethylene glycol)-
b-poly(L-lactide-co-caprolactone) (PELCL)-based scaffold that VEGF and PDGF dual 
delivery from the scaffold could help promote in vivo vessel regeneration (Zhang et 
al., 2013). Polyurethane (PU) conduits loaded with SDF-1 and VEGF demonstrated 
better tissue compatibility and promoted endothelialisation in vivo (Guo et al., 2017). 
Secondly, seeding of the synthetic grafts with cells proves to increase the 
biocompatibility as well as the mechanical property. Cell sources that have anti-
thrombogenic capacity include ECs, endothelial progenitor cells and perhaps bone 
marrow mononuclear cells. Lastly, preconditioning of the grafts in vitro to 
haemodynamic environments might help to increase the chance for the grafts to 
match better with in vivo vascular haemodynamics. What’s more encouraging is that 
the development of novel material manufacturing techniques such as electrospinning 
and 3D printing techniques helps revolutionise the field of vascular tissue engineering 
(Duan, 2017; Elliott and Gerecht, 2016; Rocco et al., 2014). For example, owing to 
innovative electrospinning technique, elastic polyurethane and reinforcing poly-
glycolic acid could be engineered to act in a “J-shaped” mode upon cyclic strain 
application mimicking the in vivo action of elastin and collagen in response to cyclic 
strain in native vessels (Rapoport et al., 2012).  
1.5.2.3. First report of natural scaffold in 1986  
In 1986, Weinberg and his colleagues managed to generate a tubular like structure 
in vitro that resembled the in vivo artery structure (Weinberg and Bell, 1986). By 
mixing culture medium, collagen and SMCs and casting them in an annular mould, 
the first layer would be formed shortly consisting SMCs and collagen matrix. Later, 
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the fibroblast layer with a mixture of matrix and fibroblast cells was cast outside to 
mimic the adventitia layer. A Dacron mesh would then be placed outside the tubular 
structure to provide additional mechanical support. In the end, an endothelial layer 
was added by seeding the cells inside the lumen after peeling the tubular structure 
off the mandrel. The mechanical strength of the assembled vessel was then 
examined. It was found that without the Dacron mesh, the graft was greatly 
distensible and got easily dilated with a low pressure (<10 mmHg). With one layer 
Dacron mesh protection, however, the vessel managed to tolerate the burst pressure 
as high as 40 to 70 mmHg. Furthermore, the mechanical strength of the graft was 
proportional to the concentration of the Matrigel in the mixture (Weinberg and Bell, 
1986). In 1993, L’Heureux et al. utilised a similar way to construct a vessel in vitro 
that managed to contract and reorient under periodic mechanical stimulation from the 
casting mandrel (L'Heureux et al., 1993).  
Other natural scaffolds that have been explored in vascular tissue engineering include 
fibrin (Swartz et al., 2005), silk fibroin (Enomoto et al., 2010; Lovett et al., 2010) and 
chitosan (Zhang et al., 2006b). 
    
1.5.3.  Decellularised vascular grafts - first report and subsequent 
development 
The first report of the vascular graft in vivo was the “vinyon N” mesh that was used in 
large diameter arteries (Voorhees et al., 1952). It not only provided enough 
mechanical strength, but also presented as a backbone for fibrin formation which was 
essential for the integrity of the vessel wall. However, their success is mainly 
restricted for large diameter vessel replacement. For small diameter vascular grafts 
which are more prone to thrombosis and long term intimal hyperplasia that can result 
in graft failure, the lack of biocompatibility has largely hampered the generalised 
application. While efforts have been invested in improving the biocompatibility of the 
synthetic materials, alternatives of vascular scaffolds which are more biocompatible 
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are explored. It is reasonable that people started from analysing the protein 
components of the extracellular matrix of native vessels. What was initially found out 
is that collagen and elastin are the two major proteins in the extracellular matrix. It 
was then investigated whether homogeneous collagen itself could be applied in 
vascular tissue engineering, which led to the first case report of natural material based 
scaffold for vascular graft in 1986 by Weinberg and his colleagues (Weinberg and 
Bell, 1986). However, it turned out that between mechanical strength and bio-
compatibility, only one could be achieved with that approach. Collagen-based 
scaffold failed to provide sufficient mechanical strength which had to be 
complemented by a synthetic material reinforcement outside the engineered graft. 
This intrinsic limit of natural material based scaffold then resulted in numerous efforts 
to achieve the satisfying mechanical strength of the graft including using crosslinking 
agents and hybrids of other natural materials. In the meanwhile, new ideas emerged 
in 2001 that the extracellular matrix of the whole native vessel might be possible to 
be used as a scaffold for vascular grafts. What encumbered people from doing so 
might be the allogeneic immunologic response which might cause severe rejection of 
the vascular grafts followed by the graft failure. To utilise the whole vascular 
backbone as a scaffold and at the same time get rid of the cells, a decellularisation 
process of the native vessel was performed.  
In 2001, Kaushal et al. were the first to use porcine iliac vessels to generate 
decellularised vascular grafts. Decellularisation was achieved through Triton X-100 
and ammonium hydroxide. These decellularised grafts were not able to remain patent 
for more than 15 days after the implantation in sheep as carotid interposition grafts 
whereas pre-seeding of the graft with endothelial progenitors significantly improved 
the patency rate (Kaushal et al., 2001). The excellent biocompatibility and mechanical 
strength led to more attempts to engineer vascular grafts with other cell sources which 
would be explained in detail later. Enzyme-based, detergent-based and perfusion-
based methods are all explored in decellularising the native vessel which exhibit 
different efficacy and would influence the features of the vessel. When optimising the 
decellularisation method, a balance between removal of the allogeneic cellular 
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fractions and the reservation of the mechanical strength as well as extracellular matrix 
integrity should be achieved.  
 
1.5.4.  Self-assembled scaffold free vascular grafts  
When we use natural scaffolds to engineer vascular grafts, what we normally use are 
the purified extracellular matrix proteins in the native vessel such as collagen I and 
fibrin. However, one drawback of this method is that the extracellular matrix in native 
vessels is a complex network and contains multiple fractions. To better recapitulate 
the native composition of the extracellular matrix, efforts have been invested in 
directly utilising cells to produce them rather than use of purified extracellular matrix 
proteins. It has led to another method to generate vascular grafts: engineering 
vascular grafts with self-assembly. The concept and development of self-assembled 
vascular grafts was largely driven by the L’Heureux group. 
To achieve the goal of constructing vascular grafts with a better extracellular matrix 
complex, SMCs were firstly grown on a surface for about 3 weeks to form cell sheets. 
After the maturation of SMCs and the production of extracellular matrix from them, 
the cell sheets were rolled around a mandrel to form a tubular structure, which was 
allowed to further mature for 1 week. Later, the fibroblasts were seeded outside to 
form the adventitia layer and allowed 7 weeks to mature. ECs were seeded inside the 
lumen after peeling the sheets from the mandrel and allowed one more week for their 
growth (L'Heureux et al., 1998). Vascular grafts generated in this manner contained 
more biological extracellular matrix and displayed mechanical strength similar to that 
of native vessels with the burst pressure to be over 2000 mmHg (L'Heureux et al., 
1998). Also, in vivo evaluation of the grafts demonstrated that they were easy to 
handle and tough enough to be sutured with native vessels (L'Heureux et al., 1998). 
Further modification with glycation of the extracellular matrix was explored to 
strengthen the grafts produced and proved to be beneficial (Girton et al., 2000; Girton 
et al., 1999). Comparison of mechanical property including tensile strength and 
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stiffness between tissue rings formed with cell seeded collagen or fibrin gel and tissue 
rings assembled by cells demonstrated a significant advantage of self-assembled 
grafts (Adebayo et al., 2013).  
Preclinical examination of the self-assembled vascular grafts was then encouraged 
by the experimental results and transplantation of the graft into dogs, nude rats and 
primates was carried out. Autologous cells were used in canine and nude rat 
experiments and human cells were used in primates along with immuno-suppressive 
treatment (L'Heureux et al., 2006). Further checking of the graft showed the existence 
of both collagen and elastic fibres within the extracellular matrix. In vivo integration of 
the grafts was observed with the formation of adventitial vasa vasorum and intact 
endothelial lining 90 days after the graft implantation (L'Heureux et al., 2006). These 
safety and efficacy results accumulated from different species paved the way of the 
self-assembled vascular grafts into the clinics. In 2007, 10 patients who needed 
alternative arteriovenous shunts for haemodialysis were grafted with the self-
assembled conduits engineered with autologous cells. Results showed that these 
grafts were feasible to be used as a temporary arteriovenous shunt although an 
aneurysm was still observed in sites which were punctured frequently (L'Heureux et 
al., 2007). Long term follow-up of patients showed 78% patency rate after 1 month 
and 60% patency rate after 6 months (McAllister et al., 2009). 
Although self-assembled vascular grafts are shown to be effective, the process to 
construct a graft is especially time-consuming which largely hinders their application 
in the clinics. However, people who need vascular bypass surgery could in a way be 
predicted according to the disease condition which may grant enough time for 
vascular tissue engineering. Moreover, the utilisation of self-assembled vascular 
grafts could be more cost-effective if less time was required for construction. Much 
effort has been invested in generating “off-the-shelf” self-assembled vascular grafts 
to achieve this goal. The “off-the-shelf” vascular grafts were constructed without the 
last endothelialisation step and then dehydrated and devitalised. After storage at -
80 °C for more than 9 months, the mechanical strength remained. 5 days before the 
implantation of the grafts in patients, endothelialisation was performed on the graft 
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with autologous cells to prevent thrombosis. These grafts served as haemodialysis 
shunts in patients for up to 11 months without signs of dilation or degradation 
(Wystrychowski et al., 2011; Wystrychowski et al., 2014). The fibroblasts utilised to 
generate the grafts could be allogeneic since fibroblasts are not immunologically 
active and don’t express major histocompatibility complex class II antigens 
(Wystrychowski et al., 2014). Thus, the whole process from the stored “off-the-shelf” 
grafts to ready-to-use grafts was minimised to less than a week. However, it still 
requires further exploration to determine whether the allogeneic fibroblasts could be 
utilised without compromising their efficacy. Decellularisation of the constructed 
scaffold to bypass the immuno-activity issue was also explored (Bourget et al., 2012). 
The fibroblast cell sheets were decellularised and then used to serve as support of 
SMCs (Bourget et al., 2012). Apart from saving time for vascular graft construction, 
another advantage of this process is that the extracellular matrix production is not 
anymore crucially dependent on the SMCs seeded which allowed the use of SMCs 
from some elder or diseased patients in tissue engineering since the capacity of the 
cells to secrete extracellular matrix might be compromised (Bourget et al., 2012). 
Apart from mature vascular cells, stem cells have also been explored including 
BMMSCs and UCMSCs in generating self-assembled vascular grafts (Bourget et al., 
2015; Zhao et al., 2012). It was shown that BMMSCs could act like ECs and prevent 
thrombolisation. Moreover, the time needed for generating the graft was shortened to 
2 weeks without compromising the in vivo performance of the grafts (Bourget et al., 
2015; Zhao et al., 2012).  
 
1.5.5.  Mechanical stimuli  
The engineered vascular grafts would be under constant mechanical pressure in vivo 
imposed by dynamic blood flow in vivo. Therefore, when constructing the blood vessel 
grafts, the mechanical properties of the graft should be evaluated. Subsequently, 
efforts should be invested in engineering grafts with reinforced mechanical strength. 
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For coronary artery bypass, it was introduced earlier that the internal thoracic artery 
would be the golden standard for the bypass surgery with a long-term patency. 
However, its application sometimes is hampered by the relatively severe complication 
that would be caused by the harvesting process or by the precedent atherosclerotic 
lesion involvement. Saphenous vein was presented as a secondary choice with a 
relatively lower long-term patency rate. In order to achieve satisfying results when 
engineering blood vessels, the mechanical property of the graft comparable to the 
internal thoracic artery or saphenous veins should be obtained (Catto et al., 2014; 
Sarkar et al., 2006). Mechanical parameters that should be firstly evaluated include 
the burst pressure, suture retention strength and compliance. They are respectively 
3072 mmHg, 1.72 N and 11.5% /100 mmHg for the internal thoracic artery and 2134 
mmHg, 1.92 N, and 25.6% /100 mmHg for the saphenous vein (Konig et al., 2009). 
Other terms such as the tensile strength or pliability of the vessel were sometimes 
used as well (Yokota et al., 2008). These features provide the basic information as to 
whether the engineered vessel would be able the handle the pressure brought by the 
highly dynamic blood flow in vivo.  
However, the mechanical behaviour of native vessels is far more complex. When 
examined further, it was revealed that when handling the pressure, native vessels in 
vivo normally display a J-shaped mode to deal with the cyclic strain. Under low strain 
pressure, compliant and elastic elastin fibres could handle it with only small cyclic 
stress changes, whereas under high strain pressure, the corrugated collagen could 
stretch and result in rapid cyclic stress changes (Pashneh-Tala et al., 2016; Rapoport 
et al., 2012). As the extracellular matrix proteins elastin and collagen are both crucial 
contributors to vessel mechanical strength, inclusion of both in vascular tissue 
engineering could be pertinent (Rapoport et al., 2012). 
However, since we always aim at engineering vessels with the internal thoracic artery 
or the saphenous vein as the golden standard, the ultimate effect of the engineered 
grafts would not surpass those manifested by them. Mechanical properties also 
variate depending on the patients’ gender, age and the location of the vessel 
(Ozolanta et al., 1998). To provide personalised medical care with tailor made 
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vascular grafts, these factors should be taken into consideration as well for the better 
performance of the graft. 
 
1.5.6.  Cells utilised in tissue engineered vascular grafts 
Although in the first Vinyon “N” cloth scaffold that was transplanted in vivo for canine 
abdominal aorta replacement, the scaffold was nude without any cell seeding or 
modification, the relatively satisfying patency rate could not be duplicated when the 
nude graft with only the synthetic material was utilised to engineer small diameter 
vascular grafts (Seifu et al., 2013). The lack of biocompatibility as well as mechanical 
compliance contributes significantly to the high thrombosis rate in small diameter 
vascular grafts since the velocity of the blood flow is much lower. To increase the 
biocompatibility, numerous cell types are explored for their potential to improve the 
graft performance in vivo. 
1.5.6.1. Mature cells 
Efforts in engineering vascular grafts first took advantage of mature vascular cells for 
biomimicry of the in vivo vascular structures. ECs were utilised for its anti-
thrombogenic effect and SMCs were used due to its capacity to produce extracellular 
matrix and mechanical support for the vessel. Sometimes fibroblasts were applied to 
the outer layer of the engineered graft to further provide an “adventitial” like layer 
(Niklason et al., 1999; Shinoka et al., 1998; Weinberg and Bell, 1986). This approach 
was successful in animal models and later encouraged the first clinical case to utilise 
in vitro cultured vascular cells from the peripheral vein to construct pulmonary artery 
(Shin'oka et al., 2001). After seeding the in vitro cultured SMCs and ECs onto the 
polycaprolactone-polylactic acid copolymer reinforced with woven polyglycolic acid, 
the graft was transplanted in a child patient and no graft occlusion or aneurysm was 
observed after 7 months.  
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However, the intrinsic limit for utilising mature vascular cells lies in their finite life span 
and proliferation capacity. It takes relatively a long time (around 8 weeks) to get 
enough cells and these autologous cells might be in a compromised state due to the 
disease condition of the host (Shin'oka et al., 2001). To overcome this disadvantage, 
hTERT, a reverse transcriptase constituting human telomerase, was ectopically 
expressed in human SMCs and the proliferative ability was retained which shortened 
the time needed to culture enough cells to generate vascular grafts (McKee et al., 
2003; Poh et al., 2005). 
Apart from this, more attention was gradually placed on a large variety of stem cells 
which are proliferative in vitro and display the differentiation capacity towards vascular 
lineages. These include the embryonic stem cells, induced pluripotent stem cells and 
adult stem cells such as bone marrow mononuclear cells, mesenchymal stem cells, 
endothelial progenitor cells and muscle-derived stem cells. 
1.5.6.2. Embryonic stem cells 
Embryonic stem cells are the first to come in sight while alternative sources for 
vascular tissue engineering were being searched due to their highly proliferative 
potential and totipotency. Regarding vascular graft engineering, it is shown that 
embryonic stem cells can differentiate towards vascular lineages including ECs and 
SMCs (Levenberg et al., 2002; Odorico et al., 2001; Xiao et al., 2009; Yamashita et 
al., 2000). Harnessing the endothelial differentiation potential, the vascular graft was 
generated with mouse embryonic stem cell-derived ECs together with mature SMCs 
isolated from artery (Shen et al., 2003). Histological analysis demonstrated the 
integral endothelial lining on the luminal side of the polyglycolic acid scaffold (Shen 
et al., 2003). The differentiation capacity of embryonic stem cells towards SMCs was 
also explored and harnessed in vascular graft engineering. When SMCs 
differentiated from the embryonic stem cells were seeded onto polyglycolic acid 
polymer mesh scaffold and cultured under pulsatile conditions for 8 weeks, vascular 
graft resembling the native vessels with regard to smooth muscle marker expression 
in the media layer was obtained (Sundaram et al., 2014a). Isolation of c-kit+ cells from 
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embryonic stem cells was carried out, and these cells displayed vascular lineage 
potential towards both ECs and SMCs, both of which were utilised to generate 
vascular grafts with decellularised mouse aorta as the scaffold. The survival rate was 
higher when grafts seeded with both ECs and SMCs were transplanted in vivo as a 
vein graft compared to decellularised scaffold only (Campagnolo et al., 2015b). 
Although the attempts to generate vascular grafts from embryonic stem cells are 
rather gratifying, drawbacks remain as well. First, it is ethically controversial to use 
embryonic stem cells in the clinics. Secondly, embryonic stem cells are totipotent. 
Apart from vascular lineage differentiation capacity, they could also differentiate 
towards various other cell lineages. They might generate teratoma or cancer when 
transplanted in vivo. Additionally, their differentiation potential towards osteogenic 
lineages and chondrogenic lineages might contribute to the vessel wall calcification 
in engineered vascular grafts which would hamper their efficacy (Sundaram et al., 
2014a).  
1.5.6.3. Induced pluripotent stem cells 
Since the discovery of Yamanaka factors that could drive the terminally differentiated 
adult cells back to the pluripotent stage, numerous attempts have emerged 
elucidating the underlying mechanism as well as harnessing the pluripotency for 
tissue regeneration. The discovery was also encouraging since it might help realise 
the popular concept of personalised medicine in the clinics. These adult cells derived 
pluripotent stem cells could bypass embryonic stem cells and the associated ethical 
concerns when stemness was required in tissue regeneration. It was demonstrated 
that the pluripotent stem cells could differentiate towards vascular lineages. In 2012, 
researchers from the Shinoka group differentiated the human induced pluripotent cell 
line towards both SMCs and ECs with the hanging drop method. The biodegradable 
scaffold seeded with the differentiated cells was then transplanted to mice as an 
interposition graft, with no development of graft rupture, thrombosis, aneurysm or 
calcification formation (Hibino et al., 2012). In the same year, Margariti et al. utilised 
lung fibroblasts and directly reprogrammed them towards ECs which successfully 
endothelialised the vascular scaffold decellularised from mouse aorta (Margariti et al., 
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2012). Later, people from the same group managed to reprogram embryonic lung 
fibroblasts and differentiate them towards the smooth muscle lineage. These SMCs 
derived from reprogrammed lung fibroblasts were then combined with previously 
derived ECs to engineer functional vascular grafts with both smooth muscle and 
endothelial layers (Karamariti et al., 2013a). Furthermore, it was demonstrated by the 
Niklason group, who are the first to utilise the bioreactor system in vascular tissue 
engineering for mechanical preconditioning, that mechanical stimuli provided by the 
bioreactor system also contributed significantly in engineering vascular grafts with 
induced pluripotent stem cells by increasing the mechanical strength or potentiating 
the arterial specification of derived ECs (Sivarapatna et al., 2015; Sundaram et al., 
2014b). All in all, exploration of vascular tissue engineering with induced pluripotent 
stem cell might help bring the concept of personalised treatment in cardiovascular 
disease one step further. 
1.5.6.4. Bone marrow mononuclear cells 
Bone marrow mononuclear cells are among the most extensively studied adult stem 
cells. Their potential in engineering small diameter vascular grafts was first explored 
in 2003 on biodegradable scaffolds. It was found that scaffolds seeded with bone 
marrow mononuclear cells displayed significantly higher patency rate compared to 
the non-seeded scaffolds when transplanted in dogs in the inferior vena cava 
(Matsumura et al., 2003). The seeded cells were labelled with green fluorescence 
that enabled the in vivo tracking of the cells. Further examination of the explanted 
graft after 4 and 8 weeks revealed co-staining of both endothelial and smooth muscle 
markers with the green fluorescence, demonstrating the in vivo differentiation of 
seeded bone marrow mononuclear cells and their participation in the in vivo 
regeneration of the graft (Matsumura et al., 2003). The application of bone marrow 
mononuclear cells does not necessarily require in vitro differentiation towards 
vascular lineages, largely shortening the time needed for vascular graft engineering 
(Hibino et al., 2005). It is also implicated that bone marrow cells might exhibit other 
features apart from differentiating towards vascular lineages. SDF-1 is a potent cell 
mobilisation factor and could be secreted by bone marrow nuclear cells which might 
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attract other progenitors from the circulation to regenerate the implanted graft. The 
success of bone marrow mononuclear cells in generating vascular graft led to clinical 
trials with engineered grafts that could serve as extra-cardiac cavopulmonary 
conduits to treat patients with single ventricle (Hibino et al., 2010; Shin'oka et al., 
2005). Long term follow-up after an average of 5.8 years of the clinical trial showed 
no graft-related mortality. Aneurysm formation, conduit wall calcification, or graft 
rupture was not observed. Graft stenosis was seen in 4 patients out of 42 and was 
successfully intervened with percutaneous angioplasty (Hibino et al., 2010). However, 
it is noteworthy that the satisfying result of the clinical trial has to be partially attributed 
to the relatively large diameter of the conduit which renders the graft less prone to 
thrombosis and stenosis. 
Other than directly seeding the bone marrow nuclear cells onto biodegradable 
scaffolds, the bone marrow cells were also differentiated in vitro first to generate 
vascular SMCs and ECs. The differentiated cells were then seeded on the 
decellularised vessel scaffold. Grafts seeded with cells displayed better patency rate 
(Cho et al., 2005). A similar approach was utilised in 2012 to generate vascular grafts 
by seeding bone marrow-derived SMCs and ECs onto decellularised allogenic iliac 
vein to serve as a bypass branch for the hepatic vein. Patient follow-up after 9 months 
was normal. Although graft narrowing was observed in 1 year, it was not caused by 
the graft itself but the pressuring adjacent tissues, which was successfully taken care 
of by removing the pressing tissue (Olausson et al., 2012). Overall, bone marrow 
mononuclear cells prove to be a promising cell source for vascular tissue engineering. 
1.5.6.5. Mesenchymal stem cells 
Vascular tissue engineering with mesenchymal stem cells would be discussed later 
in detail in the thesis. 
1.5.6.6. Other adult stem cells 
Potential of other adult stem cells to generate small diameter vascular grafts has also 
been explored including the muscle-derived stem cells (Nieponice et al., 2008), bone 
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marrow-derived muscle progenitors (Liu et al., 2007) and hair follicle stem cells (Peng 
et al., 2011). 
1.5.6.7. Revival of acellular vascular grafts 
In recent years, more efforts have been invested in exploration of novel material 
manufacturing methods which could in the end provide comparable results with those 
biocompatible cell-seeded scaffolds (Wu et al., 2012; Zhang et al., 2013). Indeed, cell 
seeding onto the scaffolds provides exceptional advantages. But the cell seeding 
process is time consuming and brings with them immunogenic problems if allogeneic 
cells were used. With the emergence of novel biomaterials (Wu et al., 2012), novel 
manufacturing methods (Rapoport et al., 2012) as well as further understanding of 
the mechanism how cells provide their benefits, acellular scaffold might have the 
potential to bring revolutionary changes in the field of vascular graft engineering. 
 
1.5.7.  Vascular graft engineering with mesenchymal stem cells 
After the initial exploration of vascular tissue engineering with mature vascular SMCs 
and ECs as well as adult fibroblasts, stem cells emerge as alternative cell sources for 
vascular tissue engineering to overcome the inherent in vitro limited proliferation 
capacity and compromised function of the mature cells. All kinds of stem cell sources 
have been examined for their potential for engineering functional and patent small 
diameter vascular grafts, such as embryonic stem cells, induced pluripotent stem 
cells, bone marrow mononuclear cells, endothelial progenitor cells and mesenchymal 
stem cells from various origins as introduced earlier. The application of embryonic 
stem cells is hampered by the ethical issues they bring with them as well as the 
totipotent differentiation capacity which might cause cancer or 
unintended/uncontrolled cell lineage differentiation. Induced pluripotent stem cells 
prove to promising as they bear the potential to personalize the engineering of 
vascular grafts with completely autologous adult cells which are easily available and 
abundant. Researches are still ongoing to improve their performance in in vivo 
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implantation experiments. (Dash et al., 2016; Gui et al., 2016) Stem cells from the 
bone marrow are the earliest recognized and well-established adult stem cells. 
Numerous efforts have been invested which have demonstrated their potential in 
vascular graft engineering. However, the harvesting procedure from the bone marrow 
is invasive and it is difficult to get an adequate number of cells. Thus, it is necessary 
to look for new stem cell sources to engineer vascular grafts. 
Mesenchymal stem cells could be isolated from almost all tissues around the body, 
such as the bone marrow, adipose tissue, umbilical cord, cord blood and hair follicle. 
As introduced earlier, they not only exhibit multiple differentiation capacities towards 
adipocytes, osteocytes and chondrocytes, they are also capable to differentiate 
towards vascular lineages such as SMCs (Gong and Niklason, 2008b) and ECs 
(Oswald et al., 2004). The vascular lineage differentiation capacities are crucial in 
generating vascular grafts which resemble the structure of native vessels. In addition, 
the immuno-modulation function of the mesenchymal stem cell presents a possibility 
to engineer vascular grafts with allogeneic cells which significantly expands the cell 
sources available that could be utilised in the clinics as autologous cell might not be 
of a sufficient amount or might be of compromised function caused by the disease 
status in patients (Aggarwal and Pittenger, 2005; Uccelli et al., 2008). It has also been 
reported that mesenchymal stem cells might display anti-thrombogenic ability (Hashi 
et al., 2007).  
1.5.7.1. Bone marrow-derived mesenchymal stem cells 
In 2007, Hashi et al. firstly seeded BMMSCs onto nanofibrous scaffolds and 
implanted the cell seeded scaffolds in vivo to examine the long-term patency. It was 
found that BMMSCs could inhibit the platelet adhesion to the scaffolds and thrombus 
formation in the short term, thus increasing the long term patency rate and inducing 
excellent in vivo vascular regeneration (Hashi et al., 2007). Promotion of scaffold 
endothelialisation might be another reason for the improved performance of grafts 
seeded with BMMSCs (Alexandre et al., 2017). To determine whether BMMSCs could 
directly take part in vascular regeneration in vivo, Mirza et al. implanted a 
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polyurethane vascular prosthesis scaffold seeded with undifferentiated and green 
fluorescent protein labelled BMMSCs in rats. After 2 weeks in vivo, cells co-
expressing smooth muscle markers and green fluorescent proteins were observed 
indicating the smooth muscle differentiation of the seeded BMMSCs (Mirza et al., 
2008).  
Furthermore, it was shown that the cells could promote the endothelialisation of the 
prostheses when seeded on the grafts (Mirza et al., 2008). 6-month long term in vivo 
performance of bone marrow-derived mesenchymal cells seeded on the vascular 
grafts was examined. After seeding undifferentiated BMMSCs onto a novel 
biodegradable tubular scaffold, the scaffold was in vitro cultured for 7 days before 
implantation in vivo as a canine abdominal aorta. Excellent patency rate and 
satisfying in vivo vascular remodelling such as formation of an integral endothelial 
layer, multiple smooth muscle layers and accumulation of the extracellular matrix 
collagen, were observed (Zhang et al., 2008). It was also explored whether in vitro 
differentiated SMCs from BMMSCs could contribute to vascular graft engineering 
(Gong and Niklason, 2008b). Combined with mature ECs, SMCs differentiated from 
BMMSCs were seeded onto polyglycolic acid scaffold and cultivated in the bioreactor 
system. Grafts bearing histological similarity with native vessels were constructed 
(Gong and Niklason, 2008b). Moreover, the excellent performance of BMMSCs in 
vascular graft engineering is not restricted to grafts constructed with synthetic 
materials. Cell sheets containing BMMSCs could be assembled to form completely 
biological vascular grafts and the cells could also be seeded onto scaffolds 
decellularised from arteries. Grafts constructed with both methods above could also 
exhibit satisfying long-term patency rate when implanted in vivo (Zhao et al., 2012; 
Zhao et al., 2010). 
However, though endothelial differentiation capacity was shown in vitro in BMMSCs, 
the differentiation capacity in vivo was still controversial and was not observed in 
some reports both in vitro and in vivo (Au et al., 2008). After establishing the beneficial 
effect of BMMSCs in vascular graft engineering, efforts were then invested in further 
improving the performance of vascular grafts to bring it even closer to that of native 
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arteries. Modification of endothelial nitric oxide synthase (eNOS) expression could 
help increase the graft performance (Zhang et al., 2006a). Fibronectin coating of the 
synthetic materials could promote the smooth muscle differentiation of BMMSCs 
while preserving its proliferation rate which might contribute to better graft 
performance as well (Shudo et al., 2016).  
1.5.7.2. Adipose tissue-derived mesenchymal stem cells 
Mesenchymal stem cells could also be derived from adipose tissues that could be 
easily harvested from the body. In fact, ADSCs are under extensive investigations for 
tissue regeneration and emerge to be a promising adult stem cell source (Krawiec 
and Vorp, 2012; Ramakrishnan and Boyd, 2017). However, they are not as widely 
investigated as BMMSCs. Most attempts examining the potential for vascular graft 
engineering are limited to in vitro studies with in vivo efficacy of the cells in vascular 
tissue engineering not that well established. In 2008, ADSCs were in vitro expanded 
and cultured for one passage before being seeded onto electrospun collagen and 
elastin hybrid scaffolds. The cell seeded scaffolds were cultured in the bioreactor 
system for 2-4 weeks. The cells could attach well to the scaffold and depending on 
the cell culture medium, the seeded cells either exhibited smooth muscle features or 
endothelial features (Heydarkhan-Hagvall et al., 2008). This study implicated the 
potential to use ADSCs to generate vascular grafts. Apart from the in vitro cultured 
undifferentiated ADSCs, partially differentiated cells in response to specific growth 
factors were also investigated. It was shown that under TGFβ1 stimulation, ADSCs 
could be differentiated towards SMCs, and these partially differentiated cells could 
also attach to scaffolds such as the polyglycolic acid mesh (Wang et al., 2010a) and 
the decellularised saphenous vein (Harris et al., 2011) which resulted in reinforced 
mechanical property of the vascular grafts. Endothelial differentiation capacity of the 
cells contributed to the endothelial layer formation of the decellularised grafts 
(Bertanha et al., 2014). Furthermore, it was demonstrated that ADSCs displayed dual 
differentiation capacities towards both vascular SMCs and ECs which could be 
seeded then to the biodegradable polycaprolactone (PCL)-gelatin mesh to construct 
a two layered vascular graft (Zhou et al., 2016a). Overall, differentiation capacity of 
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adipose tissue derived stem cells towards vascular lineages could be utilised in 
vascular tissue engineering. Like BMMSCs, ADSCs could also form cell sheets in 
vitro and then be assembled to generate completely biological vascular grafts (Costa 
et al., 2017). 
To speed up the process of vascular tissue engineering, stromal vascular fraction 
which was the primarily digested adipose tissue without in vitro culturing, was 
compared with in vitro expanded ADSCs (Krawiec et al., 2016). Not as good but 
comparable performance was observed in terms of in vivo patency at 8 weeks 
(Krawiec et al., 2016). This implies that in vitro culture of ADSCs might be omitted to 
save time given some further improvement of the stromal vascular fraction seeded 
grafts such as growth factor incorporation. Proteomic profile of the adipose tissue 
derived stem cells seeded onto synthetic scaffolds was compared with cells from 
native vessels as an investigation of the mechanism through which to improve the 
vascular graft performance (Wang et al., 2013). Differentially expressed proteins 
include enzymes, anchored proteins and those that are involved in cell apoptosis, 
cellular organisation, energy metabolism and so on. However, it requires further 
experiments to pinpoint those that are related to the functional differences and could, 
in the end, contribute to improved vascular graft function (Wang et al., 2013). 
1.5.7.3. Mesenchymal stem cells from other origins 
Other mesenchymal stem cell (MSC) sources explored in vascular tissue engineering 
include umbilical cord blood derived mesenchymal stem cells, amniotic fluid derived 
mesenchymal stem cells, hair follicle-derived mesenchymal stem cells and pericytes. 
Although it is still controversial whether pericytes are included in the classification of 
mesenchymal stem cells, they bear so many similarities that pericyte utilisation in 
vascular tissue engineering would be explained here as well.  
Through self-assembling, cell sheets formed by umbilical cord blood derived 
mesenchymal stem cells could be rolled around a mandrel and give rise to a vascular 
conduit with a higher mechanical burst pressure and better contractile response 
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compared to grafts formed by cell sheets of SMCs or fibroblasts (Bourget et al., 2015). 
Mesenchymal stem cells could be isolated from amniotic fluid and display the 
potential to differentiate towards SMCs which lays the foundation for their use in 
vascular tissue engineering (Weber et al., 2016).  
Similarly, smooth muscle differentiation capacity was demonstrated in hair follicle 
derived mesenchymal stem cells and the expression of the induced smooth muscle 
markers could be maintained when they were seeded on decellularised scaffolds 
(Gao et al., 2014a; Liu et al., 2010). The investigation of hair follicle derived 
mesenchymal stem cells is mainly limited to in vitro studies. Synthetic scaffolds 
incorporated with pericytes demonstrated 100% patency rate compared to unseeded 
controls. Examination of the explants after 8 weeks showed nice in vivo integration 
as displayed by the functional smooth muscle layers and integral endothelial layer 
(He et al., 2010). Furthermore, pericytes could work synergistically with peptides 
contained by the synthetic scaffolds to promote endothelialisation and growth factor 
preservation (Campagnolo et al., 2016). 
 
1.5.8.  TGFβ1 in vascular graft engineering 
As introduced earlier, TGFβ1 is a potent growth factor and could induce smooth 
muscle differentiation from multiple stem cells as well as SMC phenotypic switching 
from the secretory phenotype to the contractile phenotype (Goldsmith et al., 2006; 
Goumans et al., 2009). For the native vessel, the extracellular matrix, the cellular 
components and the haemodynamic environment work synergistically to maintain its 
normal function. In the process of vascular graft engineering, factors, which could 
influence these basic elements of vessel function, have the potential to improve the 
performance of the graft. Growth factors including TGFβ1, mechanical flow exposure, 
and extracellular matrix production have all been elucidated to contribute to smooth 
muscle phenotypic change to the contractile phenotype and the resultant enhanced 
vascular graft function (Beamish et al., 2010). When stem cells are employed in 
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vascular graft engineering, it could be concluded from the part “Cells utilised in tissue 
engineered vascular grafts” that they are either allowed to differentiate in vitro towards 
vascular lineages including SMCs and ECs, or they are seeded on the graft in the 
undifferentiated state and allowed to differentiate and participate in vascular 
regeneration in vivo.  
When stimulating stem cell differentiation in vitro, TGFβ1 is a widely used growth 
factor. It has been applied in various vascular graft engineering systems involving 
different origins of stem cells such as smooth muscle progenitors, BMMSCs (Gong 
and Niklason, 2008a; Hahn et al., 2007), hair follicle derived mesenchymal stem cells 
(Gao et al., 2014b; Liu et al., 2008), adipose tissue derived stem cells (Parvizi et al., 
2016; Zhou et al., 2016a), and embryonic stem cells (Sundaram et al., 2014a). 
However, TGFβ1 alone sometimes is not potent enough to drive gratifying smooth 
muscle differentiation (Au et al., 2008). As a result, among these studies, several 
combined the application of TGFβ1 with bone morphogenetic protein 4 (BMP4) to 
give rise to SMCs with satisfactory function (Wang et al., 2010a; Wang et al., 2013; 
Zhou et al., 2016a). Other factors that could be utilised in inducing smooth muscle 
differentiation include AngII and sphingosylphosphorylcholine (SPC) (Harris et al., 
2011).  
Furthermore, since the recognition of the significance of mechanical stimuli in 
vascular tissue engineering, most studies have included the bioreactor system in their 
vessel manufacturing process. It has also been implicated that the mechanical 
stimulation could help drive the differentiation of stem cells towards the smooth 
muscle lineage (Bulick et al., 2009). And when combined with endothelial presence, 
mechanical stimulus could drive more differentiated SMCs than TGFβ1 as evidenced 
by the higher increase of smooth muscle markers (Au et al., 2008; Bulick et al., 2009). 
Differentiated SMCs have been proved to maintain the differentiated state after being 
seeded to the vascular graft. Addition of TGFβ1 in the culture medium when 
mechanical stimuli was applied to the vessel could further reinforce the differentiation 
(Riha et al., 2005). Apart from smooth muscle differentiation, TGFβ1 has also been 
shown in one study to drive the embryonic stem cells to form embryonic bodies which 
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was later further driven towards the endothelial lineage and employed in generating 
vascular grafts (Shen et al., 2003).   
Also, TGFβ1 has long been shown to upregulate the production of elastin in the 
extracellular matrix which could in turn lead to stronger mechanical strength of the 
graft (Long and Tranquillo, 2003; Neidert et al., 2002). Although another study did not 
observe significant mechanical feature improvement with TGFβ1 incorporation within 
the scaffold, it was found that the bio-compatibility of the graft was greatly increased 
(Yao et al., 2005). Notably, it was shown that miR-29 inhibition performs better in 
inducing elastin production than TGFβ1 treatment in fibroblasts and vascular SMCs 
(Rothuizen et al., 2016). This might be due to the potent but various function of TGFβ1 
which might result in the activation of too many signalling pathways. In the end, along 
with the development of numerous scaffold modification methods, TGFβ1 was also 
found feasible to be conjugated with scaffold materials containing functionalised 
poly(ester amide)s (Knight et al., 2014). However, further studies should be done to 
examine its potential to activate downstream signalling pathways (Knight et al., 2014). 
 
1.6. Hypothesis and aim of the study 
MSCs are characterised by their certain phenotypic marker profile and multi-lineage 
differentiation potentials which present them as a promising cell type for tissue 
engineering. Compared to other stem cells, human umbilical cord derived 
mesenchymal stem cells (hUCMSCs) have superior proliferation capacity which 
facilitates their application in tissue engineering.  
In our program, we explored the differentiation potential of hUCMSCs into vascular 
SMC lineages and the application of SMCs derived from hUCMSCs to vascular graft 
engineering. The main aims of the project are summarised in the figure 1-11.  
The protocols of differentiating hUCMSCs into SMCs are firstly established before 
proceeding to engineer vascular grafts. TGFβ1, which is a recognised growth factor 
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to drive stem cell to SMC lineage, is applied to stimulate the differentiation of 
hUCMSCs towards SMCs. 
MicroRNA array analysis is subsequently performed on undifferentiated MSCs and 
differentiated cells to identify microRNA candidates regulating the differentiation 
process. Bioinformatics prediction and literature review were combined to pinpoint 
possible microRNA targets after which microRNA loss and gain-of-function 
experiments are utilised to confirm the role of specific microRNAs as well as their 
targets in the regulation of the SMC differentiation. Afterwards, the miRNA oriented 
mechanism was explored including the upstream regulation of miRNA level and the 
downstream 3’-UTRs of target genes.  
Vascular grafts will be subsequently generated with decellularised vessel scaffold 






Figure 1-11 Schematic graph of the hypothesis and aims in the project 
Firstly, SMC differentiation potential from hUCMSCs would be explored (aim 1). After that, 
the differentiation mechanism (aim 3) would be checked as to uncover novel miRNAs in MSC-
SMC differentiation process as well as their upstream and downstream regulation 
components. In the end, the hUCMSC-derived SMCs would be applied in the bioreactor 
system to explore their potential in generating vascular grafts (aim 2). The graph of the 




2. Materials and Methods 
2.1 Materials 
hUCMSCs were purchased from ATCC and cultured in manufacturer’s recommended 
medium. TGFβ1 was from Peprotech, and aliquoted into stock solution (10 ng/μl) in 
10 mM citric acid with 0.5% BSA. Total RNAs were extracted with the RNesay mini 
kit and microRNAs were extracted with miRNeasy mini kit from Qiagen. TaqMan 
microRNA Reverse Transcription kit, human TaqMan microRNA assay primers, and 
TaqMan universal master mix were purchased from Applied Biosystems. Matrigel for 
in vivo subcutaneous Matrigel assay was from Corning. All the materials including the 
reagents, chemicals and kits are listed in the table (Table 2-1). Primers and antibodies 
used in each experiment were listed in the Methods part.  
Table 2-1 Materials  
Reagents or kits Company Cat. No. 
U6 snRNA Life Tech 4427975   001973 
TaqMan® MicroRNA Assays; 
hsa-miR-503-5p 
Life Tech 4427975    001048 
TaqMan® MicroRNA Assays; 
hsa-miR-222-5p 
Life Tech 4427975    002097 
TaqMan® MicroRNA Assays; 
hsa-miR-503-3p 
Life Tech 4440885   476380_mat 
TaqMan® MicroRNA Assays; 
hsa-miR-424-5p 
Life Tech 4427975   000604 
TaqMan® MicroRNA Assays 
hsa-miR-145 
Life Tech 4427975 
miRNeasy Mini Kit (50) QIAGEN 217004 
TaqMan® MicroRNA Reverse Transcription Kit, Life Tech 4366597 
TaqMan® Universal Master Mix II, no UNG Life Tech 4440040 
miRNA Mimic, Negative Control #1 Life Tech 4464058 
hsa-miR-503-5p mimic Life Tech 4464066    MC10378 
hsa-miR-222-5p mimic Life Tech 4464066    MC12656 
Negative control A 
miRCURY LNA™ microRNA inhibitor control, 
Exiqon 199006-001 
hsa-miR-503-5p 
miRCURY LNA™ microRNA inhibitor 
Exiqon 4100899-001 
hsa-miR-222-5p 
miRCURY LNA™ microRNA inhibitor 
Exiqon 4101567-001 
RNAiMax Life Tech 13778-075 
opti-MEM Life Tech 31985062 
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miRNA Target clone control vector for pEZX-MT06 Genecopoeia CmiT000001-MT06 
miRNA 3´UTR target expression clone for Human ACTA2 
NM_001141945.1 
Genecopoeia HmiT054221-MT06 
miRNA 3' UTR target clone for human NM_001190821.1, 
SMAD family member 7, 
Genecopoeia HmiT055200-MT06 
custom 3'UTR target clone for human ROCK2 with custom 
2026bp 
Sequence (NM_001321643.1, 3'UTR positions: 1651-
3676), in pEZX-MT06 vector 
 
Genecopoeia CS-HmiT088447-MT06-01 
QuikChange Lightning Site-Directed Mutagenesis Kit, 10 
Rxn 
Agilent Tech 210518 
Detection of Firefly Luciferase Activity Promega E1501 
Detection of Renilla Luciferase Activity Promega E2810 
SiRNA negative control Life Tech AM4611 
Human Smad7 siRNA Life Tech AM16708 155241 
Human ROCK2 siRNA Life Tech Cat AM51331    110867 
Umbilical Cord-Derived Mesenchymal Stem Cells; Normal, 
Human 
ATCC ATCC® PCS-500-010™ 
Mesenchymal Stem Cell Basal Medium for Adipose, 
Umbilical and Bone Marrow-derived MSCs 
ATCC ATCC® PCS-500-030™ 
Mesenchymal Stem Cell Growth Kit for Adipose and 
Umbilical-derived MSCs - Low Serum 
ATCC ATCC® PCS-500-040™ 
Human recombinant TGFβ1 Peprotech 100-21 
Cultrex Rat Collagen I, 100 mg R&D systems 3440-100-01 
Smad4 Antibody(H-552)  X Santa Cruz sc-7154 X 





2.2.1 Cell culture of umbilical cord-derived stem cells 
HUCMSCs were purchased from ATCC (Cat No: PCS-500-010) and cultured on 
gelatin coated flasks (0.04% diluted from 2% Solution Type B from Bovine Skin, 
Sigma G1393) in ATCC Mesenchymal Stem Cell Basal Medium (PCS-500-030) 
supplemented with 1 kit of Mesenchymal Stem Cell Growth Kit–Low serum (PCS-
500-040), (see Table 2-2) and 100 U/ml penicillin and streptomycin in a humidified 
incubator supplemented with 5% CO2. Cells were passaged every second day at the 
ratio of 1:2. Cells below passage 15 were used for all experiments.  
 
Table 2-2  Mesenchymal Stem Cell Growth Kit for Adipose and Umbilical-derived 
MSCs Low Serum Components 
Component Volume Final Concentration 
MSC Supplement 10 mL 2% FBS 
5 ng/mL rh FGF basic 
5 ng/mL rh FGF acidic 
5 ng/mL rh EGF 
L-Alanyl-L-Glutamine 6 mL 2.4 mM 
 
hUCMSCs were ensured by the manufacturer to have more than 98% of the cells 
expressing CD73, CD90, CD105, CD44, CD29, CD166 and less than 2% of the cells 
expressing CD14, CD31, CD34 and CD45. Furthermore, trilineage differentiation 





Figure 2-1 Characterisation of hUCMSCs   
(A) hUCMSC were characterised by surface marker panel and trilineage differentiation 
capacity. More than 98% of hUCMSC were positive for CD29, CD44, CD73, CD90, CD105 
and CD166, but less than 2% were positive for CD14, CD31, CD34 and CD45. (B) 
Additionally, hUCMSCs were shown to have adipogenic (1), chondrogenic (2) and osteogenic 
(3) differentiation capacity. The figure is copied from the datasheet. 
2.2.2 Smooth muscle differentiation 
hUCMSCs were seeded on gelatin coated flasks and maintained in differentiation 
medium for several time points. For SMC differentiation, the differentiation medium 
was αMEM (minimum essential medium) with 1% or 10% FBS and 0 or 5 ng/ml 
TGFβ1 as specified in each experiment. The culture time and seeding density varied 
as mentioned in the text. To prevent the cells from being too dense, the seeding 
density is carefully controlled to ensure that the cell density is around 80% upon 
harvesting. Before establishing the final SMC differentiation protocol, the experiment 
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conditions are optimised including serum concentration, differentiation time and the 
effect of TGFβ1. 
2.2.3 Flow cytometry analysis  
hUCMSCs were detached from the flasks by trypsin, after which cells were counted. 
Cells were then fixed with 4% paraformaldehyde (PFA) for 15 minutes at room 
temperature. After washing with PBS, cells were re-suspended in 5% swine serum 
and blocked with Fc Receptor Blocking Solution (Human TruStain FcX™, BioLegend, 
Cat No: 422301; TruStain fcX™ (anti-mouse CD16/32) Antibody, BioLegend, Cat No: 
101319) for 5 minutes. Aliquots of about 2x105 cells were then incubated with specific 
antibodies (human CD44 antibody: PerCP anti-mouse/human CD44 antibody, Cat No. 
BioLegend 103035; IgG control: PerCP IgG2b, κ Isotype Ctrl Antibody, Cat No. 
BioLegend 400629) at manufacturer suggested concentration for 1 hour at 4 °C. 
Three additional washes were conducted before the cells were taken to be analysed 
at the flow cytometer (BD FACS Canto™ II system). Further analysis was done with 
Flow Jo. Gating was set as less than 1% of marker expression in IgG control group. 
2.2.4 RNA extraction 
Total RNA from cells was extracted using the RNeasy mini kit (Qiagen Cat. No: 
74106). It was performed according to the manufacturer’s protocol with a 
centrifugation speed of more than 10000rpm/8000g. Cells were lysed in 350 μl RLT 
lysis buffer and then homogenised with QIAshredder spin column to shear high 
molecular weight genomic DNA and other cellular components. After an equal volume 
of 70% ethanol was added to the homogenised lysate, a total volume of 700 μl of the 
sample was added to the RNeasy spin column. The column was centrifuged for 30 
sec and the flow-through was discarded. 700 μl of RW1 buffer was then added to the 
column followed by centrifugation for 15 seconds. Another two washes were carried 
out by adding 500 μl RPE washing buffer. The flow-through was again discarded. The 
washing buffer was applied to remove the salts in the lysis buffer which could later 
interfere with the reactions of reverse transcription of mRNA and polymerase chain 
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reaction of cDNA. An additional centrifugation without additional buffer was carried 
out to further remove any remaining solution before 30-50 μl of RNase free water was 
added to the spin column membrane. After spinning for 1 minute, the flow-through 
was the sample containing total RNA. The RNA concentration was measured with a 
Nanodrop Spectrophotometer and RNA quality was controlled with 260/280 ratio and 
260/230 ratio to rule out possible contamination of the sample by protein and other 
reagents such as phenol and guanidine.  
2.2.5 Reverse transcription (RT) of RNA  
Reverse transcription of RNA was performed with the QuantiTect Reverse 
Transcription Kit (QIAGEN, Cat No: 205314). 1000 ng of total RNA was used for each 
reaction of reverse transcription. After adding a corresponding volume of DEPC water 
to the calculated volume of RNA to reach a total volume of 12 μl of the sample, 2 μl 
of gDNA wipeout buffer was added to the sample. The final volume of mix A was 14 
μl. Mix A was briefly vortexed and centrifuged before being taken to the reverse 
transcription system (prime thermal cycler) in which the samples were kept at 42 °C 
for 2 minutes. Meanwhile mix B was prepared with the composition of 1 μl Quantiscrpt 
Reverse Transcriptase, 4 μl 5x Quantiscrpt RT buffer and 1 μl RT primer included in 
the kit. (The composition of master mix A and B is listed in Table 2-3) At the end of 
the 2-minute incubation at 42 °C, mix B was added to the sample and incubation at 
42 °C for 15 minutes in the system was followed. Finally, a temperature of 95 °C for 
3 minutes was applied to inactivate the Quantiscript Reverse Transcriptase. cDNA 
obtained was diluted with 80 μl DEPC treated water to reach a final concentration of 
10 ng/μl.  
Table 2-3 Composition of master mix A and B for RNA reverse transcription 





Mix A RNA x (1000 ng)  
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Quantiscript RT Buffer, 
5x 
4 1x 
RT Primer Mix 1  
Total volume  20  
 
2.2.6 Quantitative polymerase chain reaction (Q-PCR) 
Gene expression level in cells was detected by Q-PCR using Eppendorf Mastercycler 
ep realplex. Each Q-PCR reaction was a 20 µl reaction composed of 10 µl 2x 
qPCRBIO SyGreen Mix (qPCRBIO SyGreen Mix Hi-ROX, PCRBIOSYSTEMS, Cat 
No: PB20.12-20), 0.8 µl forward primer, 0.8 µl reverse primer, 2 µl cDNA and 6.4 µl 
RNase free water. Before putting the 96 well plates (Eppendorf, twin. tec real time 
PCR plates) in Eppendorf Mastercycler ep realplex, samples were loaded in the 
plates and the plates underwent a brief centrifugation. The Q-PCR program was 2 
minutes at 95 °C followed by 40 cycles of 95 °C for 5 seconds (denaturation) and 
60 °C for 30 seconds (annealing and extension) as suggested in the manufacturer’s 
protocol. Every sample had duplicates. Wells loaded with water rather than samples 
were utilised to serve as a blank control. The primers used for Q-PCR were designed 
using software provided by DNA integrated Technologies and are listed below. The 
specificity of each primer was ensured with post-amplification melting curve. The 
threshold cycle (Ct) value was automatically obtained in excel format and the Ct value 
of GAPDH was used to serve as internal control. Fold change of gene of interest 
induced by specific treatment was calculated by the Ct value difference against 
internal control GAPDH with the following algorithm. (Primer sequences used in Q-
PCR are listed in Table 2-4.) 
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ΔCt (Treatment) = Ct (Gene of interest) - Ct (GAPDH) 
ΔCt (Control) = Ct (Gene of interest) - Ct (GAPDH) 
ΔΔCt = ΔCt (Treatment) - ΔCt (Control) 
Fold change = 2(-ΔΔCt) 
 
Table 2-4 Primer sequence used in Q-PCR 
Gene 
Symbol 
Sequence (5’→3’) Ct value range 
Human 
GAPDH 
F: 5-CAT GTT CGT CAT GGG TGT GAA CCA-3 




F: 5-TTG AGG CCA ACG ACC TGT TTG AGA-3 




F: 5-TTG AAG GCA AAG ACA TGG CAG CAG-3 




F: 5-TGA CAA TGG CTC TGG GCT CTG TAA-3 
R: 5-TTC GTC ACC CAC GTA GCT GTC TTT-3 
20-23 
Human 
Collagen I  
F: 5-CTG CAA AGG CAG CCA AAT AC-3 




F: 5-TGA GTG CCA CTG GCT TTG AAG AGA-3 




F: 5-TTG AAA GCG GAG AAA TGC CAG CAG-3 




F: 5-ATC CAT CCT CAC TCC TCG TAT C-3 




F: 5-TGT TCC TGG ACT TGG AGT TG-3 
R: 5- GCT CCA TAT TTG GCT GCT TTA G-3 
29-32 
2.2.7 MicroRNA extraction 
Extraction of RNA including microRNA was performed with miRNeasy mini kit 
(Qiagen, Cat No: 217004) at room temperature unless otherwise specified. Briefly, 
trypsinised cells were lysed with 700 µl Qiazol lysis buffer provided in the kit, and then 
homogenised by intensive vortexing for 60 seconds. After the homogenate was kept 
at room temperature for 5 minutes, 140 µl chloroform (VWR, Cat No: BDH1109-4LG) 
was added to the sample, followed by intensive vortexing for 30 seconds. Before the 
samples were centrifuged at 4 °C for 15 minutes at 12000 g, they were left at room 
temperature for 3 minutes. After centrifugation, the homogenate was separated into 
three phases: an upper aqueous phase, a white interphase and a lower red organic 
100 
 
phase. The aqueous phase, approximately 350 µl, was then transferred to a new tube, 
and 1.5 volumes (525 µl) of absolute ethanol were added. Up to 700 µl of the mix was 
pipetted into the RNeasy mini spin column, followed by centrifugation at 8000 g for 
15 seconds. This step was repeated for the rest of the mix with the same column. The 
flow-through was discarded. 700 µl RWT buffer was then added to the column 
followed by centrifugation at 8000 g for 15 seconds, after which, two additional 
washes were performed with 500 µl RPE buffer, with centrifugation time of the second 
wash to be 2 minutes. Before pipetting 30-50 µl RNase free water directly to the 
membrane of the RNeasy spin column, another empty centrifugation without any 
buffer was performed. Finally, a RNeasy spin column with RNase free water was 
centrifuged and the flow-through was the RNA (including microRNA) containing 
sample. RNA concentration was measured with Nanodrop Spectrophotometer. 
2.2.8 Reverse transcription and pre-amplification of RNA 
(including microRNA) 
After measuring the RNA concentration, samples were diluted to 10 ng/μl with RNase 
free water. 2 μl of RNA was used as input in each reverse transcription reaction. RNA 
was transcribed with primers from Applied Biosystems (Human Pool A and human 
pool B). Reverse transcription reaction was performed according to manufacturer’s 
recommendations. Briefly, a master mix was first prepared as listed in Table 2-5 and 
then 5.5 μl master mix was mixed with 2 μl of the diluted RNA. Then, the program for 
reverse transcription was 16 °C for 2 min, 42 °C for 1 min and 50 °C for 1 s for 40 
cycles and then incubation at 85 °C for 5 min using a Veriti thermocycler (Applied 
Biosystems).  
1 μl of the reverse transcription product was then mixed with 9 μl of master mix B 
(Components are listed in Table 2-6) prepared as follows. Then pre-amplification was 
performed by heating samples to 95 °C for 10 min, followed by 12 cycles of 95 °C for 
15 s and 60 °C for 4 min.  Finally, samples were heated to 95 °C for 10 min to ensure 
enzyme inactivation. Pre-amplification products were diluted to a final volume of 40 
μl and stored at -20 °C. Pre-amplification was performed to enable detection of 
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microRNAs at very low levels, enabling the generation of a comprehensive 
expression profile using as little as 1 ng of input total RNA. 
Table 2-5 Reagents and their volume used in reverse transcription of RNA (including 
microRNA) 
 
Table 2-6 Reagents and their volume used in pre-amplification of RNA (including 
microRNA) 
 
2.2.9 TaqMan Q-PCR assay 
TaqMan microRNA assay was used to assess the expression of individual 
microRNAs. 1 μl of the pre-amplification product was combined with 5 μl TaqMan 
master mix 2X, 0.5 μl primer (TaqMan assay 20X), and 3.5 μl distilled water and then 
loaded to a 96 well plate. Q-PCR was performed on an Applied Biosystems 7900 HT 
thermocycler at 95 °C for 10 min followed by 40 cycles of 95 °C for 15 s and 60 °C 
for 1 min. All samples were run in duplicates and standardised to U6.  
2.2.10 Protein extraction 
30-50 µl RIPA buffer (RIPA Lysis and Extraction Buffer, Life Tech, Cat No: 89901) 
with phosphatase inhibitor tablets and protease inhibitor tablets resolved in 
Reagent Volume (μl) 
Primer pool A/B 0.8 
dNTPs 0.2 
10 x RT buffer 0.8 
MgCl2 0.9 
RT 1.5 
RNase inhibitor 0.1 
Rnase free water/DEPC treated water 1.2 
Final volume 5.5 
Reagent Volume (μl) 
Preamp mastermix 2x 5 
Megaplex preamp primers pool A/B 1 
RNase free water 3 
Final volume 9 
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(Phosphatase Inhibitor Tablets, Roche, Cat No: 04906845001, 1 tablet/10 ml RIPA 
buffer; Protease Inhibitor Tablets, Roche, Cat No: 04693159001, 1 tablet/10 ml RIPA 
buffer) was added to harvested cell pellets and sonicated with Branson Sonifier 150 
at the lowest setting for 12 s. After incubation at 4 °C for 45 minutes, the lysate was 
centrifuged at highest speed (more than 10000 g) for 10 minutes at 4 °C. The 
supernatant containing protein was then transferred to a new tube and protein 
concentration was measured with Biorad Protein Assay. Briefly, 2 µl of the 
supernatant of the protein lysate was added to 998 µl 1x Bio-Rad Protein Assay Dye 
Reagent (Bio-Rad Protein Assay Dye Reagent Concentrate, 5x, BIO-RAD, Cat No: 
5000006). The sample was well mixed and incubated at room temperature for 5 
minutes. Each measurement was measured with duplicates and the concentration 
was measured with Bio-Rad Spectrophotometer 3000. An equal volume of lysis buffer 
was measured to serve as a blank control.  
2.2.11 Western blot 
10-50 µg of the protein was mixed with a ¼ volume of the boiled 5x SDS loading 
buffer and then adjusted to the same volume with 1x SDS loading buffer. The mix 
was then boiled at 95 °C for 10 minutes before being loaded to the NuPage 4-12% 
Bis Tris gel immersed in NuPage MOPS SDS running buffer in a XCell SureLock 
Mini-Cell (Life Technologies, Cat No: NP0335BOX). Protein ladder (Precision Plus 
Protein Ladder, Bio-rad, Cat No: 161-0374) was loaded into a separate well together 
with the samples and the gel was run at 160 V for about 75 minutes until the marker 
with lowest molecular weight was at the bottom of the gel. Protein was then 
transferred from the gel to the membrane (Transfer membranes, BioTrace™ NT, 
VWR, Cat No: 732-3031) in 1X transfer buffer (Thermo Fisher Scientific, NuPAGE® 
Transfer Buffer (20X), Cat No: NP-0006-1) for 45 minutes. The membrane was then 
blocked with 5% milk in PBS-Tween and incubated with primary antibody diluted in 
5% milk at room temperature for 2 hours or at 4 °C overnight. After being washed 
with PBS-Tween for three times with 10 minutes each, the membrane was incubated 
with secondary antibody for 1 hour at room temperature. Secondary antibodies were 
HRP-conjugated and purchased from Dako (Polyclonal Rabbit anti-goat, Cat No: 
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P0449; Polyclonal Rabbit anti-mouse, Cat No: P0260; Polyclonal Swine anti-rabbit, 
Cat No: P0217). Further 3 washes were performed before addition of ECL detection 
solutions (ECL Western Blotting Detection Reagents, Fisher Scientific, Cat No: 
RPN2106). After incubation with the detection solution for 2 minutes, exposure of the 
films (Amersham Hyperfilm ECL, Fisher Scientific, Cat No: 28-9068-37) was carried 
out with the Compact X4 (Xograph Imaging System) in the dark room. Primary 
antibodies and their corresponding concentration are listed in Table 2-7. 
Table 2-7 Primary antibodies and their dilution used in Western blot 
 
2.2.12 Immunofluorescence 
Cells were trypsinised and resuspended in medium and were then seeded on 8-well 
chamber slides (Millicell EZ SLIDE 8-well, Merck Millipore, Cat No: PEZGS0816) 
coated with gelatin. After the cells were cultured on the slides for an intended time in 
differentiation medium with medium change every second day, the slides were taken 
out of the 5% CO2 humidified incubator and washed with PBS followed by fixation of 
the cells with 4% paraformaldehyde (PFA) for 15 minutes at room temperature. 
Permeabilisation was then performed with 0.1 Triton-X-100 in PBS for 10 minutes at 
room temperature. An additional wash in PBS was carried out before continuing. For 
the frozen sections of vessels harvested from ex vivo experiments, the samples were 
fixed with 100% cold acetone for 10 minutes and then washed with PBS for three 
times. After fixation and permeabilisation, all slides were blocked with 5% swine 
serum in PBS for 30 minutes at room temperature. The primary antibodies used and 
Primary Antibody Company and Catalogue 
Number 
Dilution (in 5% milk in PBS-
Tween) 
Human Calponin Abcam ab46794 1:1000 
Human SM22 Abcam ab14106 1:3000 
Human  αSMA Sigma A2547-100 1:3000 
Human SMMHC Abcam ab53219 1:500 
Human Myocardin Santa Cruz sc34238 1:2000 
Human SRF Abcam ab33147 1:2000 
Human Smad7 R&D systems MAB2029 1:1000 
Human ROCK2 Abcam ab71598 1:1000 
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their corresponding concentration were listed in Table 2-8. Incubation was carried out 
at 37 °C for 1 hour. The slides were then again washed with PBS (3 times, 5 minutes 
each) followed by incubation with secondary antibody (secondary antibodies were 
Alexa Fluor conjugates purchased from Life Technologies) at 37 °C for 45 minutes. 
Slides were washed 3 times with 5 minutes each before staining with DAPI (1:1000) 
for 5 minutes at room temperature. Another 3 washes with PBS were carried out 
before mounting the slides with fluorescent mounting media (Dako, Fluorescent 
Mounting Media, Cat No: S3023). Images were taken with Axio Imager M2 
microscope and Volocity software.  
Table 2-8 Primary antibodies and their dilution used in immunofluorescence 
Primary Antibody Company and Cat No. Dilution (in 5% swine serum in PBS-
Tween) 
Calponin Abcam ab46794 1:200 
SM22 Abcam ab14106 1:200 
αSMA Sigma C6198-2ML 1:200 
αSMA Abcam ab184675 1:400 
SMMHC  Abcam ab53219 1:100 
CD31 Santa Cruz sc1506 1:50 
2.2.13 Transient transfection of miRNA mimics, miRNA inhibitors 
and siRNAs 
MicroRNA mimics, siRNAs, transfection reagent RNAiMax and transfection media 
opti-MEM were from Life Technologies. MicroRNA inhibitors were purchased from 
Exiqon. HUCMSCs were seeded at 1x104 /cm2 one day before transfection on gelatin 
coated plates to reach 60%-70% density the next day. For one well of 6 well plate, 
medium was changed to 1 ml empty αMEM without antibiotics or FBS approximately 
20 minutes before the transfection. In final experiments, mix A (50 μl opti-MEM/well 
+ 0.5 μl siRNA or miRNA mimic/well) and mix B (50 μl opti-MEM/well + 2 μl 
RNAiMax/well) was prepared. For miRNA inhibitors, the amount of each component 
in mix A and B was as follows: mix A, 50 μl opti-MEM/well + 2 μl miRNA inhibitors; 
mix B, 50 μl opti-MEM/well + 3 μl RNAiMax/well. The final concentration of siRNA 
and miRNA mimic was 12.5 nM and for miRNA inhibitor, the final concentration was 
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60 nM. In protocol optimisation experiments, a series of different amounts of reagent 
were used. After being mixed separately by pipetting up and down, mix A and mix B 
were then mixed together and let stand for 10 minutes at room temperature. 95 μl of 
the final mixture was then added to the each well. After 5 hours, 1 ml of αMEM with 
antibiotics and 2% FBS with or without 10 ng/ml TGFβ1 was added to each well. Cells 
were harvested after 1-3 days for gene expression detection experiments. For protein 
level analysis with cells grown and harvested in T-75 flasks, amount of all transfection 
reagents was scaled up accordingly. SiRNA negative control (Cat No. AM4611, Life 
Tech) and Smad7 siRNA (Cat No. AM16708 155241, Life Tech) was purchased from 
Life Technologies. Transfection reagent RNAiMax (Cat No. 13778-075, Life Tech) 
and transfection media opti-MEM (Cat No. 31985062, Life Tech) were also from Life 
Technologies. 
2.2.14 Luciferase reporter assays 
MiRNA target specificity was examined by luciferase reporter assays. Plasmids 
utilised in miRNA target validation experiment were purchased from Genecopoeia. A 
plasmid containing the 3’-UTR of target genes was cloned downstream of humanised 
Firefly luciferase and Synthetic Renilla luciferase gene was included in the plasmid 
for indication of plasmid transfection efficiency. A backbone of the plasmid was shown 
in the figure (Figure 2-2).  
1.5x104 HEK293 cells were seeded in each well of 24 well plates and transfected next 
day upon the density of 60% to 70%. Medium was first changed to 200 μL αMEM 
medium without either antibiotics or FBS. Mix A and mix B was prepared separately 
according to the table (Table 2-9) and then mixed, and let stand for 10 minutes before 
being added to the well. The final concentration of miRNA was 37.5 nM. 200 μl αMEM 
medium with double the concentration of antibiotics and 20% FBS was added to each 
well after a 5-hour incubation. Firefly and Renilla luciferase activity was detected with 




Table 2-9 Mixture components for dual transfection of miRNA and plasmid 
Mix A Mix B 
50 μl opti-MEM 50 μl opti-MEM 
0.375 μl miRNA negative control or mimic 0.5 μl Lipofectamine 3000 
50 ng plasmid  
0.5 μl p3000  
 
 
Figure 2-2 Schematic graph of miRNA target reporter plasmids 
The graph is reproduced from the datasheet of the plasmid. 3’-UTR of a specific gene was 
cloned into the plasmid downstream of humanised firefly luciferase gene. Moreover, synthetic 
Renilla luciferase was utilised as an indication of the plasmid concentration transfected into 
the cells. For control plasmid, there is no gene segment cloned to the miR Target site.  
2.2.15 Site mutation of plasmids 
Mutation of the target site in plasmids was performed with QuikChange Lightning Site-
Directed Mutagenesis Kit from Agilent Tech following the manual. Briefly, primers for 
mutation of the target site was first designed with the website 
www.agilent.com/genomics/qcpd based on the intended mutation. Primers used for 
each 3’-UTR mutation were listed as follows (Table 2-10). Secondly, mutation and 
amplification of the DNA template of plasmids bearing 3’-UTR of the target gene were 
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mutated with the following reaction. The reaction mix contains 5 μl 10x reaction buffer, 
50ng dsDNA template, 125 ng mutation primer 1, 125 ng mutation primer 2, 1 μl dNTP 
mix, and 1.5 μl QuickSolution reagent. Water was added at the end to reach the total 
volume of 50 μl. After the following mix was prepared, 1 μl of QuickChange Lightning 
Enzyme was added. Program of the reaction has 3 stages, with the first to be one 
cycle of 2 mins at 95 ˚C, the second to be 18 cycles of 20 seconds at 95 ˚C, 10 
seconds at 60 ˚C and varied time at 68 ˚C and the third stage to be one cycle of 5 
mins at 68 ˚ C. The varied time at the second stage is decided by the length of plasmid, 
with the time to be 30 seconds for every kilobase of the plasmid. Upon completion of 
the reaction, 2 μl of Dpn I restriction enzyme was added to the final solution and mixed 
thoroughly by pipetting up and down. After incubation for 5 minutes, the parental or 
nonmutated dsDNA template was digested. Transformation of mutated dsDNA and 
amplification of single colony was then carried out. Amplified plasmids were extracted 
with Qiagen mini prep kit (Qiagen, cat: 27104).  
Table 2-10 Mutation primer of the plasmids containing 3’-UTR segments of specific 
gene 
3’-UTR  Mutation primer 
hSmad7 m1 1: 5'-AGCACTCAGGAGGAAAATATTACGTGCAAAGTAGTTTGAAGTGTGGC-
3' 
2: 5'-GCCACACTTCAAACTACTTTGCACGTAATATTTTCCTCCTGAGTGCT-3' 






hROCK2 m1 1: 5'-CAAAACCAGTTTCAGTCTATCTGCACGCCAGTAGCTACTCTTCAGTT-3' 
2: 5'-AACTGAAGAGTAGCTACTGGCGTGCAGATAGACTGAAACTGGTTTTG-
3' 
hROCK2 m2 1: 5'-GGGAAGGAGAGGTGAGTCTGCACCAGTGTCAATGCAGACTC-3' 
2: 5'-GAGTCTGCATTGACACTGGTGCAGACTCACCTCTCCTTCCC-3' 









2.2.16 Chromatin immunoprecipitation 
Chromatin Immunoprecipitation experiments were performed with a kit from Millipore 
(Cat No. 17-295, Millipore) and immunoprecipitation was performed following the kit 
manual. Briefly, 1x106 hUCMSCs that were treated with or without 5 ng/mL TGFβ1 
for 4 hours were crosslinked with 1% formaldehyde for 10 minutes by adding 270 μL 
37% formaldehyde into 10 mL of growth medium in the flask. Cells washed and 
harvested were lysed with SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris, pH 
8.1 1X protease inhibitors). DNA was sheared by sonication (15 cycles of 15 
seconds sonication and 15 seconds pause). Sonicated lysate was centrifuged and 
180 μl supernatant was diluted 10 times with ChIP Dilution Buffer. 20 μl of the 
sonication lysate supernatant was saved to serve as input. Diluted cell supernatant 
was blocked with 75 μl of Protein A Agarose/Salmon Sperm DNA (50% Slurry) for 
30 minutes at 4˚C. 10 μl of immunoprecipitating antibody (anti-Smad4 antibody: sc-
7154 X, Santa Cruz; IgG control: Cat No. ab37415, Abcam) was then added to the 
supernatant after pelleting and was incubated overnight at 4˚C with rotation. 60 μl 
Protein A Agarose/Salmon Sperm DNA (50% Slurry) was added next day for 1 hour 
at 4 ˚C to collect the antibody/histone complex. Agarose was pelleted by gentle 
centrifugation at 1000 rpm at 4 ˚C for 1 min. Pelleted protein A 
agarose/antibody/histone complex was then washed with Low Salt Immune 
Complex Wash Buffer, High Salt Immune Complex Wash Buffer, LiCl Immune 
Complex Wash Buffer, and TE buffer. Histone complex was then eluted from the 
antibody by adding 250 μl freshly prepared elution buffer (1% SDS, 0.1 M NaHCO3) 
to the pelleted complex. Elution was repeated once and eluates were combined. 
Histone-DNA crosslinks were reversed with 20 μl 5 M NaCl by heating at 65 ˚C for 
4 hours. Crosslinks of input material was also reversed. 10 μl of 0.5 M EDTA, 20 μl 
1 M Tris-HCl and 2 μl of 10 mg/ml Proteinase K was then added to the combined 
eluates and incubated for 1 hour at 4 ˚C.  
DNA was then recovered by phenol/chloroform extraction and ethanol precipitation. 
An equal volume of phenol was added to the tube and then vigorous vortex was 
performed. Different phases were then separated by centrifugation at top speed. 
109 
 
The aqueous phase was transferred to another tube and remnant phenol was 
removed by adding an equal volume of chloroform:isoamyl alcohol. 1/10 volume 3 
M sodium acetate, 1/2 volume 5 M ammonium acetate and 2 volumes of 100% 
ethanol were added in the order they were mentioned and the sample was then 
frozen in -80 ˚C for 1 hour. The centrifugation at full speed was performed for 30 
minutes and the supernatant was discarded. The pellet was washed with 70% 
ethanol and air dried at room temperature. Afterwards, 50 μl of buffer TE was added.  
Q-PCR was performed to examine the enrichment of Smad4 at the promoter region 
of miR-503. Fold change of enrichment was calculated against input material and 
IgG control. The promoter of GAPDH was used to serve as negative control. Primers 
used were listed in the following table (Table 2-11).  
Table 2-11 Primers for GAPDH and miR-503 promoter 
 
2.2.17 Collagen gel contraction assay 
hUCMSCs cultured in medium (αMEM with 1% FBS) with or without 5 ng/ml TGFβ1) 
were detached and then mixed with collagen gel. After detachment, cells were 
resuspended in medium (5x αMEM with 5% FBS) at the concentration of 2x105 /ml. 
100 μl of the cell suspension was later mixed with 200 μl empty αMEM medium and 
200 μl collagen gel reagent (R&D systems, 3440-100-01). The mixture was later 
neutralised with 5 μl of 1M NaOH. The final concentration of the collagen gel was 2 
mg/ml. 500 μl final mixture was placed in one well of 24 well plates for 24 hours before 
the gel was formed and then detached with the pipette tips. The contraction of the 
collagen gel was observed every 2 hours and pictures were taken 5 hours after the 
Gene promoter primer 
GAPDH F: 5’-GGC CTC CAA GGA GTA AGA CC-3’ 
R: 5’-AGG GGT CTA CAT GGC AAC TG-3’ 
miR-503 primer 1 F: 5’-GAG AGA AGG TAC ATC GTG TGT T-3’ 
R: 5’-CAC TTC AGG AGA GGG TCA TTC-3’ 
miR-503 primer 2 F: 5’-AAA CAG GAA GGA GCG ACT TG-3’ 
R: 5’-TCT TAC ACT ATC GTT GCG ACA TAT AC-3’ 
miR-503 primer 3 F: 5’-GAG TGA AGT GGC CTA GTC ATA AG-3’ 
R: 5’-CCT GGT GGC AGG AAC AC-3’ 
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gel detachment. Triplicates were included for both undifferentiated cells and 
differentiated ones. The surface area of the gel was measured with Image J. Mean 
value was obtained between triplicates and then subjected to calculation of surface 
area ratio between cells treated without and with TGFβ1.  
2.2.18 Subcutaneous Matrigel plug assay 
hUCMSCs were differentiated with αMEM with 1%FBS and 5 ng/ml TGFβ1 for 5 days. 
After that, 0.5 million differentiated cells were harvested and mixed with 0.5 million 
HUVECs in 100 μl Matrigel and injected subcutaneously into nude mice. The same 
number of undifferentiated cells mixed with the same number of HUVECs was used 
as a control. The Matrigel plug was harvested 2 weeks after the injection and 
subjected to cryostat sectioning. H&E staining as well as immunofluorescent staining 
of the slide for SMC marker and EC marker was subsequently carried out to examine 
the vasculogenesis capacity of the cell mixture. Four Matrigel plugs were obtained in 
each experiment group. Animal-related experiments were all approved by the 
Institutional Committee for Use and Care of Laboratory Animal according to standard 
protocols. 
2.2.19 Cell seeding and vascular graft engineering with the 
bioreactor system 
Cells seeding and bioreactor establishment was conducted following standard 
protocol with minor modifications (Wong et al., 2015). Differentiated hUCMSCs were 
seeded on aortic scaffold which was previously decellularised (with 0.075% SDS and 
washed with PBS), in a specially constructed bioreactor with shear stress applied. 
Briefly, a roller pump (Masterflex: Standar Drive, mode 7520, Standard pump head, 
mode 7018-20, Tubing, Core-Parmer UK) was utilised to apply shear stress on the 
decellularised scaffold. The graft was fixed between two 25 G needles after 
connecting them on plastic tubes fixed by 8-0 silk sutures (8-0 black virgin silk, 
Ethicon Inc., Johnson and Johnson, Norderstedt, Germany). The complete set up 
was put in a 5% CO2 incubator at 37 °C and the scaffold was connected to a self-
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constructed chamber. The scaffold was preconditioned in culture media for 2 hours 
and then 1.5 million of differentiated hUCMSCs (differentiated with αMEM with 1% 
FBS and 5 ng/ml TGFβ1) were resuspended in 100 μl Matrigel which was liquified at 
4 °C overnight beforehand. Resuspended cells were seeded onto the outer side of 
the scaffold and the chamber was maintained at room temperature until the Matrigel 
was solidified. Media in the chamber consists of αMEM with 10% FBS and 5 ng/ml 
TGFβ1. Circulating medium consists of 30 ml αMEM with 10% FBS. After establishing 
the bioreactor system, shear stress was applied to the bioreactor by applying 3 ml/min 
fluid speed to the system which would be increased gradually to 5 ml/min over a 24-
hour period. The system was kept in the incubator for at least 5 days for the cells to 
migrate into the vessel wall. After 5 days, the graft was harvested, and cryostat 
sectioned to get frozen sections which were later subjected to H&E staining and 
immunofluorescent staining of SMC markers.  
2.2.20 Statistical analysis 
The data analysis was carried out with GraphPad Prism 6 software (GraphPad 
Software Inc.). All data were tested for normal distribution first with D’Agostino & 
Pearson omnibus normality test. Data between two groups with normal distribution 
were analysed with unpaired and ungrouped t-test, and data that were not normally 
distributed between two groups were analysed with unpaired and nonparametric 
Mann-Whitney test. Data across multiple groups were analysed with one-way ANOVA 
test, followed by Bonferroni post-hoc analysis if the P value was less than 0.05. Data 
were shown as the Mean ± SEM (standard error of mean) and graphs were generated 
using GraphPad Prism 6 software. P value <0.05 was considered statistically 





3.1 Characterisation of human umbilical cord-derived 
mesenchymal stem cells (hUCMSCs) 
3.1.1 Surface marker expression of hUCMSCs 
hUCMSCs were characterised by their marker profile, as suggested by the minimal 
criteria proposed by the ISCT (Dominici et al., 2006). The cells are characterised by 
the manufacturer and more than 98% of the cells are positive for CD29, CD44, CD73, 
CD90, CD105 and CD166, while at the same time less than 2% of the cells are 
positive for CD14, CD31, CD34 and CD45. Their trilineage differentiation potential 
into adipocytes, osteocytes and chondrocytes was also ensured. Furthermore, FACS 
analysis showed that more than 98% of the cells still express CD44 at passage 10 
(Figure 3-1).  
 
Figure 3-1 More than 98% of the cells still express CD44 after 10 passages 
Human UCMSCs were cultured in mesenchymal stem cell basal medium supplied by the 
manufacturer. Cells were passaged at 1:2 ratios at 60%-80% confluence. CD44 expression 
was examined at passage 10.  
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3.1.2 Analysis of SMC markers in hUCMSCs 
hUCMSCs were maintained in a basal medium as suggested and supplied by the 
manufacturer. The basal expression of contractile SMC markers was examined by 
Western blot. Compared to human umbilical artery-derived SMCs, hUCMSCs (P10) 
did not express Calponin, SMA or SMMHC, but expressed a certain level of SM22 
(Figure 3-2). This is consistent with the published study (Rodriguez et al., 2006) 
showing that some early markers for smooth muscle differentiation were found to be 
spontaneously transcribed in undifferentiated mesenchymal stem cells.  
 
Figure 3-2 Basal expression of SMC specific markers in hUCMSCs 
Compared to human umbilical artery-derived SMCs (hSMCs), hUCMSC expressed a low 
fraction of SM22, but did not express Calponin, SMA or SMMHC at the protein level. 
Representative picture of 3 individual experiments was shown. 
 




3.2.1 Establishment and optimisation of the differentiation protocol 
3.2.1.1 hUCMSCs were induced to differentiate into SMCs with 
TGFβ1  
TGFβ1 is a multifunctional regulator of vascular development and is widely utilised 
for promoting SMC differentiation (Hu et al., 2003; Qiu et al., 2003; Qiu et al., 2005). 
Firstly, in order to identify the optimal conditions to induce SMC differentiation from 
hUCMSCs, cells were cultured in differentiation medium (αMEM with 1% FBS) with 
or without TGFβ1. Quantitative gene expression analysis showed an upregulation of 
Calponin, SM22, SMA and SMMHC when cells were cultured in αMEM with 1% FBS 
(Figure 3-3 A, B). This upregulation of SMC markers was further significantly 
enhanced by adding 5 ng/ml TGFβ1 in the differentiation medium (Figure 3-3 A, B). 
It is worth noting that the expression of specific SMC marker SMMHC was induced 
from less than 10 folds to more than 20 folds by the addition of 5 ng/ml TGFβ1 (Figure 
3-3 B). Furthermore, genes related to extracellular matrix synthesis (collagen I and 
elastin) were also induced by TGFβ1 at the gene expression level (Figure 3-3 C).  
 
Figure 3-3 Induction of hUCMSCs differentiation into SMCs by TGFβ1 
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hUCMSCs displayed an increase in the expression of SMC specific markers including 
Calponin, SM22, SMA and SMMHC at the mRNA level in differentiation medium for 3 days. 
Differentiation medium is composed of αMEM with 1% FBS. The seeding density is 3x105 
cells/ T25 flask. Negative control consists of cells at the same passage before cells were 
plated in differentiation medium. (A, B) 5 ng/ml TGFβ1 could enhance the expression of SMC 
markers. Moreover, TGFβ1 significantly enhanced the expression of SMMHC. (C) Human 
UCMSCs displayed an increase in the expression of extracellular proteins collagen I and 
elastin at the mRNA level in differentiation medium for 3 days. Differentiation medium is 
composed of αMEM with 1% FBS. 5 ng/ml TGFβ1 could also enhance this significantly. Data 
are shown as mean ± SEM. Statistics are obtained with one-way ANOVA test, followed by 
Bonferroni post-hoc analysis. *P < 0.05; **P < 0.01 and ***P < 0.001.  
3.2.1.2 Low concentration of serum promotes SMC 
differentiation  
The optimal serum concentration was subsequently tested. To elucidate the effect of 
serum concentration, we compared cells cultured in 1% FBS and 10% FBS with or 
without TGFβ1. Results showed an increase of SMC contractile markers in cells 
cultured in both 1% FBS or 10% FBS for 3 days. However, the increase induced by 
1% FBS is significantly higher than that induced by 10% FBS (Figure 3-4 A, B). The 
same trend was observed when cells were cultured in medium with 5 ng/ml TGFβ1 
with 1% or 10% FBS. These results led us to conclude that low serum concentration 





Figure 3-4 Effect of serum concentration in SMC differentiation 
Compared to medium with 10% FBS, medium with 1% FBS has the better efficiency to induce 
the increase of SMC contractile genes, with or without 5 ng/ml TGFβ1. (A and B) At the 3-
day time point, cells in αMEM medium with 1% FBS displayed a higher increase of Calponin, 
SM22, αSMA and SMMHC. The same was observed in medium with 5 ng/ml TGFβ1. Data 
are shown as mean ± SEM. Statistics are obtained with one-way ANOVA test, followed by 
Bonferroni post-hoc analysis. *P < 0.05 and **P < 0.01. 
 
3.2.1.3 TGFβ1 stimulates SMC differentiation in a time-
dependent manner 
We have established that differentiation medium containing 1% FBS and 5 ng/ml 
TGFβ1 showed optimal ability to induce hUCMSCs differentiation towards SMCs. 
Therefore, this medium was applied in following experiments. The time course of 
differentiation from 6 hours to 5 days was studied. The quantitative gene expression 
was analysed at all the time points. Results demonstrated that all SMC markers 
started to increase at a low level from 6 hours of differentiation and continued to 





Figure 3-5 Time course study of SMC marker expression in hUCMSCs treated with 
TGFβ1 
(A and B) Human UCMSCs were induced to differentiate into SMCs in a time-dependent 
manner at the mRNA level. Differentiation medium consists of αMEM with 1% FBS and 
5ng/ml TGFβ1. Each time point was compared to the time point next to each other. Data are 
shown as mean ± SEM. Statistics are obtained with one-way ANOVA test, followed by 
Bonferroni post-hoc analysis. *P < 0.05; **P < 0.01 and ***P < 0.001. 
 
3.2.2 Morphology of hUCMSC-derived SMCs 
We observed a different morphology of hUCMSC-derived SMCs (differentiated in 
αMEM with 1% FBS and 5 ng/ml TGFβ1 for 3 days), as compared to the 
undifferentiated MSCs. While undifferentiated MSCs displayed a stellate, fibroblastic 
morphology, differentiated cells displayed more of a spindle shape morphology 
typically observed in SMCs (Figure 3-6).  
 
Figure 3-6 Morphology of hUCMSCs-derived SMCs and undifferentiated hUCMSCs 
hUCMSCs displayed a spindle shaped morphology after 3 days in differentiation medium 
(αMEM with 1% FBS and 5 ng/ml TGFβ1). Light microscope images displayed that MSC-
derived SMCs exhibited a SMC like morphology (B) compared to control cells (A). Images 
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were taken with Nikon Eclipse TS100 at 10X magnification. Images were representative of 3 
independent experiments. 
 
3.2.3 Expression of SMC specific markers in hUCMSC-derived 
SMCs at the protein level 
To confirm the expression of SMC markers at the protein level, Western blot analysis 
was performed on hUCMSC-derived SMCs at different time points. Differentiation 
medium consists of αMEM with 1% FBS and 5 ng/ml TGFβ1. SMC contractile 
markers significantly increased during the differentiation at the protein level (Figure 
3-7). 
 
Figure 3-7 Typical SMC marker changes of hUCMSCs-derived SMCs at the protein 
level 
hUCMSC differentiation medium consists of αMEM with 1% FBS and 5 ng/ml TGFβ1 and 
cells were differentiated for 1 day, 2 days and 3 days before being harvested. Seeding density 
for different time points are 1.8x106 /T75 flask, 1.5x106 /T75 flask, and 1.2x106 /T75 flask for 





Furthermore, expression of SMC markers at day 1 and 3 was examined by 
immunofluorescent staining. Cells were cultured in αMEM with 1% FBS and 5 ng/ml 
TGFβ1 for 1 day and 3 days followed by staining of Calponin, SM22, and αSMA. Cells 
cultured in mesenchymal stem cell basal medium for 3 days were used as 
undifferentiated control. In accordance with previous results, it was demonstrated that 




Figure 3-8 Immunofluorescent staining of hUCMSCs-derived SMCs for SMC markers 
Cells were cultured in αMEM with 1% FBS and 5 ng/ml TGFβ1 for 1 day and 3 days before 
being fixed and stained. Control undifferentiated cells were cultured in the mesenchymal stem 
cell basal medium until they reached 80% confluence. The seeding density was 2x104 
cells/well and 1.2x104 cells/well in 8 well chamber slides for 1 day and 3 days respectively. It 
was shown that SMC markers (αSMA, Calponin and SM22) significantly increased at day 3 
compared to control undifferentiated cells cultured in the basal medium. Representative 
picture of at least 3 experiments is shown. 
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3.3 Functional characterisation of differentiated SMCs 
derived from hUCMSCs 
To functionally characterise the SMCs differentiated from hUCMSCs, the cells were 
subjected to collagen gel contraction assay and subcutaneous Matrigel assay. SMCs 
differentiated from hUCMSCs displayed better contracting capacity as displayed by 
the collagen gel contraction assay compared to cells cultured without TGFβ1 (Figure 
3-9). Furthermore, the differentiated cells and control undifferentiated cells were 
separately mixed with human umbilical vein endothelial cells (HUVECs) into Matrigel 
and injected subcutaneously into the mouse. H&E staining showed finer tubular 
structures in Matrigel plug with differentiated cells and HUVECs, which was not 
observed in Matrigel plugs containing undifferentiated hUCMSCs and HUVECs 
(Figure 3-10 A). Immunofluorescent staining of Matrigel plug frozen sections with 
SMC marker αSMA and endothelial marker CD31 demonstrated close proximity of 





Figure 3-9 Collagen gel contraction assay showed better contractility of SMCs 
differentiated from hUCMSCs compared to cells cultured without TGFβ1 
hUCMSCs cultured in medium (αMEM with 1% FBS with or without 5 ng/ml TGFβ1) were 
both detached and then mixed with collagen gel. The final concentration of the cells was 
2x105 /500 μl, and the final concentration of the collagen gel was 2 mg/ml. Neutralisation of 
the mixture was with the addition of 5 μl of 1 M NaOH. 500 μl of the neutralised mixture was 
added to one well of 24 well plates in triplicates for 24 hours before the gelled cell-collagen 
mixture was detached by pipette tips. (A) Pictures were taken 5 hours after the detachment. 
(B) The ratio of the surface area was calculated with the mean value of the surface area 
analysed with ImageJ between triplicates. Data are obtained from at least three independent 




Figure 3-10 Subcutaneous Matrigel plug assay demonstrated the potential of 
hUCMSCs-derived SMCs to form vessel-like structures 
hUCMSCs were differentiated with αMEM with 1% FBS and 5 ng/ml TGFβ1 for 5 days. After 
that 0.5 million differentiated cells were harvested and mixed with 0.5 million HUVECs in 100 
μl Matrigel and injected subcutaneously into nude mice. The same number of undifferentiated 
cells mixed with the same number of HUVECs was used as a control. The Matrigel plugs 
were harvested 2 weeks after the injection and subjected to cryostat sectioning. H&E staining 
and immunofluorescent staining of the slide were subsequently carried out. (A) H&E staining 
showed tubular structure formation with finer walls in the group containing hUCMSC-derived 
SMCs and HUVECs compared to control. (B) Immunofluorescent staining demonstrated the 
proximity of EC marker CD31 and SMC marker αSMA as well as an upregulation of SMC 
marker αSMA in the group with hUCMSC-derived SMCs and HUVECs compared to control. 
Four Matrigel plugs were obtained in each experiment group. Undiff + HUVECs means the 
mixture of undifferentiated hUCMSCs with HUVECs and diff + HUVECs means the mixture 
of differentiated hUCMSCs with HUVECs.  
 
3.4 Mechanism involved in hUCMSC towards SMC 
differentiation: confirmation of established mechanism 
As discussed earlier, Myocardin and SRF are potent regulators of SMC differentiation. 
Therefore, we evaluated their expression along the process of MSC to SMC 
differentiation. The result demonstrated that Myocardin and SRF expression had a 
transient upregulation at 6 hours and lasted for 24 hours (Figure 3-11). Therefore we 
hypothesised that this increase contributed to the induction of SMC specific markers 
(Calponin, SM22, αSMA, and SMMHC) which also started to express at the time as 
early as 6 hours and lasted for 5 days. There is evidence that the increase of 
Myocardin and SRF levels could promote their interaction, and then drive the gene 
expression at the CArG element of the controlled genes, including almost all SMC 
markers. Therefore, the increase of Myocardin and SRF levels at the early time point 
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of the differentiation process might play an important role in initiating and further 
enhancing the SMC contractile gene expression.  
 
 
Figure 3-11 Time course study of Myocardin and SRF expression 
Myocardin and SRF, two important regulators for SMC differentiation, were induced at early 
time point (6 hours and 24 hours). The increase peaked at 6 hours and then decreased. Data 
are obtained from at least three experiments and shown as mean ± SEM. Statistics are 
obtained with one-way ANOVA test, followed by Bonferroni post-hoc analysis. *P < 0.05. 
 
MicroRNAs are of vital importance in regulating SMC differentiation process by 
regulating the expression of proteins that play important roles in SMC differentiation. 
Among these microRNAs, miR-145 is well established to induce the expression of 
SMC contractile proteins by repressing the expression of Klf4 and Elk1. As both Klf4 
and Elk1 are SMC differentiation repressors, working by recruiting HDAC2 and 
HDAC5 to the Myocardin-SRF-CArG complex (Yoshida et al., 2008). HDAC2 and 
HDAC5 subsequently decrease acetylated histones (Yoshida et al., 2008). As a result, 
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decreased KLF4 and ELK1 promote acetylation of the histone within CArG elements, 
which respectively increases the expression of SMC contractile markers. During 
hUCMSC differentiation towards SMCs, miR-145 level was detected and found to 
increase steadily over the first 24 hours (Figure 3-12). Besides, microRNA array 
analysis was performed for undifferentiated MSCs, cells differentiated towards SMCs 
for 6 hours and 24 hours. Novel microRNAs and their target genes regulating the 
differentiation would be further explored, which could shed new light on SMC 
differentiation mechanism.  
 
Figure 3-12 Time course study of miR-145 expression in hUCMSCs differentiated with 
TGFβ1 
The level of miR-145 was increased at early time points of SMC differentiation. Differentiation 
medium (αMEM with 1% FBS and 5 ng/ml TGFβ1) led to the increase of miR-145 during the 
process. Data are from one experiment.  
3.5 Mechanism involved in hUCMSC towards SMC 
differentiation: miRNA-oriented mechanism 




To search for novel miRNAs involved in SMC differentiation, hUCMSCs differentiated 
for 6 hours and 24 hours were harvested and subjected to miRNA array analysis with 
undifferentiated hUCMSCs as control. The miRNAs upregulated more than 1.5-fold 
or downregulated more than 0.5-fold in comparison with the level in undifferentiated 
samples at either 6-hour time point or 24 hour time point were selected as shown in 
the tables (Table 3-1 and Table 3-2). P value indicates the statistical significance of 
the fold change. The cutoff value of the fold change was selected according to several 
published studies which also utilised miRNA array to provide valuable information 
about miRNAs involved in diseases or pathological processes (He et al., 2005; Kung 
et al., 2017). It has been established that miR-143 and miR-145 are important 
regulators in determining smooth muscle cell fate (Cordes et al., 2009). Consistent 
with what has been reported in the literature, miR-143-5p and miR-145-5p were 
upregulated in the differentiated hUCMSCs at 24-hour time point in the microRNA 
array analysis when compared to undifferentiated cells, although the level of miR-
143-5p and miR-145-5p was not altered after 6 hours of differentiation (Table 3-1). 
Notably, this pattern of miR-145 expression is in accordance with what has been 
confirmed by the TaqMan miRNA assay (Figure 3-12). These collectively served as 
evidence that results obtained from the microRNA array are robust and of predicative 
value.  
Among all the miRNAs that were upregulated, apart from the established miR-
143/145 family of miRNAs, miRNAs among the upregulated group are from the miR-
15 family, including the miR-503 mature strand miR-503-5p and the miR-503 star 
strand miR-503-3p. Furthermore, stem loop forms or precursor forms of miR-503 and 
miR-424 are both upregulated. There were several studies published demonstrating 
the importance of miR-424 and miR-503 in pulmonary hypertension (Kim et al., 2013) 
and diabetes mellitus-related vascular dysfunction (Caporali et al., 2015). In both 
studies, the effect of miR-503 or miR-424 has in part attributed to their roles in 
regulating pericyte or smooth muscle cell function. In addition, miR-424/322 (miR-322 
is the ortholog of miR-424 in rats) displayed protective role in neointimal formation in 
the rat by inhibiting smooth muscle proliferation and preventing the phenotypic 
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switching to secretory phenotype (Merlet et al., 2013). Collectively, these studies 
implied the probable involvement of miR-503 and miR-424 in the smooth muscle-
related pathological processes, but it merits further examination whether they play 
any regulatory role in smooth muscle differentiation from stem cells, which is the main 
issue being explored in the present study. Other upregulated miRNAs including hsa-
miR-6890-5p, hsa-miR-6780b-5p, hsa-miR-7106-5p, hsa-miR-6730-5p, hsa-miR-
6813-5p and hsa-miR-670-5p are not reported to be related to any physiological or 
pathophysiological conditions yet. Hsa-miR-3651 was found to be a promising 
biomarker of oral squamous cell carcinoma and oesophageal squamous cell 
carcinoma (Ries et al., 2014; Wang et al., 2015). More importantly, none of these 
miRNAs were reported to be related to cardiovascular diseases in any studies. 
Therefore, we excluded these miRNAs for further investigation. 
In addition to the upregulated miRNAs, the list of downregulated miRNAs was also 
examined (Table 3-2). After reviewing the literature with all the miRNAs in the list, we 
found that most of them are more related to diverse types of cancers rather than 
cardiovascular diseases. The exception was miR-222. Thus, miR-222-5p was 
selected as a further candidate. Even though miR-222-5p is the star strand of miR-
222, which was conventionally interpreted as the non-functional miRNA strand, this 
concept is gradually changed with star strand of various miRNAs getting recognised 
as functional participants in physiological or pathophysiological processes (Yang et 
al., 2011).  
Before moving on to check the involvement of these selected miRNAs in the 
regulation of smooth muscle differentiation process, the expression of these miRNAs 
in differentiated cells at the chosen time points as well as upon the treatment with 
TGFβ1 were first confirmed with TaqMan miRNA assay (Figure 3-13). Consistent with 
microRNA array results, the level of miR-503-5p and miR-424-5p was both 
significantly increased after 24-hours of differentiation, and miR-222-5p was 
significantly downregulated both at both 6-hour and 24-hour time points (Figure 3-13 
A). Moreover, the changes in expression of these miRNAs are all in a time-dependent 
manner. Additionally, the expression of these miRNAs was also compared between 
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samples treated with or without TGFβ1, with the intention to determine the attribution 
of TGFβ1 in the change of miRNA level (Figure 3-13 B). It was revealed that TGFβ1 
was the indeed the major contributor to the miRNA level changes, which suggests 
the possible involvement of these miRNAs in TGFβ1 signalling pathways, although 
further investigations are needed to decide the specific signalling pathways. 
Although miR-503-3p was significantly upregulated after being cultured in 
differentiation medium for 6 hours in miRNA array, this was not replicated with 
TaqMan miRNA assay. The expression level of miR-503-3p fluctuated too much 
which compromised the stability of the expression. For this reason, miR-503-3p was 
not included in further experiments and miR-503 would be used to refer to miR-503-





Table 3-1 List of miRNAs that are upregulated during the differentiation process 
miRNAs 
6 h vs undiff  
fold change 
6 h vs undiff  
p value 
24 h vs undiff  
fold change 
24 h vs undiff  
p value 
Stem loop 
hsa-mir-424 1.90669 0.02065172 2.03778 0.064650457 
Stem loop 
hsa-mir-503 1.88365 0.004096631 1.26284 0.113026727 
hsa-miR-503-3p 8.54808 0.006320632 1.42198 0.309534797 
hsa-miR-503-5p 1.57691 0.087578228 2.40261 0.007192791 
hsa-miR-145-5p 0.942784 0.09197638 1.52203 0.005327755 
hsa-miR-145-3p 1.43283 0.258517561 1.74432 0.092687102 
hsa-miR-143-5p 1.35169 0.260788654 3.6681 0.03070377 
hsa-miR-6890-5p 1.46115 0.108594122 2.47409 0.041962345 
hsa-miR-6780b-
5p 0.739608 0.242151849 2.15985 0.014754481 
hsa-miR-3651 1.87207 0.026502945 1.97064 0.152838709 
hsa-miR-7106-5p 1.83961 0.016278885 1.73873 0.164114267 
hsa-miR-6730-5p 1.33398 0.164746662 1.49796 0.031673769 
hsa-miR-6813-5p 2.1279 0.007201024 1.21515 0.468215359 







Table 3-2 List of miRNAs that are downregulated during the differentiation process 
miRNAs 
6 h vs undiff  
fold change 
6 h vs undiff  
p value 
24 h vs undiff 
fold change 
24 h vs undiff  
p value 
hsa-miR-222-5p 0.290659 0.001763729 0.0931996 0.005217518 
hsa-let-7a-2-3p 0.331328 0.004959387 0.365227 0.030661528 
hsa-miR-4443 0.398348 0.020406356 0.34834 0.048534934 
hsa-miR-3617-5p 0.487689 0.00411999 0.427699 0.002948294 
hsa-miR-5100 0.506476 0.003142387 0.470805 0.017901315 
hsa-miR-92a-1-5p 0.356325 0.053660566 0.227752 0.030589371 
hsa-miR-3617-5p 0.487689 0.00411999 0.427699 0.002948294 
hsa-miR-378f 0.864318 0.204306421 0.437807 0.049394981 
hsa-miR-758-5p 0.424597 0.060956051 0.451407 0.004627807 
hsa-miR-1303 0.701947 0.235036451 0.468029 0.043837473 
hsa-miR-1260b 0.716034 0.090153928 0.484455 0.000412866 
hsa-miR-4286 0.477653 0.011969736 0.484873 0.027230141 






Figure 3-13 Change of miRNA expression during the differentiation process 
confirmed by TaqMan miRNA assay 
(A) MiR-503-5p and miR-424-5p were confirmed to be significantly upregulated 24 h after 
being seeded in differentiation medium, while miR-222-5p was significantly downregulated. 
(B) The upregulation of miR-503-5p and miR-424-5p as well as the downregulation of miR-
222-5p was mediated by TGFβ1. hUCMSCs were cultured in basal medium for one day 
before the medium was changed αMEM with 1% FBS with or without TGFβ1. Cells were 
harvested 24 hours after the medium change. Data are shown as mean ± SEM and are 
analysed from at least three experiments. Statistics are obtained with one-way ANOVA test, 
followed by Bonferroni post-hoc analysis. *P < 0.05 and ***P < 0.001. 
 
3.5.2 MiR-503 is transcriptionally upregulated through Smad4-
dependent pathway and promotes SMC differentiation through 
directly targeting Smad7 
As established earlier, miR-503 and miR-424 were among the upregulated miRNAs 
and therefore were further studied to determine their role in MSC-SMC differentiation. 
To achieve this goal, miRNA mimics and inhibitors were utilised to examine the gain-
of-function and loss-of-function effects of miR-503. The transfection efficiency was 
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first confirmed 24 hours after transfection as shown by the more than 100-fold 
increase in miR-503 expression in cells transfected with the miR-503 mimics when 
compared to those transfected with miRNA control mimics (Figure 3-14 A). 
Transfection of miR-503 mimics in hUCMSCs promotes SMC differentiation with 
increased expression of SMC markers including Calponin, SM22, αSMA and SMMHC 
at the mRNA level after 3 days as confirmed by Q-PCR (Figure 3-14 B). Upregulation 
of Calponin, SM22 and αSMA was further confirmed by their increased protein level 
using Western blot analysis (Figure 3-14 C and D).  
Loss-of-function effects of miR-503 were demonstrated by the transfection of miR-
503 inhibitors in the cells. One day after transfecting the cells with inhibitors, the level 
of miR-503 was significantly decreased (Figure 3-15 A). SMC markers including 
Calponin, SM22, and αSMA were not altered at the gene expression level as shown 
by Q-PCR (Figure 3-15 B). But moderate reduction in expression of these SMC 
markers could be observed at the protein level (Figure 3-15 C and D). This suggested 
that some other post-transcriptional regulation processes influencing mRNA 
translation and protein stability might exist (Filipowicz et al., 2008).  
MiR-424 belongs to the same miRNA family as miR-503. The level of miR-424 was 
upregulated during the differentiation process. The gain-of-function study with miRNA 
mimic transfection experiments showed the potential of miR-424 to promote SMC 
differentiation as demonstrated by the upregulation of SMC markers Calponin and 
SM22 3 days after transfection (Figure 3-16). However, the degree of expression 
changes in both markers at the gene expression level by miR-424 overexpression 
was not as great as that induced by miR-503 mimics. Furthermore, αSMA and 
SMMHC was not significantly altered (Figure 3-16), which implied the limited capacity 
of miR-424 in inducing SMC differentiation. In the view of the greater capacity of miR-
503 in promoting MSC-SMC differentiation, miR-503 was therefore chosen to be 




Figure 3-14 miR-503 mimic promotes SMC differentiation from hUCMSCs 
HUCMSCs were seeded in culture flask at 1x104  /cm2 and allowed to grow for one day before 
transfection with either miR-503 mimics or control mimics using lipofectamine RNAiMax with 
the final concentration of 12.5 nM. The medium was changed every second day. (A) miR-
503-5p is significantly upregulated 24 hours after transfection. Transfection of miR-503 
promoted the differentiation of SMCs as shown by the change of SMC markers including 
Calponin, SM22, αSMA and SMMHC, both at the gene expression level (B) and at the protein 
level (C) as demonstrated with q-PCR and Western blot 3 days after transfection. Statistical 
analysis of protein level change from three in dependent experiments was also shown (D). 
Mim ctrl indicates miRNA mimic negative control, and mim 503 indicates the treatment of 
cells with miR-503 mimics. Data are obtained from at least three independent experiments 
and shown as mean ± SEM. Statistics are obtained with student t-test. *P < 0.05; **P < 0.01 




Figure 3-15 miR-503 inhibitor downregulates SMC differentiation from hUCMSCs 
HUCMSCs were seeded in culture flask at 1x104 /cm2 and allowed to grow for one day before 
transfection with miR-503 inhibitor or control inhibitor using lipofectamine RNAiMAX, with 
final concentration of 62.5 nM. The medium was changed every second day. (A) MiR-503-5p 
is significantly downregulated 24 hours after transfection of miR-503 inhibitor. (B) Inhibition 
of miR-503-5p did not inhibit the SMC marker expression at the gene expression level. (C 
and D) Treatment of miR-503-5p inhibitor in the cells downregulated SMC markers at the 
protein level, however, the inhibition was only statistically significant in Calponin and SM22. 
Inhi ctrl indicates the negative control of miR-503, and inhi 503 indicates the miR-503 
inhibitors. Data are obtained from at least three independent experiments and shown as 





Figure 3-16 miR-424 promotes SMC differentiation, but at a lesser degree compared 
to miR-503 
HUCMSCs were seeded in culture flask at 10000/cm2 and allowed to grow for one day, before 
transfection with either miR-424 mimic or control mimic using lipofectamine RNAiMax, with 
final concentration of 12.5 nM. SMC markers Calponin and SM22 were significantly 
upregulated 3 days after transfection, whereas no statistically meaningful change was 
observed for αSMA and SMMHC. Mim ctrl indicates miRNA mimic negative control, and mim 
424 indicates the treatment of cells with miR-424 mimics. Data are obtained from at least 
three independent experiments and shown as mean ± SEM. Statistics are obtained with 
student t-test. *P < 0.05. 
 
3.5.2.1  Exploration of potential targets of miR-503 
In the exploration of potential targets of miR-503, algorithm based bioinformatic 
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As introduced earlier, miRNAs functions by binding to the 3’-UTR region of target 
mRNA and induce mRNA degradation or translation inhibition. Prediction of miRNA 
targets could be based on the mainstream seed site rule. It was explained earlier in 
the introduction that the most prominent miRNA targets bind with miRNAs in a 
complimentary mode to the 2nd to 7th nucleotides at the 5’ end. Binding of the 8th 
nucleotide to the mRNA and the presence of an A at 3’ end of the target sites on the 
mRNA further increases the reliability of target prediction. However, these target 
prediction algorithms will need further experimental validation. 
To predict targets of miR-503, TargetScan and miRbase were mainly used for 
algorithm based target prediction. After obtaining the list of predicted targets, further 
screening for those related to TGFβ1 signalling pathway was carried out, given the 
importance of TGFβ1 in SMC differentiation and the involvement of it in promoting 
miR-503 expression. Among these, mothers against decapentaplegic homolog 7 
(Smad7), SMAD specific E3 ubiquitin protein ligase 2 (Smurf2), Ski, ADP ribosylation 
factor like GTPase 2 (Arl2) and E2F transcription factor 3 (E2F3) were selected for 
further analysis. Smad7, Smurf2 and Ski are potent negative regulators of the TGFβ1 
signalling pathway (Deheuninck and Luo, 2009; Kavsak et al., 2000; Nakao et al., 
1997). E2F3 is a transcription factor implied in other pathological processes to be 
indirectly involved in TGFβ1 signalling (Hu et al., 2000). Arl2 is a GTPase that might 
be indirectly involved in ROCK/GTPase pathway which could affect SMC 
differentiation and it has been validated to be a direct target of miR-424 (Nishi et al., 
2010). Genome browsing in the UCSC genome sequence database confirmed that 
the 3’-UTR segments of these selected genes all contain at least one site of 
“GCUGCUA” sequence. 
One day after transfecting the cells with miR-503 mimics, which would give rise to 
miR-503-5p strand within the cells, the samples were harvested and subjected to 
gene expression analysis with Q-PCR. Although the best way to experimentally 
screen for miRNA targets is to examine the expression changes at the protein level 
since miRNA may target that mRNA by translation inhibition rather than mRNA 
degradation, it requires much more efforts to validate all possible targets with Western 
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blot. Therefore, we started the screening process with gene level detection. It was 
shown in samples transfected with miR-503 mimics for one day that only Arl2 level 
was clearly downregulated (Figure 3-17 A). This is reasonable since 3 sites of 
“GCUGCUA” were found in the 3’-UTR segment of Arl2 mRNA which might allow a 
stronger target recognition and subsequent inhibition by miR-503. Although Smad7 
and Smurf2 level was not downregulated, given their importance to negatively 
regulate Smad-dependent TGFβ1 signalling pathways, their level was examined 
further after a longer exposure time of cells to miR-503 mimics. Three days after 
transfection with miR-503 mimics, mRNA expression of Smad7 was significantly 
downregulated, whereas Smurf2 is instead upregulated after three days (Figure 3-17 
B). These indicated that the downregulated SMAD7 could potentially be a target of 
miR-503, while the upregulated SMURF2 is not likely the target since this is not 
consistent with the inhibitory effect of miRNA. Thus, Smurf2 was excluded as a direct 
target of miR-503 and not checked further in future experiments. Arl2 was still greatly 
suppressed at the three-day time point by miR-503 mimics which makes it a 
promising direct target of miR-503, but a further functional study of it was required to 
establish its role in SMC differentiation system in which it was not demonstrated 
before in literature to be involved (Figure 3-17 B). Validation of the protein level 
change for Smad7 and Arl2 showed significant downregulation after 3 days of 
treatment in miR-503 mimics (Figure 3-18 A and B).  
The time-dependent and TGFβ1-dependent changes of these two markers were also 
examined. Smad7 was upregulated with increased time of differentiation and by 
TGFβ1 at the gene expression level, whereas Arl2 was downregulated with time and 
by TGFβ1 at the gene expression level (Figure 3-19). Collectively, these results 
strongly imply that Smad7 and Arl2 might be targets of miR-503, and as expression 
of both genes change upon TGFβ1 stimulation, they both might be involved in TGFβ1 




Figure 3-17 Expression of potential targets after miR-503 mimic treatment 
HUCMSCs were treated with miR-503 mimics and then harvested for after one day for gene 
expression analysis. (A) Potential targets including Smad7, Smurf2, Ski, Arl2 and E2F3 were 
examined with q-PCR. Arl2 was the only gene found to be downregulated with miR-503 
treatment one day after mimic transfection. Results were from 2 independent experiments. 
(B) The effect of miR-503 mimic on Smad7 and Arl2 3 days after transfection was also 
explored and a statistically significant decrease of these two genes at the gene expression 
level was observed. Mim ctrl indicates miRNA mimic negative control, and mim 503 indicates 
the treatment of cells with miR-503 mimics. Data are obtained from at least three independent 





Figure 3-18 Change at the protein level after miR-503 mimic treatment 
HUCMSCs were treated with miR-503 mimics and then harvested 3 days after transfection.  
(A) Both Smad7 and Arl2 were significantly downregulated at the protein level as 
demonstrated by Western blot. (B) Statistical analysis of the Western blot results showed 
consistent results. Mim ctrl indicates miRNA mimic negative control, and mim 503 indicates 
the treatment of cells with miR-503 mimics. Image is representative of at least three 





Figure 3-19 Time-dependent and TGFβ1-dependent changes of Smad7 and Arl2 
expression 
(A) HUCMSCs were differentiated in differentiation medium (αMEM with 1% FBS and 5 ng/ml 
TGFβ1) for 1, 2 and 3 days and then harvested for gene expression analysis for Smad7 and 
Arl2 with q-PCR. Undifferentiated cells were used as a control. (B) The change of Smad7 
and Arl2 at the gene expression level after 2 days in culture was also examined between 
TGFβ1 treated and untreated group to confirm the relationship of the change with TGFβ1. 
Undiff indicates undifferentiated cells that were kept in basal medium. 0 indicates that the 
cells were cultured in medium (αMEM with 1% FBS) without TGFβ1, and 5 indicates that the 
cells were cultured in medium (αMEM with 1% FBS) with 5 ng/ml TGFβ1. Data are obtained 
from at least three independent experiments and shown as mean ± SEM. Statistics are 
obtained with student t-test. *P < 0.05 and **P < 0.01. 
 
3.5.2.2 Promotion of SMC differentiation by miR-503 is not through Arl2 
inhibition 
As displayed in previous experiments, Arl2 and Smad7 were the two main potential 
targets for miR-503. Arl2 was subjected to further examination first. It was shown in 
cardiac myocytes that miR-15b family could directly target Arl2 and modulate cellular 
ATP levels through mitochondrial degeneration (Nishi et al., 2010). Although it was 
miR-424 but not miR-503 that was included in the study, miR-503 and miR-424 
belong to the same miRNA family and share similar seed sequence. It was 
reasonable to postulate that miR-503 could also directly target Arl2 3’-UTR sequence. 
Furthermore, no published study has yet established Arl2 in relation to SMC 
differentiation process. To examine the function of Arl2, loss-of-function study by 
siRNA knockdown was carried out. Arl2 gene knockdown was firstly confirmed with 
Q-PCR with the decrease of Arl2 at the gene expression level 2 days after treating 
the cells with Arl2 siRNA. However, a further check on SMC markers including 
Calponin, SM22 and αSMA did not reveal any change at the gene expression level 
(Figure 3-20). Further examination at the protein level was not carried out later as the 
experimental evidence suggests that Arl2 was not functionally involved in the SMC 
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differentiation process. Downregulation of Arl2 and subsequent incidents are not 
likely to be the driving factors for SMC differentiation. Although Arl2 could be a direct 
target of miR-503, and it was evident that Arl2 expression decreases during the 
differentiation process, after treatment with TGFβ1 and after transfection with miR-
503 mimics, Arl2 involved change might only be an unrelated subsequence of miR-
503 upregulation without a functional role in SMC differentiation. 
 
Figure 3-20 Arl2 gene knockdown by siRNA does not alter SMC differentiation 
HUCMSCs were seeded at 1x104 /cm2 for one day before getting transfected with Arl2 siRNA 
(Life Tech). Arl2 siRNA was transfected with RNAiMax in differentiation medium at a final 
concentration of 10 nM. Cells were harvested 2 days after transfection. (A) Gene expression 
level of Arl2 detection showed successful knockdown of Arl2 gene. (B) Examination of SMC 
markers including Calponin, SM22 and αSMA at the gene expression level did not 
demonstrate a statistically significant change of these markers. Si ctrl indicates siRNA 
negative control and si Arl2 indicates the knockdown of Arl2 by siRNA. Data are obtained 
from at least three independent experiments and shown as mean ± SEM. Statistics are 




3.5.2.3 MiR-503 promotes SMC differentiation through directly targeting 
Smad7 
Smad7 was an established negative regulator in the Smad-dependent TGFβ1 
signalling pathway (Kavsak et al., 2000). It works through binding to the activated 
type I receptor of TGFβ1 that blocks the binding of R-Smads to the receptor, or 
through recruiting ubiquitin E3 ligase Smurf1/2 and could result in the degradation of 
the receptor (Yan et al., 2009). Furthermore, Smad7 could be upregulated by TGFβ1 
which suggests a mode of negative feedback loop regulation. Consistent with what 
has been established in the literature, Smad7 upregulation in the differentiation 
process and upon treatment of TGFβ1 was also examined in my study.  
To further demonstrate whether miR-503 could participate in TGFβ1 signalling 
pathway through inhibition of Smad7, thereby promoting SMC differentiation, we first 
cloned Smad7 3’-UTR to a miRNA target reporter clone with firefly luciferase gene 
lying upstream of the Smad7 3’-UTR and Renilla luciferase as an internal control of 
the plasmid transfection efficiency. Target sites at Smad7 3’-UTR was pinpointed by 
miRNA target prediction algorithms and the target site was then mutated (Figure 3-
21 A). It was revealed that miR-503 could inhibit the relative luciferase activity 
compared to miRNA control, whereas the inhibition would be recovered if the target 
site on the 3’-UTR segment was mutated (Figure 3-21 B).  
After building up the direct inhibition relationship of miR-503 on Smad7, experiments 
to check the role of Smad7 in the present SMC differentiation system were carried 
out. Loss-of-function study by siRNA knock down experiments showed that loss of 
Smad7 could result in a moderate but statistically significant upregulation of SMC 
marker SM22 and αSMA at the mRNA level (Figure 3-22 A and B). At the protein 





Figure 3-21 Smad7 is a direct target of miR-503 
(A) Alignment of miR-503 and the 3’-UTR of smad7 gene showed the postulated target 
binding sites (marked in red) and induced mutations (marked in blue). 3’-UTR of Smad7 was 
cloned into a miRNA target reporter (Genecopoeia). (B) Co-transfection of miR-503 mimics 
and reporter with wild type Smad7 3’-UTR segment showed reduced relative luciferase 
activity as compared to vector with empty plasmid, while mutation of target binding sites 
recovered the reduction. Relative luciferase activity was calculated with firefly luciferase 
activity/Renilla luciferase activity. Mim ctrl indicates miRNA mimic negative control, and mim 
503 indicates the treatment of cells with miR-503 mimics. Data are obtained from at least 
three independent experiments and shown as mean ± SEM. Statistics are obtained from two-




Figure 3-22 Knockdown of Smad7 augmented SMC differentiation 
(A) Transfection of Smad7 siRNA resulted in a significantly lower level of Smad7 at the gene 
expression level after 1 day. (B) Cells were harvested 2 days after siRNA transfection for 
mRNA and protein analysis. Knockdown of Smad7 by siRNA upregulated the level of smooth 
muscle markers SM22 and αSMA at the mRNA level. (C and D) Knockdown of Smad7 by 
siRNA prompted a notable increase of Calponin at the protein level whereas the changes in 
SM22 and αSMA were not significant, as assessed by Western blot. Si ctrl indicates siRNA 
negative control and si Smad7 indicates the knockdown of Smad7 by siRNA. Q-PCR data 
are obtained from at least three independent experiments and shown as mean ± SEM. 
Western blot images are representative of at least three experiments. Statistics are obtained 
from unpaired student t-test. *P < 0.05 and ***P < 0.001. 
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3.5.2.4 TGFβ1 transcriptionally upregulates miR-503 through Smad4-
dependent pathway 
After establishing Smad7 as a direct target of miR-503, miR-503 was implied to be a 
new component of TGFβ1 signalling pathway. As demonstrated earlier, Smad7 and 
miR-503 are both transcriptionally upregulated by TGFβ1. A possible explanation of 
this is that the miR-503 upregulation could serve as a limiting factor to prevent the 
uncontrolled upregulation of Smad7. Smad7 is mainly involved in Smad-dependent 
TGFβ1 signalling pathway: its upregulation is activated through Smad4-dependent 
pathway and it exerts its inhibitory effect through inhibiting R-Smads from binding to 
TGFβ1 type I receptor. In addition, there is a direct relationship between miR-503 and 
Smad7. Thus, it is reasonable to postulate that the upregulation of miR-503, similar 
to Smad7, might be regulated by Smad-dependent TGFβ1 signalling pathway.  
To explore whether the hypothesis is valid, knockdown experiments of Smad4 was 
carried out since Smad4 is the co-Smad which is necessary for all R-Smads to 
function. Confirmation of Smad4 knockdown was shown by the significant decrease 
in expression of Smad4 and downstream SMC markers including Calponin, SM22 
and αSMA (Figure 3-23 A and B). Next, the level of miR-503 was examined after the 
Smad4 knockdown. The level of miR-503 was significantly downregulated when 
Smad4 is depleted in medium with TGFβ1, whereas its level is not affected if the 
medium does not contain TGFβ1 (Figure 3-23 C and D). These results imply that 
Smad4 might play a key role in TGFβ1 mediated upregulation of miR-503. 
To further explore the direct involvement of Smad4 in promoting miR-503 
upregulation, the physical interaction of Smad4 with the promoter region of miR-503 
was checked with ChIP experiments. Enrichment of Smad4 at the promoter region of 
miR-503 was confirmed. At the same time, Smad4 was not enriched at the promoter 
region of GAPDH, which served as a negative control and ensured the robustness of 




Figure 3-23 Upregulation of miR-503 by TGFβ1 is Smad4-dependent 
HUCMSCs were seeded in the culture flask at 1x104 /cm2 the day before Smad4 siRNA 
transfection. The final concentration of the siRNA was 5 nM. (A) Knockdown of Smad4 gene 
was confirmed with q-PCR 48 hours after transfection. (B) Smad4 knockdown also resulted 
in statistically significant downregulation of SMC markers including Calponin and SM22 at 
the gene expression level 2 days after transfection of Smad4 siRNA. Gene expression of 
αSMA also displayed a trend to be decreased, but it was not statistically significant. In the 
knockdown experiments cells were cultured in medium with 5 ng/ml TGFβ1. The level of miR-
503 was also checked after 48 hours. (C and D) It was found that Smad4 siRNA could 
downregulate miR-503 level in medium with TGFβ1 but not in medium without TGFβ1. Si ctrl 
indicates siRNA negative control and si Smad4 indicates the knockdown of Smad4 by siRNA. 
Data are obtained from at least three independent experiments and shown as mean ± SEM. 





Figure 3-24 Smad4 directly binds to the promoter region of miR-503 
HUCMSCs were cultured in medium (αMEM with 1% FBS) at 1x104 /cm2 for 24 hours before 
the medium is changed to serum free αMEM with antibiotics. After 5 hours starvation of the 
cells, TGFβ1 is added and cells are harvested 4 hours later for ChIP experiments. Cells 
cultured in the same condition but without TGFβ1 addition is used as a control. Different 
primers specific to the promoter region of the miR-503 promoter are used to detect the 
enrichment of Smad4 at the promoter region. A primer specific to GAPDH promoter region 
was used as a negative control. It was demonstrated that at the promoter region of miR-503 
that is detected by primer 2, the Smad4 was enriched. For GAPDH, Smad4 was not enriched 
in its promoter region. Data are obtained from at least three independent experiments and 
shown as mean ± SEM. Statistics are obtained with one-way ANOVA test, followed by 
Bonferroni post-hoc analysis. *P < 0.05. 
 
3.5.2.5 Schematic representation of miR-503-related differentiation 
mechanism 
Taken together, it could be concluded that miR-503 is transcriptionally upregulated 
upon TGFβ1 treatment through a Smad4-dependent pathway and subsequently 
targets Smad7 which is a negative regulator of Smad-dependent signalling pathway. 
(Figure 3-25) This adds another layer of regulation into the already complex network 




















tuning of various pathways, which could be crucial to obtain the balance of signalling 
pathways in physiological and pathophysiological conditions. 
 
Figure 3-25 Schematic representation of miR-503 in SMC differentiation 
Upon TGFβ1 treatment, Smad2/3 get phosphorylated by the activated receptors and binds 
to co-Smad Smad4. This complex would then be translocated into the nucleus and bind to 
the Smad binding element (SBE) of target gene promoters including SMC marker, Smad7 
and miR-503. Interestingly, Smad7 and miR-503 both display regulatory role in the TGFβ1 
signalling pathway, and their effects are contrary to each other. Smad7 takes its inhibitory 
effect in TGFβ1 Smad-dependent signalling pathway through blocking the direct binding of 
Smad to the receptor or phosphorylation of it. MiR-503 exerts further regulatory significance 
in TGFβ1 signalling pathway through imposing another layer by inhibiting Smad7. 
 
3.5.3 Downregulation of miR-222-5p in differentiation process is 
important for de-repression of SMC markers 
3.5.3.1 MiR-222-5p inhibits SMC differentiation from hUCMSCs 
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MiR-222-5p is the most prominent miRNA that was downregulated in the 
differentiation process as revealed by miRNA array and subsequent confirmation with 
TaqMan miRNA assay. The role of the miR-222 mature strand miR-222-3p has been 
established to have a crucial role in inhibiting SMC proliferation both in vitro and in 
vivo (Liu et al., 2009). Moreover, miR-222, which belongs to the same miRNA family 
as miR-221, was identified as an important modulator in platelet-derived growth factor 
(PDGF)-induced SMC phenotypic change (Davis et al., 2009). However, it is the 
mature strand that was studied in both studies, whereas the downregulated miR-222-
5p during MSC-SMC differentiation is the passenger strand, whose role has not been 
established. Although the passenger or star strand of miR-222 (i.e. miR-222-5p) was 
widely accepted to be destined for degradation without any function after maturation, 
numerous studies have recently emerged to depict the pathological importance of 
passenger strands of miRNAs (Bang et al., 2014; Matsushita et al., 2016). 
For the reasons mentioned above, even though miR-222-5p is the passenger strand, 
it was worth being examined for its role in SMC differentiation process. The influence 
of miR-222-5p on the differentiation process first was checked by transfecting miR-
222-5p mimics into hUCMSCs. The success of miRNA mimic transfection was 
confirmed by the significant increase of miRNA mimics inside the cells (Figure 3-26). 
Increased level of miR-222-5p prompts the downregulation of SMC markers including 
Calponin and αSMA both at the gene expression level as exhibited by Q-PCR (Figure 
3-27 A) and the protein level as exhibited by Western blot and immunofluorescent 
staining (Figure 3-27 B and C, Figure 3-28), thus demonstrated the capacity of miR-
222-5p mimics in inhibiting SMC differentiation. However, the influence of miR-222-
5p mimics on SM22 was limited which could be observed in the unchanged level of it 
both at the gene expression level and the protein level (Figure 3-27 and Figure 3-28). 
SMMHC level was not altered at the gene expression level but was downregulated at 
the protein level as displayed in the Western blot (Figure 3-27). Inhibitors of miR-222-
5p, which are single stranded RNAs that complimentary bind to miR-222-5p, were 
also used to treat the cells to provide information about the loss-of-function effect. 
MiR-222-5p level was significantly downregulated after treatment with miR-222-5p 
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inhibitor (Figure 3-29 A). MiR-222-5p inhibitors resulted in only limited upregulation 
of SMC markers including Calponin, SM22 and αSMA, with the fold change to be less 
than 1.5-fold (Figure 3-29 B). As revealed by the miRNA array and TaqMan miRNA 
assay, miR-222-5p level was significantly downregulated at 24-hour time point to 
around one tenth of its level in cells cultured in basal medium. Thus, on top of this 
downregulation, further inhibition of miR-222-5p might only have minimal effect. This 
might explain the asymmetry of the function between miR-222-5p mimics and 
inhibitors. 
 
Figure 3-26 miR-222-5p level is significantly upregulated after miR-222-5p mimic 
transfection 
HUCMSCs were cultured at the density of 1x104 /cm2 for 1 day in medium (αMEM with 1% 
FBS) before they were transfected with miR-222-5p mimics. The final concentration of the 
mimics was 12.5 nM. Cells were harvested 1 day after transfection. The success of miRNA 
mimic transfection was confirmed by the level of miR-222-5p inside the cells. Data are 
obtained from at least three independent experiments and shown as mean ± SEM. Statistics 
are obtained from unpaired student t-test. ***P < 0.001. 
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Figure 3-27 miR-222-5p mimic inhibits SMC differentiation as shown by Q-PCR and 
Western blot 
HUCMSCs were cultured at the density of 1x104 /cm2 for 1 day in medium (αMEM with 1% 
FBS) before they were transfected with miR-222-5p mimics. The final concentration of the 
mimics was 12.5 nM. Cells were harvested 2 days after transfection. Cells cultured in the 
same condition but transfected with miRNA mimic negative control was used as a control. 
TGFβ1 was not added to the medium in the entire process. (A) It was shown that miR-222-
5p mimics could downregulate the level of Calponin and αSMA at the gene expression level 
as demonstrated by q-PCR, but the effect on the SM22 and SMMHC expression was limited. 
(B) Examination of SMC markers at the protein level displayed downregulation of Calponin, 
αSMA and SMMHC, but there was no effect on SM22 level. (C) Statistical analysis of Western 
blot results showed significant inhibition of Calponin and αSMA. Mim ctrl indicates miRNA 
mimic negative control, and mim 222-5p indicates the treatment of cells with miR-222-5p 
mimics. Q-PCR data are obtained from at least three independent experiments and shown 
as mean ± SEM. Western blot images are representative of at least three independent 
experiments. Statistics are obtained from unpaired student t-test. *P < 0.05, **P < 0.01 and 








Figure 3-28 miR-222-5p mimic inhibits SMC differentiation as shown by 
immunofluorescent staining 
HUCMSCs were cultured at the density of 1x104 /cm2 for 1 day in medium (αMEM with 1% 
FBS) before they were transfected with miR-222-5p mimics. The final concentration of the 
mimics was 12.5 nM. Cells cultured in the same condition but transfected with miRNA mimic 
negative control was used as a control. TGFβ1 was not added to the medium in the entire 
process. Cells were fixed and stained 2 days after transfection and visualised with confocal 
microscope. Effect of miR-222-5p mimics on SMC markers at the protein level was also 
checked with immunofluorescence. The downregulation of Calponin and αSMA was evident 
by miR-222-5p mimics whereas no obvious effect of the mimics on SM22 at the protein level 
was observed. Mim ctrl indicates miRNA mimic negative control, and mim 222-5p indicates 
the treatment of cells with miR-222-5p mimics. Image shown here is representative of at least 
three independent experiments.  
 
 
Figure 3-29 miR-222-5p inhibitor promotes SMC differentiation 
HUCMSCs were cultured at the density of 1x104 /cm2 for 1 day in medium (αMEM with 1% 
FBS) before they were transfected with miR-222-5p inhibitors. The final concentration of the 
inhibitors was 62.5 nM. Cells were harvested 2 days after transfection. Cells cultured in the 
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same condition but transfected with miRNA inhibitor negative control was used as a control. 
TGFβ1 was not added to the medium in the entire process. (A) Successful inhibition of miR-
222-5p level was confirmed by the significant downregulation of miR-222-5p level inside the 
cells. (B) It was shown that miR-222-5p inhibitor could to some extent promote SMC 
differentiation as demonstrated by the upregulation of SMC markers Calponin, SM22 and 
αSMA, but the promotion ability is limited since the fold change of the SMC markers are 
minimal and are less than 1.5. Data are obtained from at least three independent experiments 
and shown as mean ± SEM. Statistics are obtained from unpaired student t-test. *P < 0.05 
and ***P < 0.001. 
 
3.5.3.2 3’-UTR of αSMA is a direct target of miR-222-5p 
Given the prominent inhibitory effect of miR-222-5p mimics on αSMA expression both 
at the gene expression and the protein levels, it was postulated that αSMA 3’-UTR 
might be directly targeted by miR-222-5p which that results in the degradation of 
αSMA mRNA and subsequent decreased expression of αSMA at the protein level. 
To test this hypothesis, the sequence of miR-222-5p was aligned with αSMA mRNA 
and complementarity was found at both the 5’ and 3’ end of miR-222-5p with the 3’-
UTR of αSMA mRNA (Figure 3-30 A).  Luciferase reporter gene assays with inserts 
of either αSMA 3’UTR sequence or mutated sequence at predicted complementary 
sites were then utilised to validate whether 3’-UTR of αSMA mRNA could be directly 
targeted by miR-222-5p. Dual transfection of the plasmid encoding αSMA 3’-UTR 
sequence and miR-222-5p mimics into HEK293 cells revealed that miR-222-5p 
mimics inhibited αSMA 3’-UTR and mutation of the target site on the 3’-UTR rescued 
the inhibition (Figure 3-30 B). However, the rescue of the inhibition was not 
statistically significant (Figure 3-30 B). Collectively, this evidence implies that miR-
222-5p might directly target αSMA 3’-UTR and lead to downregulation of αSMA both 




Figure 3-30 3’-UTR of αSMA is a direct target of miR-222-5p 
(A) Alignment of miR-222-5p sequence and partial sequence of αSMA 3’-UTR was shown in 
the figure. The possible complimentary binding between the two sequences are marked in 
red. Mutation of the predicted binding site was mutated which was marked in blue. (B) The 
3’-UTR of αSMA was constructed into miRNA target reporter plasmids with humanised firefly 
luciferase as a reporter of the inhibition of target 3’-UTR and the Renilla luciferase as the 
internal control of plasmid transfection efficiency (Genecopoeia). Dual transfection of 
plasmids and miR-222-5p into HEK293 cells demonstrated the inhibition of the miRNA on the 
3’-UTR of αSMA, and mutation of the predicted target site recovered the inhibition. No 
significant influence of miR-222-5p on empty plasmid or miRNA mimic negative control on 
the plasmid with 3’-UTR of αSMA was observed. Data are obtained from at least three 
independent experiments and shown as mean ± SEM. Statistics are obtained with two-way 





3.5.3.3 ROCK2 is a potential target of miR-222-5p 
Although αSMA was demonstrated as a direct target of miR-222-5p, it was not 
sufficient to explain the potent inhibition of Calponin upon treatment of cells with miR-
222-5p mimics. Probable explanation was that miR-222-5p in the meanwhile had 
other targets that could affect SMC differentiation. As introduced earlier, SMC 
differentiation could also be promoted through RhoA/ROCK pathway. Thus, proteins 
in this pathway along with proteins involved in Smad-dependent TGFβ1 signalling 
pathway was checked to see whether there were any potential miR-222-5p targets. 
3’-UTR sequences of selected genes were subjected to screening to search for the 
putative seed site of miR-222-5p “CTACTGA”. It was revealed that ROCK2 contained 
two putative seed sites which strongly implied that it might be targeted by miR-222-
5p.  
Before moving on to examine the gain- and loss-of-function effect of ROCK2 in the 
differentiation process and the direct interaction between miR-222-5p and ROCK2, 
the expression of ROCK2 during MSC-SMC differentiation was firstly explored. Q-
PCR analysis demonstrated an upregulation of ROCK2 at the gene expression level 
in a time-dependent manner (Figure 3-31 A). However, no definite influence of TGFβ1 
on the ROCK2 level was demonstrated (Figure 3-31 B). Next, the ROCK2 level was 
investigated after miR-222-5p mimic treatment. Q-PCR analysis showed the 
downregulation of ROCK2 at the gene expression level 1 day after miR-222-5p mimic 
treatment (Figure 3-32 A). Protein level inhibition was also demonstrated by Western 
blot analysis and immunofluorescent staining (Figure 3-32 B and Figure 3-33). To 
conclude, ROCK2 expression changes in a time-dependent manner during 





Figure 3-31 ROCK2 level is upregulated in a time-dependent manner but not TGFβ1-
dependent manner 
HUCMSCs were differentiated in differentiation medium (αMEM with 1% FBS and 5 ng/ml 
TGFβ1) at 1x104 /cm2 for 1 to 3 days before being harvested. ROCK2 level was detected with 
primer at the gene expression level with q-PCR. (A) It was shown that ROCK2 level increased 
in a time-dependent manner along with the differentiation process. (B) In comparison with 
cells cultured in the same condition but without TGFβ1, it was found that ROCK2 level was 
not altered in cells cultured with TGFβ1. Data are obtained from at least three independent 
experiments and shown as mean ± SEM. Statistics are obtained with one-way ANOVA test, 





Figure 3-32 ROCK2 is inhibited by miR-222-5p 
HUCMSCs were cultured in medium (αMEM with 1% FBS) for 1 day at the density of 1x104 
/cm2 before being transfected with miR-222-5p mimics. Final concentration of miR-222-5p 
mimics was 12.5 nM. TGFβ1 was not added in the entire process. Cells were harvested 1 
day after transfection for q-PCR analysis. (A) It was shown that miR-222-5p mimics could 
potently inhibit the level of ROCK2 at the gene expression level. (B) Further protein level 
examination of ROCK2 1 and 2 days after miR-222-5p mimic treatment was conducted with 
Western blot analysis. It was demonstrated that ROCK2 could be greatly inhibited at the 
protein level as early as 1 day after mimic treatment and this inhibition persisted until 2 days 
after the treatment. Q-PCR data are obtained from at least three independent experiments 
and shown as mean ± SEM. Western blot images are representative of at least three 






Figure 3-33 ROCK2 is inhibited at the protein level by miR-222-5p mimics 
HUCMSCs were cultured in medium (αMEM with 1% FBS) for 1 day at the density of 1x104 
/cm2 before being transfected with miR-222-5p mimics. Final concentration of miR-222-5p 
mimics was 12.5 nM. TGFβ1 was not added in the entire process. Cells were harvested 2 
days after transfection for Immunofluorescent staining of ROCK2. It was shown in the figure 
that miR-222-5p mimic could downregulate the expression of ROCK2 at the protein level as 
observed by immunofluorescent staining. Images shown here are representative of at least 





3.5.3.4 ROCK2 knockdown by siRNA inhibits SMC differentiation 
Two requirements are elemental for ROCK2 to be a direct functional target of miR-
222-5p. First, ROCK2 needs to be functionally involved in the differentiation process. 
Secondly, miR-222-5p should directly target the 3’-UTR segment of ROCK2. 
Knockdown of ROCK2 with siRNA was first examined to check the importance of 
ROCK2 in SMC differentiation. Confirmation of ROCK2 knockdown was first 
demonstrated at both the gene expression and protein level (Figure 3-34 A, C and 
Figure 3-35). Subsequent examination of SMC markers displayed significant 
inhibition of SMC markers including Calponin and αSMA both at the gene expression 
level and protein level (Figure 3-34 B and D, Figure 3-35). Even so, the effect of 
ROCK2 on SMC differentiation was evident. A possible explanation of the limited 
influence with the presence of TGFβ1 was that TGFβ1 was a very potent growth 
factor and could activate other signalling pathways to compensate ROCK2 




Figure 3-34 Knockdown of ROCK2 with siRNA inhibits the expression of SMC markers 
at the gene expression level 
HUCMSCs were cultured in medium (αMEM with 1% FBS) for 1 day at the density of 1x104 
/cm2 before being transfected with ROCK2 siRNA. The final concentration of ROCK2 siRNA 
was 5 nM. TGFβ1 addition was as mentioned in the figure. The effects of ROCK2 siRNA 
knockdown were checked in culture conditions with and without TGFβ1. Cells were harvested 
2 days after transfection. (A and C) ROCK2 decrease at the gene expression level was 
confirmed by q-PCR. (B) In culture condition without TGFβ1, the effect of ROCK2 knockdown 
was potent with the downregulation of Calponin, SM22 and αSMA at the gene expression 
level. (D) In culture condition with TGFβ1, the effect of ROCK2 knockdown was less 
prominent with the only significant decrease of Calponin at the gene expression level. Data 
are obtained from at least three independent experiments and shown as mean ± SEM. 
Statistics are obtained from unpaired student t-test. *P < 0.05 and ***P < 0.001. 
Figure 3-35 Knockdown of ROCK2 with siRNA inhibits the expression of SMC markers 
at the protein level   
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HUCMSCs were cultured in medium (αMEM with 1% FBS) for 1 day at the density of 1x104 
/cm2 before being transfected with ROCK2 siRNA. The final concentration of ROCK2 siRNA 
was 5 nM. TGFβ1 addition was as mentioned in the figure. The effects of ROCK2 siRNA 
knockdown were both checked in culture conditions with and without TGFβ1. Cells were 
harvested 2 days after transfection. (A) ROCK2 decrease at the protein level was firstly 
confirmed. (B) Moreover, in culture condition without TGFβ1, the effect of ROCK2 knockdown 
was potent with the downregulation of Calponin and αSMA at the protein level. (C and D) 
Statistical analysis of Western blot results showed signification downregulation of Calponin 
and αSMA in culture condition with TGFβ1. Result shown is representative of three 
independent experiments and shown as mean ± SEM. Statistics are obtained from unpaired 
student t-test. *P < 0.05 and **P < 0.01. 
 
3.5.3.5 ROCK2 3’-UTR is a direct target of miR-222-5p 
After establishing that miR-222-5p mimics decreases ROCK2 expression and the 
functional role of ROCK2 in promoting SMC differentiation, it is essential to explore 
whether miR-222-5p inhibits ROCK2 through directly targeting ROCK2 3’-UTR or 
through other mediators. To examine whether ROCK2 3’-UTR was directly targeted 
by miR-222-5p, the 3’-UTR segment was cloned into miRNA target reporter plasmids. 
Mutation of the two putative target sites within the 3’-UTR segment was carried out 
separately or together to check whether the inhibition was through the complimentary 
binding to either or both putative target sites. Results showed that compared to the 
empty plasmid, the plasmid containing the wild type ROCK 3’-UTR demonstrated 
lower relative luciferase activity when co-transfected with miR-222-5p mimics and this 
effect was not observed when the plasmids were co-transfected with miRNA mimic 
negative control. Mutation of both target sites, but not a single target site, could 
rescue the inhibited relative luciferase activity and mutation (Figure 3-36). Taken all 
into consideration, it could be concluded that ROCK2 3’-UTR is a direct target of miR-
222-5p and the inhibitory effect requires the presence of both putative target sites on 






Figure 3-36 3’-UTR of ROCK2 is directly targeted by miR-222-5p 
(A) Sequence alignment of miR-222-5p and ROCK2 3’-UTR showed two separate putative 
target sites (site 1 and site 2) which was marked in red. Mutated nucleotides within the target 
site were marked in blue. Site 1 and site 2 was first separately mutated to obtain plasmid m1 
and m2 respectively. Next, site 2 was mutated in plasmid m1 to obtain a plasmid containing 
the ROCK2 3’-UTR with both target sites mutated, which was annotated m1 + m2 in later 
luciferase experiments. (B) Empty miRNA target luciferase reporter plasmid (ctrl), plasmid 
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containing wild type ROCK2 3’-UTR (wt), plasmid with target site 1 mutated (m1), plasmid 
with target site 2 mutated (m2) and plasmid with both target sites mutated (m1+m2) were 
transfected into HEK293 cells together with miRNA mimic negative control or miR-222-5p 
mimics one day after the cells were seeded onto the 24 well culture flask. Lipofectamine 3000 
was used as the transfection reagent. 50 ng of plasmid and 25 nM of miRNA plasmids were 
used in each well of 24 well plate. Cells were harvested 24 hours after transfection for 
luciferase detection. Ratio of firefly luciferase activity and Renilla luciferase activity (relative 
luciferase activity) was utilised as the parameter for 3’-UTR activity. It was demonstrated that 
miR-222-5p mimics could result in inhibition of relative luciferase activity in wt plasmids 
compared with that in empty plasmids. This inhibition was not observed in cells transfected 
with miRNA mimic negative control. De-repression was only achieved when both target sites 
were at the same time mutated and mutation of the single target site (target site 1 or target 
site 2) was not adequate to recover the inhibition. Data are obtained from at least three 
independent experiments and shown as mean ± SEM. Statistics are obtained with two-way 
ANOVA test, followed by Bonferroni post-hoc analysis. *P < 0.05. 
 
3.5.3.6 Summary of miR-222-5p-involved differentiation mechanism 
In the SMC differentiation process, miR-222-5p was downregulated which de-
repressed αSMA and ROCK2. ROCK2 was established in other studies to facilitate 
the polymerisation of glomerular actin (G-actin) to filamentous actin (F-actin), which 
helped the release of MRTFs from G-actin and free MRTFs were subsequently 
translocated to the nucleus to work together with SRF and activate the downstream 
SMC markers. The de-repression of ROCK2 from miR-222-5p could augment SMC 




Figure 3-37 Schematic representation of miR-222-5p involved signalling pathway 
MiR-222-5p was downregulated in the differentiation system. It directly targeted αSMA and 
ROCK2. Thus, the downregulation of miR-222-5p further potentiated the upregulation of 
αSMA and ROCK2. ROCK2 was confirmed to augment SMC differentiation with knockdown 
experiments. Downstream ROCK2 involved signalling was not further explored in our 
differentiation system, but it was established in other studies that ROCK2 activation signals 
through MRTF-dependent pathway to activate SMC markers. 
 
3.6 Vascular graft engineering with hUCMSC-derived 
SMCs 
Tissue engineered vascular grafts emerge to be a promising surgical alternative for 
cardiovascular diseases. Exploration of novel cell choices and methods for vascular 
graft engineering continues to be a great research interest which bears significant 
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clinical importance. Our lab has previously established an ex vivo bioreactor system-
based method to generate cell seeded vascular grafts with scaffold decellularised 
from mouse aorta. The constructed vascular grafts displayed comparable structure 
with native vessels and demonstrated improved patency and function in comparison 
with decellularised grafts that were not seeded with cells (Campagnolo et al., 2015a; 
Margariti et al., 2012; Wong et al., 2015).  
 
3.6.1 Confirmation of decellularisation efficiency 
Mouse aorta was harvested and decellularised with detergents as described in the 
Method section. The efficiency of the decellularisation was shown by DAPI staining 
of the graft in en face samples. Decellularised vascular graft demonstrated weak 
staining of destructed nucleus fraction, whereas the nucleus was intact and in an 
undamaged shape in the cells within the normal aorta (Figure 3-38). Further 
inspection of the SMC marker reminiscence on the cross-sections of decellularised 
aorta displayed minimal SMC marker staining including Calponin and αSMA, and in 
comparison, the staining of these markers on the normal aorta demonstrated much 
stronger signal (Figure 3-39). Collectively, successful decellularisation of the mouse 





Figure 3-38 Decellularisation of mouse aorta 
Mouse aorta was harvested and decellularised with detergents as depicted in method part. 
Decellularised aorta was subjected to en face staining with DAPI. DAPI staining showed that 
cell nucleus on the decellularised vascular graft were destructed with minimal reminiscent 
nucleus fraction stained, and the nuclei in the cells on the normal aorta displayed their 
characteristic shape. De indicates decellularised aorta, and Aorta indicates normal mouse 





Figure 3-39 SMC markers were not stained in decellularised vascular graft 
Decellularised aorta grafts as well as normal aortas were cut into sections in 30 μm thickness 
and then stained with DAPI and SMC markers. Consistent with the previous figure, 
decellularised graft only displayed minimal reminiscent nuclear fraction staining, whereas the 
DAPI staining in the normal aorta demonstrated the normal shape of cell nuclei. Moreover, 
compared with the normal aorta, decellularised grafts were not staining with SMC markers 
Calponin and αSMA, which displayed the efficiency of decellularisation. De indicates 
decellularised aorta, and Aorta indicates normal mouse aorta. Images shown are 




3.6.2 Engineering of vascular graft with hUCMSC-derived SMCs 
After confirmation of the decellularisation efficiency, cell seeding was then performed 
for the construction of vascular grafts. SMCs differentiated from hUCMSCs were 
mixed in Matrigel and then wrapped outside the decellularised scaffold that was 
connected to the bioreactor system. The medium was then added to the culture 
chamber and inside the system after the solidification of the Matrigel. The graft was 
harvested 5 days after it was kept in the bioreactor system with medium flowing inside. 
Staining of the graft with DAPI showed the colonisation of seeded cells in the 
decellularised scaffold compared to the scaffold that was not seeded with cells 
(Figure 3-40). Further examination of the generated graft with SMC marker staining, 
including Calponin, SM22, αSMA and SMMHC, demonstrated that the seeded cells 
retained SMC marker expression after they migrated inside the decellularised 
scaffold (Figure 3-41).  
 
Figure 3-40 Cell seeding onto the decellularised vascular grafts 
HUCMSCs were cultured in differentiated medium (αMEM with 1% FBS and 5 ng/ml TGFβ1) 
for 5 days and then mixed in Matrigel which was then wrapped outside the decellularised 
vascular graft and connected to the bioreactor system. Medium in the chamber and flowing 
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inside the bioreactor system was αMEM with 10% FBS and 5 ng/ml TGFβ1. After being kept 
in the bioreactor system for 5 days, the graft was harvested and subjected to frozen 
sectioning with the thickness of 30 μm. DAPI staining demonstrated the colonisation of 
seeded cells in the decellularised vascular graft, whereas decellularised vascular graft was 
not stained with DAPI. Images from two representative experiments are shown and three 





Figure 3-41 Differentiated cells migrated into the decellularised vascular graft and 
expressed SMC markers 
HUCMSCs were cultured in differentiation medium (αMEM with 1% FBS and 5 ng/ml TGFβ1) 
for 5 days and then mixed in Matrigel to be wrapped outside the decellularised vascular graft 
which was then connected to the bioreactor system. The medium in the chamber and flowing 
inside the bioreactor system was αMEM with 10% FBS and 5 ng/ml TGFβ1. After being kept 
in the bioreactor system for 5 days, the graft was harvested and subjected to frozen 
sectioning with the thickness of 30 μm. Staining of the vascular grafts for SMC markers 
including Calponin, SM22, αSMA and SMMHC showed that the differentiated cells seeded 
outside the graft managed to migrate inside and retain the SMC marker expression. 





In this study, I have successfully established an efficient protocol to differentiate 
hUCMSCs towards the SMC lineage and have explored the underlying miRNA-
related mechanisms. Furthermore, I have tested the potential of these differentiated 
SMCs for vascular graft engineering. The SMC differentiation was achieved through 
culturing the cells in low serum medium with the addition of TGFβ1, an established 
and potent stimulator for SMC differentiation. Notably, these differentiated cells 
exhibited typical functional SMC properties, including increased contractility and 
vasculogenesis capacity. Subsequently, the miRNA centred mechanism involved in 
this differentiation process was elucidated with the identification of novel regulatory 
miRNAs (miR-503-5p and miR-222-5p). Moreover, these miRNAs participate in SMC 
differentiation through targeting known components of established TGFβ1 signalling 
pathways, including the Smad-dependent pathway and ROCK-dependent pathway. 
Finally, vascular grafts could be generated utilising the differentiated SMCs from 
hUCMSCs, indicating the potential application of the cells in vascular tissue 
engineering. 
 
4.1 Establishment of the differentiation protocol from 
hUCMSCs towards the SMC lineage 
The differentiation of stem cells towards SMCs is usually achieved through the 
manipulation of the cell culture condition including the addition of various 
biochemicals, the concentration of serum and duration of differentiation. Numerous 
growth factors like TGFβ1, bone morphogenetic protein 4 (BMP4), angiotensin II (Kim 
et al., 2008), sphingosine 1- phosphate (Lockman et al., 2004) and thromboxane A2 
(Kim et al., 2009) could all be utilised to stimulate SMC differentiation (Elcin et al., 
2017). Among these reagents, TGFβ1 is a potent stimulator for SMC differentiation 
from stem cells both in vitro and in vivo (Grainger et al., 1998; Guo et al., 2013; 
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Yamazaki et al., 2017). It promotes the induction of SMC contractile markers including 
Calponin, SM22, αSMA and SMMHC in cultured SMCs (Bjorkerud, 1991; Deaton et 
al., 2005). Furthermore, these factors could cooperate or interact with each other. 
The promotion of SMC differentiation from human mesenchymal stem cells by 
sphingosine-1-phosphate was dependent on TGFβ1 signalling pathway (Jeon et al., 
2006). Studies also showed that only when TGFβ1 was combined with BMP4 could 
contractile SMCs be obtained (Elcin et al., 2017; Wang et al., 2010b).  
Due to the potency and widespread use of TGFβ1 in inducing SMC differentiation, it 
was tested in this study. It demonstrated a concentration-dependent and time-
dependent enhancement of SMC marker level both at the gene expression and the 
protein level, together with augmented contractility and vasculogenesis potential, 
which are functions typically displayed by SMCs. For this reason, further addition of 
BMP4 was not necessary. Apart from the induction of contractile SMC markers during 
the differentiation process, induction of extracellular matrix proteins such as collagen 
I and elastin by TGFβ1 demonstrates the potential of these differentiated cells to be 
utilised in vascular graft engineering as production of extracellular matrix proteins 
would help increase the mechanical strength and bio-compatibility of the graft. This 
is consistent with published results showing elastin matrix enhancement in vascular 
SMCs upon stimulation of TGFβ1 and hyaluronan (Kothapalli et al., 2009).  
Another culture condition that was optimised in the experimental system was the 
serum concentration. In vitro culture condition with high serum concentration induces 
the smooth muscle cells to enter the proliferative synthetic phenotype which is similar 
to the smooth muscle cell phenotypic switching during vascular injuries (Poliseno et 
al., 2006; Shankman et al., 2015). The synthetic phenotype can be switched back to 
contractile phenotype upon serum deprivation as indicated by the increases in 
contractile markers (Poliseno et al., 2006). In SMC differentiation from stem cell 
sources such as pluripotent stem cells, BMMSCs and skin-derived precursors, 
contractile SMCs were acquired with lower serum concentration (Steinbach et al., 
2011; Tamama et al., 2008; Wanjare et al., 2013). Although contradictory studies 
exist demonstrating that serum concentration in the culture medium does not affect 
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SMC marker expression, these reports are few and isolated (Gong et al., 2009). Thus, 
it could be concluded overall that serum concentration reduction or deprivation are in 
favour of functional SMC differentiation. 
As to whether lower serum concentration could enhance SMC differentiation, 
experimental evidence was gathered in the present differentiation process from 
hUCMSCs to SMC lineage. Compared to differentiation medium containing 10% FBS, 
hUCMSCs differentiated in medium containing 1% FBS displayed at least two-fold 
higher expression of almost all SMC contractile markers including Calponin, SM22, 
and αSMA either with or without TGFβ1 except for SMMHC. The unaffected level of 
SMMHC in conditions with different serum concentrations in TGFβ1 containing 
medium might be explained by the potent effect of TGFβ1 that masked the effect of 
serum concentration. This result is reasonable considering that the serum 
concentration of the basal culture medium for hUCMSCs is 2% which is already quite 
low. Therefore, differentiation medium with 1% FBS and TGFβ1 was utilised in 
subsequent experiments as established differentiation condition unless otherwise 
specified.  
Furthermore, it is noteworthy that the basal culture medium of hUCMSCs contains 2% 
FBS as well as growth factors including basic fibroblast growth factor (bFGF), acidic 
fibroblast growth factor (aFGF) and epidermal growth factor (EGF). It was shown by 
several studies that bFGF helps promote the proliferation capacity of mesenchymal 
stem cells and retain the multi-potent differentiation capacity which justifies its 
utilisation in MSC culture (Eom et al., 2014; Hori et al., 2004; Solchaga et al., 2005; 
Sotiropoulou et al., 2006; Tsutsumi et al., 2001). In the meantime, it was found in 
vascular SMCs that FGF signalling inhibits TGFβ-induced SMC phenotypic switching 
from synthetic phenotype to contractile phenotype, which suggests that FGF 
signalling pathway inhibits the low basal expression of SMC markers present in MSCs 
(Chen et al., 2016; Schuliga et al., 2013).  
Under this postulation, the switch of the culture medium of hUCMSCs from basal 
medium with bFGF to differentiation medium without bFGF might retract the 
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suppression of bFGF on SMC marker expression and manifest the spontaneous 
differentiation capacity of hUCMSCs. This is proved to be crucial as shown by the 
significant increase of contractile SMC markers expression both at the mRNA and 
protein level in hUCMSCs cultured with medium deprived of bFGF and containing 
only 1% FBS compared to undifferentiated hUCMSCs. The lineage specific 
differentiation of hUCMSCs to SMCs was further enhanced by TGFβ1 addition.  
 
4.2 Functional characterisation of differentiated SMCs 
Physiologically, SMCs reside in the media layer of the vessel and display the 
contractile capacity to maintain the vascular tone. In vascular tissue engineering, it is 
essential to construct vascular grafts which have contractile SMCs in the media layer 
to achieve satisfying vascular tone and sufficient mechanical strength. At present, 
there are several approaches to examine the contractile function of SMCs in vitro. 
First, contractility of SMCs could be checked at the single cell level with calcium 
sensitising reagent such as KCl. Subsequent change of contractility could be 
measured with the change of force produced by the cells (Ratz et al., 2005). 
Karamariti et al. visualised the migration of SMCs derived from reprogrammed 
pluripotent stem cells with time lapse microscopy after stimulating the cells with KCl 
which provides indirect evidence of the cell function (Karamariti et al., 2013b). 
Furthermore, the contractile function of the SMCs could be detected at the cell 
population level with collagen gel contraction assay in which the cells were mixed 
with collagen I to form polymerised gel lattice (Jiang et al., 2010; Lenga et al., 2008). 
Cells with better contractility would yield collagen gel with a smaller diameter when 
the gel is freed from the culture flask (Jiang et al., 2010; Lenga et al., 2008).  
In this study, in vitro examination of the contractility was explored with collagen gel 
contraction assay given that in the established differentiation protocol from hUCMSCs 
to SMCs, more than 90% of the cells expressed contractile markers after 5 days of 
differentiation. Therefore, population level examination of the cells would be sufficient 
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to represent the contractile function improvement after differentiation. Consistent with 
the strong differentiation capacity demonstrated by the high level of contractile SMC 
marker expression, increases of in their contractile potential after differentiation 
further confirmed the efficiency of differentiation. Furthermore, SMCs are a major 
component of vessels that are with larger diameters. The hUCMSCs-derived SMCs, 
when mixed with endothelial cells in subcutaneous Matrigel plugs, exhibited the 
capacity to form finer vascular structures with αSMA-expressing media layer. This is 
evidence that differentiated cells display a better vasculogenesis function when mixed 
with endothelial cells. 
 
4.3 Exploration of SMC differentiation mechanism 
The SMC differentiation mechanism is a complex regulatory network. Exploration of 
novel miRNAs involved in the differentiation network could provide new therapeutic 
choices. In vascular tissue engineering, miRNAs that could improve SMC 
differentiation and contractile function bear great potential in improving graft 
performance. Since TGFβ1 was added to the differentiation medium and directed the 
lineage commitment of hUCMSC to SMC lineage, further exploration of the 
mechanism underlying SMC differentiation was mainly focused on merging novel 
miRNAs uncovered by the miRNA array with well-established TGFβ1-related 
signalling pathways. 
Successful differentiation protocol was confirmed first by the detected increase of 
Myocardin and SRF in the differentiation process in addition to contractile SMC 
markers. It was also confirmed that miR-145, a well-established contractile SMC 
differentiation enhancer, was also upregulated in a time-dependent manner in the 
differentiation system (Boucher et al., 2011; Cordes et al., 2009). Exploration of miR-
145-related SMC differentiation mechanism has mainly involved candidates lying 
upstream and downstream in the pathways. Apart from Myocardin and SRF, it was 
revealed that miR-145 could also be upregulated by TGFβ1 (Cordes et al., 2009; 
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Gays et al., 2017; Long and Miano, 2011). Smad binding elements were 
characterised in an enhancer region of miR-145 and the binding of Smad4 on this 
region was confirmed by chromatin immunoprecipitation experiments (Long and 
Miano, 2011). Jagged 1/Notch signalling pathway could also control the expression 
of miR-145. Downstream targets of miR-145 include Klf4 (Kruppel-like factor 4), Elk-
1 (ELK1, a member of ETS oncogene family) and Myocardin (Cordes et al., 2009). 
There are also reports in cancer cells showing that miR-145 could target Smad3 to 
inhibit TGFβ1-induced epithelial-mesenchymal transition and cancer invasion and 
target ROCK1 to inhibit proliferation and invasion of osteosarcoma cells (Hu et al., 
2016; Li et al., 2014). As Smad3 and ROCK1 are both components of TGFβ signalling 
pathways, these imply a complex interaction between miR-145 and TGFβ signalling 
pathways.  
After uncovering novel miRNAs whose expression is changed during MSC-SMC 
differentiation using miRNA array, miR-503, which is upregulated during the 
differentiation process and promotes MSC-SMC differentiation, as well as miR-222-
5p, which is downregulated in the differentiation process and de-represses MSC-
SMC differentiation, emerge to be two promising candidates. To further establish their 
roles in SMC differentiation, similar approaches to the study of miR-145 involvement 
were employed placing the exploration focuses on the upstream control of miRNA 
level and the downstream targets. More importantly, both upstream upregulation of 
miRNAs and downstream target explorations were tightly oriented within well-
established TGFβ1 signalling pathways. Detailed exploration of the mechanism will 
be discussed below. 
4.3.1 Mechanism of SMC differentiation – miR-503-related 
mechanism 
4.3.1.1 Targets of miR-503 during MSC-SMC differentiation 
MiR-503 participates in numerous pathophysiological conditions. In cancer cells, it 
can target L1CAM (L1 cell adhesion molecule), thus inhibiting the proliferation and 
invasion of glioma cells and target oncogene DDHD2, thus inhibiting the proliferation 
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of human glioma cells (Liu et al., 2015; Polioudakis et al., 2015). In pulmonary arterial 
hypertension, miR-503 can be regulated by endothelial apelin and target FGF in 
pulmonary SMCs, thereby disrupting the apelin-FGF link and mediating pulmonary 
arterial hypertension disease progression (Kim et al., 2013). Interestingly, apelin 
could be targeted by miR-503 in cardiac fibrosis, which suggests that in miRNA 
regulation of pathological conditions, at least for miR-503, feedback control exists and 
might be widespread (Zhou et al., 2016b).  
Other downstream targets of miR-503 include Cdc25A, CCND1 and Cyclin D3 which 
promote cell cycle quiescence and inhibit proliferation (Long et al., 2015; Sarkar et 
al., 2010; Xiao et al., 2013). Particularly, it was shown that miR-424, which belongs 
to the same family of miR-503, can target Cyclin D1, decrease SMC proliferation and 
ultimately attenuate neointimal formation after vascular injury (Merlet et al., 2013). 
Moreover, important components of TGFβ1 signalling pathways are also shown to be 
targets of miR-503. These include Smurf1 (SMAD specific E3 ubiquitin protein ligase 
1), Smurf2 (SMAD specific E3 ubiquitin protein ligase 2) and Smad7, among which 
the latter three are negative regulators of the TGFβ1 Smad-dependent signalling 
pathway (Cao et al., 2014; Llobet-Navas et al., 2014; Sun et al., 2017; Zhao et al., 
2017b).  
In this study, miR-503 has been confirmed to directly target Smad7 by binding onto 
its 3’-UTR, leading to RNA degradation. This is the first time that miR-503 has been 
shown to target Smad7, thereby influencing SMC differentiation process. In Smad-
dependent signalling, TGFβ1 binds to and activates the TGFβ receptors on the cell 
membrane, and subsequently mediates the phosphorylation of R-Smad/Co-Smad 
complex. The phosphorylated complex is then translocated to the nucleus, and binds 
to the Smad binding element at the promoter region of target genes, thereby 
upregulating the gene transcription (Derynck and Zhang, 2003). Smad7 exhibits an 
inhibitory effect on Smad-dependent signalling pathway by binding to the TGFβ type 
I receptor on the cell membrane, thus blocking the binding of R-Smad/Co-Smad 
complex to the receptor or the phosphorylation of the complex. Interestingly, although 
Smad7 is a well-known negative regulator of TGFβ1 Smad-dependent signalling 
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pathway, it could be transcriptionally upregulated by TGFβ1, suggesting a negative 
feedback loop control for TGFβ1 signalling (Nakao et al., 1997; Zhu et al., 2004). 
Upregulation of Smad7 during the MSC-SMC differentiation process and the 
increased SMC differentiation when Smad7 is knocked down in this study are 
consistent with those published in the literature. However, the augmented SMC 
differentiation after siRNA-mediated Smad7 knockdown was mainly exhibited on 
Calponin at the protein level, suggesting that other mechanisms mediating SMC 
differentiation might also be at play. 
In addition to Smad7, there are other potential targets of miR-503 which might 
participate in the SMC differentiation system, such as targets involved in cell cycle 
control as mentioned above. These targets are not examined in the current study 
since they might not fit into the complex network of TGFβ1 signalling pathway. 
However, the inhibition of proliferation resulted from the downregulation of these 
targets might help potentiate the upregulation of contractile SMC markers, which is 
consistent with the role of miR-503 in promoting SMC differentiation (Merlet et al., 
2013). However, the regulation of miR-503 and its specific targets are delicate and 
context-dependent, and it cannot be simply denoted here that these proliferation-
related targets are involved in this MSC-SMC differentiation system without 
experimental evidence. 
4.3.1.2 Transcriptional regulation of miR-503 
As to the upstream regulation of miR-503 transcription, peroxisome proliferator-
activated receptor γ (PPARγ) was demonstrated to be a direct regulator (Lee et al., 
2017). Under inflammatory conditions, PPARγ level and activity were both 
downregulated in endothelial cells, which led to downregulation of miR-503 and the 
upregulation of miR-503 target CD40 (Lee et al., 2017). NF-κB (nuclear factor κ-light-
chain-enhancer of activated B cells) was also proved to be a major regulator of miR-
503 expression. Upon stimulation with LPS (lipopolysaccharides), epithelial cells 
exhibited increased recruitment of NF-κB p50 and HDACs at the promoter region of 
miR-503 and subsequent downregulation of miR-503 level (Zhou et al., 2013). In 
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diabetic conditions, hyperglycemia triggered the upregulation of miR-503 through NF-
κB p75-dependent manner in vascular endothelial cells and the produced miR-503 
could exert effects on adjacent pericytes and influence vascular pericyte coverage 
(Caporali et al., 2015). MiR-503 could also be upregulated through Smad-dependent 
pathway as shown in the epithelial remodelling of the mammary gland (Llobet-Navas 
et al., 2014). 
In the current study, as suggested by the close relationship between TGFβ1 
stimulation and increased miR-503 expression, it was postulated that TGFβ1 
signalling pathway might be the dominant pathway regulating miR-503 transcription. 
This was later confirmed with the downregulation of miR-503 level after Smad4 
knockdown and the enrichment of Smad4 at the promoter region of miR-503 after 
TGFβ1 treatment as demonstrated by ChIP experiments. Consistent downregulation 
of miR-503 after Smad4 knockdown was not achieved in culture conditions without 
TGFβ1 as miR-503 is upregulated through TGFβ1 activation via Smad4. Furthermore, 
even though other potential upstream signalling pathways are not examined and 
excluded here, sufficient evidences have been obtained to conclude the definite role 
of Smad4 in miR-503 transcriptional upregulation during MSC-SMC differentiation. 
4.3.1.3 Lineage specification effect of miR-503 
Different from what is validated in our system demonstrating the vital role of miR-503 
in SMC lineage differentiation, other published reports have shown the importance of 
miR-503 in determining cardiac progenitor cell fate commitment to cardiomyocytes, 
as well as promoting monocyte differentiation from THP-1 cells (an M5-acute myeloid 
leukemia cell line containing the MLL-MLLT3 fusion) when combined with other 
miRNAs (Forrest et al., 2010; Shen et al., 2016). There are two possible explanations 
for this. First, the lineage specification of miR-503 to cardiomyocytes or monocytes is 
attributed to the anti-proliferative effects rather than lineage specification effects. In 
the promotion of monocytic differentiation, the effect of miR-503 lies in their inhibition 
of targets involved in cell proliferation and it needs to be combined with other miRNAs 
such as miR-155 and miR-222 to ultimately drive the cell differentiation towards 
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monocytes. Another explanation is that miR-503 might be a lineage-determining 
miRNA towards muscle cell lineage that encompasses cardiomyocytes, skeletal 
muscle cells and the smooth muscle cell lineage which is studied here. Furthermore, 
the context-dependent regulation should always be taken into consideration while the 
results are being interpreted. Different stem cell lines as well as different stimulators 
have been utilised in this study compared to those published studies. MiR-503 might 
play different roles in these different contexts. 
What is also noteworthy is that miR-503 gene locates within the X chromosome. 
Notably, the promotion of SMC differentiation by miR-503 might be one attributable 
factor for the different morbidity of pulmonary hypertension in subjects with different 
genders (Dempsie and MacLean, 2013; Swift et al., 2014). This is an avenue for 
future investigations on elucidating the possible relationship of this miRNA with other 
sex-linked diseases such as coronary artery disease (Yahagi et al., 2015). 
4.3.2 Mechanism of SMC differentiation – miR-222-5p-related 
mechanism 
MiR-222 participates in numerous physiological and pathophysiological conditions 
including cancer progression, skeletal muscle regeneration and vascular remodelling. 
It was reported that miR-222 targets cyclin-dependent kinase inhibitor 1B 
(CDKN1B/p27kip1) in hepatocellular carcinoma HepG2 cells and breast cancer cells, 
promoting cell proliferation and mediating tumour growth (Wang et al., 2016; Yang et 
al., 2014). In breast cancers, miR-222 starts to get recognised as a biomarker since 
it could target estrogen receptor α (ERα) (Chen et al., 2013). Inhibitory effect of miR-
222 on tumour cell proliferation was also observed. In lung cancer cells, miR-222 
induces S phase arrest in the cell cycle, thus inhibiting tumour growth (Yamashita et 
al., 2015). Apart from cancers, miR-222 also could target cyclin-dependent kinase 
inhibitor 1C (CDKN1C/p57kip2) and regenerate skeletal muscle after hindlimb 
ischemia (Togliatto et al., 2013). In vascular diseases, miR-222 was shown to exert 
a pro-proliferative and pro-migratory effect by targeting CDKN1B/p27kip1 and 
CDKN1C/p57kip2 which results in promotion of smooth muscle cell proliferation and 
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neointimal hyperplasia (Liu et al., 2009; Urbich et al., 2008). In endothelial cells, 
however, they display contrary anti-proliferative and anti-migratory effect which 
causes inhibition of re-endothelialisation after vascular injury, possibly through 
targeting c-kit (Liu et al., 2012). Different effects of miR-222 in different cell types 
imply the importance of the contexts for miRNAs to exert their functions. Furthermore, 
miR-222 was demonstrated to be crucial in vascular calcification and vascular 
remodelling upon inflammatory stimuli (Dentelli et al., 2010; Mackenzie et al., 2014). 
In one study, miR-222 was shown to repress the TGFβ1-induced growth inhibition in 
breast cancer cells (Rao et al., 2011). However, there has been no report in the 
literature demonstrating the direct relation of miR-222 with TGFβ1 signalling pathway.  
As to the upstream upregulation of miR-222, only isolated reports exist. MiR-222-3p 
was shown to be upregulated in a p53-dependent manner, but chromatin 
immunoprecipitation experiments did not demonstrate its direct binding to the 
promoter region of miR-222 (Rihani et al., 2015). In the promoter region of miR-222, 
binding sites for NF-κB p65 and c-jun were characterised and found to cooperate with 
each other to control the miR-222 transcription, which subsequently exerts oncogenic 
effect in prostate carcinoma and glioblastoma cell lines (Galardi et al., 2011).  
However, these studies have limited significance in providing information for the study 
of miR-222-5p in the current experimental system, as it was the mature strand miR-
222-3p that was examined in most publications. In the MSC-SMC differentiation 
system here, miR-222-5p, which is the passenger strand of miR-222, was examined. 
Despite the general recognition that miRNA star strand or passenger strand goes 
through degradation rapidly and does not exert any regulatory function, this 
consensus was challenged in recent years. Abundant reports have emerged and 
depicted the fate of miRNA passenger strand as well as their regulatory role in human 
diseases such as cancers, inflammatory diseases and cardiovascular diseases 
(Bhayani et al., 2012; Guo and Lu, 2010; Mah et al., 2010; Yang et al., 2011). 
Furthermore, genomic analyses revealed that more than 40% of the miRNA star 
strands displayed conservation across species and conservative targets were 
preferred when they exert effects (Okamura et al., 2008). In addition, in some miRNAs, 
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both strands would cooperate with each other to participate in the regulation of the 
same disease condition or pathological circumstance. MiR-200b-3p and miR-200b-
5p function together to inhibit the epithelial to mesenchymal transition in breast cancer 
cells (Rhodes et al., 2015). MiR-126 and miR-126* work together in regulating 
leukocyte adhesion to endothelium (Cerutti et al., 2017). What is more interesting is 
that miR-17-5p and miR-17-3p regulate the same target tissue inhibitor of 
metalloproteinase 3 (TIMP3) and modulate prostate tumour growth (Yang et al., 
2013). 
In this study, miR-222-5p is the star strand of miR-222. It was found to be important 
in regulating SMC differentiation from hUCMSCs to SMCs. Its level was significantly 
downregulated in a time-dependent manner in the differentiation process. The gain-
of-function assessment with miRNA mimics demonstrated their prominent role in 
inhibiting SMC differentiation. Moreover, its downregulation serves as a prerequisite 
for the upregulation of contractile SMC markers in differentiation. As shown in the 
Results section, however, miR-222-5p mimics did not inhibit all contractile SMC 
markers, with minimal effect on SM22 both at the gene expression and the protein 
level. This suggests that the downregulation of miR-222-5p is not sufficient in de-
repressing all contractile SMC marker expression and may only participate in the 
differentiation process as a complimentary regulation pathway. 
While exploring the underlying miR-222-5p-related mechanism, important 
components of TGFβ1 signalling pathway were screened first since the miR-222-5p 
level was found to be related to the treatment of exogenous TGFβ1. The complex 
TGFβ1 signalling network may interact with each other through miRNAs and requires 
fine tuning to reach a balance. I postulate that miR-222-5p might target other TGFβ1-
related signalling pathways other than the Smad-dependent pathway. However, there 
is no study reported to date that directly relates miR-222-3p and its targets to TGFβ1 
signalling pathway or any physiological or pathophysiological conditions. Thus, I set 
out to look for their targets with computational miRNA target prediction approaches 
like TargetScan. Among the list of predicted targets provided, ROCK2 was selected 
as the candidate target to be examined further.  
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RhoA/ROCK pathways are important regulators of cardiovascular diseases 
(Hartmann et al., 2015; Shimokawa et al., 2016). Numerous cellular events could be 
under the control of RhoA/ROCK pathway including cell proliferation, cytoskeletal 
remodelling, migration and apoptosis (Shimokawa et al., 2016). Specific to SMC 
phenotypic switching or differentiation, activation of RhoA/ROCK pathway leads to 
the glomerular actin (G-actin) to form filamentous actin (F-actin), which results in the 
release of MRTF-A/B from the glomerular actin and translocation of it to the nucleus 
to activate downstream genes (Parmacek, 2007).  
In this study, ROCK2 contained 2 target sites for miR-222-5p at the 3’-UTR region 
and its level was upregulated in a time-dependent manner which was consistent with 
the downregulation of miR-222-5p level during differentiation. Furthermore, ROCK2 
was inhibited both at the gene expression level and at the protein level after treatment 
of miR-222-5p mimics. Knockdown of ROCK2 prompted downregulation of the SMC 
markers Calponin and αSMA, which is also consistent with the effect of miR-222-5p 
mimics on these markers in its inhibition of SMC differentiation. Although TGFβ1 did 
not exert significant effect in regulating the level of ROCK2, ROCK2 was still 
confirmed to be a direct target as shown by the site mutation experiments.  
Furthermore, although αSMA 3’-UTR was not a predicted target with the 
computational prediction method, the complementarity of it with miR-222-5p was still 
examined given its predominant downregulation both at the gene expression level 
and at the protein level after miR-222-5p mimic treatment in the cells. Alignment of 
αSMA 3’-UTR sequence with miR-222-5p sequence revealed complementarity of 8 
nucleotides at the 5’-end of the miRNA and complementarity of another 4 nucleotides 
at the 3’-end of the miRNA. Subsequent target site mutation experiments confirmed 
that αSMA 3’-UTR is a direct target of miR-222-5p. However, the mutation of the 
target site complementary to the 5’-end of the miRNA did not consistently recover the 
inhibition of the miR-222-5p on plasmids containing αSMA 3’-UTR, implying that the 
site complementary to the 3’-end might also have some effect in inducing the 




4.4 Interaction of miR-503-related and miR-222-5p-related 
mechanisms 
Multiple TGFβ1-related signalling pathways could interact with each other and work 
synergistically. Apart from the well-known Smad-dependent pathway, RhoA/ROCK 
pathway was also established to be important in TGFβ1-induced SMC differentiation 
(Bhowmick et al., 2001; Chen et al., 2006). As to the cooperation of RhoA/ROCK 
signalling pathway and Smad-dependent signalling pathway, it was found that they 
could exert effects in regulating each other. ROCK could modulate the activity of 
Smad signalling pathway possibly through phosphorylation of the Smad linker region 
(Chen et al., 2006; Kamato et al., 2013). Smad-dependent pathway could upregulate 
miR-155 which targets RhoA and modulates epithelial plasticity (Kong et al., 2008). 
The mutual regulation of these two pathways was also confirmed in one study with 
loss-of-function experiments with either ROCK pathway or Smad-dependent pathway 
and observation of the activity change of the other pathway (Ji et al., 2014). In 
embryonic stem cell self-renewal and differentiation, it was found that Smad2 and 
ROCK could be both regulated by Zonula Occludens-1 (ZO-1) (Xu et al., 2012a). 
However, reports also exist showing that early activation of RhoA upon TGFβ1 
treatment was independent of Smad2/3 (Papadimitriou et al., 2011). Moreover, in 
some studies, two parallel pathways may exert similar effects on the same 
pathological setting without interaction with each other. Expression of tetraspanin 2 
(TSPAN2) was independently regulated by Smad signalling pathway and 
Myocardin/SRF  (Zhao et al., 2017a). 
As to the miRNA interactions with each other, since miRNAs are generated in pairs 
endogenously, these miRNA pairs exhibit complementarity with each other. Although 
it was originally established that one strand of the miRNA pair goes through 
degradation directly, this concept starts to change. It has been shown that these 
miRNAs might form a duplex in vivo and mutually regulate each other (Guo et al., 
2012). Some miRNAs are formed from the same cluster, regulated in similar patterns 
in pathological conditions and share high similarity in seed sequences, which 
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demonstrate their potential collaborative ways of functioning (Guo et al., 2014; Xu et 
al., 2013). Furthermore, some miRNAs could indirectly control the transcription of 
some other miRNAs. Upon co-inhibition of miR-21 and miR-221 in laryngeal 
squamous cells carcinoma, a set of pro-apoptotic miRNAs were upregulated, 
providing insights on the highly complex miRNA regulation network (Kan et al., 2016). 
With the large-scale data analysis of the expression level of miRNAs and the primary 
miRNA-like characteristics (mlRNA) which encodes miRNAs, it was demonstrated 
that miRNA level in specific tissue corresponds with the reduced level of mlRNAs, 
implying potential control of some miRNAs on the transcription of other miRNAs 
(Zhao et al., 2008). Based on experimental evidence, further interactive network of 
miRNAs was obtained with the integration of data from different diseases with 
computational method (Xu et al., 2011; Xu et al., 2016). Furthermore, miRNAs 
interacting in various types of cancers could be seen visually online (Nalluri et al., 
2017). These miRNAs were further merged into established functional modules 
(Song et al., 2015; Zhao et al., 2013). Although miRNA interaction network has been 
gradually recognised, it requires large scale data pool and subsequent bioinformatic 
analysis, which was not realistic to be achieved in the experimental system in this 
study and it may not be required anyway. For miRNA interaction in one specific 
condition like what it is in the current experimental system, it was interesting that in 
oesophageal squamous cell carcinoma cells, the combination of increases in miR-31 
and decreases in miR-338-3p correlates with the survival time, implicating the 
precedence of this type of cooperation of multiple miRNAs in a single experimental 
setting (Wu et al., 2013). 
In this study, miR-503 upregulation and miR-222-5p downregulation correspond with 
each other and work synergistically to promote MSC-SMC differentiation. However, 
apart from the parallel analysis of both miRNAs, it was rather difficult to study the 
additive effect of both miRNAs. The reason is that the miRNA gain-of-function and 
loss-of-function studies are mainly achieved through the transfection of miRNA 
mimics and inhibitors. After co-transfection of miRNA mimics or inhibitors, the relative 
concentration of the two miRNAs would be difficult to recapitulate their level within 
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cells in the differentiation process, which will make it complicated and biased for 
subsequent interpretation of results. For this reason, co-transfection experiments of 
miRNA mimics or inhibitors were not conducted. However, future work might include 
the detection of miR-503 level after miR-222-5p mimics treatment or ROCK2 
knockdown, and the detection of miR-222-5p level after miR-503 mimics treatment or 
Smad4 knockdown, which might provide further information whether the two miRNA-
involved SMC differentiation pathways studied here work independently or entangle 
with each other to exert a more complex tuning of the differentiation system. Possible 
regulatory interactions of the pathways are highlighted in the green lines in the figure 
(Figure 4-1).  
 
 
Figure 4-1 Possible interaction of the two established miRNA-related signalling 
pathways 
Upon treatment of TGFβ1, miR-503 is upregulated in a Smad4 dependent pathway and 
directly targets Smad7, which is a negative regulator of TGFβ1 Smad-dependent signalling 
pathway, to promote SMC differentiation. The level of miR-222-5p was downregulated in the 
differentiation process, which results in de-repression of ROCK2 and αSMA and further 
promotion of SMC differentiation. Based on these established miRNA-related mechanisms in 
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our experimental system, it would be interesting to examine the interaction of these two 
miRNAs, their mutual regulation on each other and interaction of the two signalling pathways. 
The possible interaction points that might exist in the regulation network are highlighted in 
green lines in the figure. 
 
4.5 Potential application of differentiated cells in vascular 
graft engineering 
Vascular graft engineering is an important research field given that the morbidity and 
mortality of cardiovascular diseases are among the highest. Vascular bypass or 
replacement surgery is crucial for the treatment of these diseases involving coronary 
arteries. Peripheral artery diseases, which are the manifestation of major end stage 
metabolic syndrome, also often require vascular replacement surgery. Vascular 
grafts, however, are not always in sufficient needs, mostly because of the disease 
involvement or previous harvesting. Engineering of vascular grafts with synthetic 
materials, bio-compatible materials, or decellularised scaffolds is of significant value 
in matching the clinical need of vascular grafts. In constructing vascular grafts, 
numerous types of stem cells have been explored. 
In our lab, c-kit positive cells from mouse embryonic stem cells and reprogrammed 
pluripotent stem cells derived from fibroblasts have been explored in engineering 
functional small diameter blood vessels, which upon transplantation in vivo 
demonstrated improvement in patency and increases of mouse mortality rate 
compared to transplantation of the grafts that have not been seeded with cells 
(Campagnolo et al., 2015a; Karamariti et al., 2013a). Mesenchymal stem cells have 
emerged to be a potential promising choice in vascular tissue engineering since they 
are multipotent and display immune modulation characteristics, which make it 
possible to engineer vascular grafts seeded with allogeneic cells (Uccelli et al., 2006). 
Moreover, mesenchymal stem cells are a large source of numerous trophic factors 
which might facilitate the vascular regeneration and integration in vivo after 
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transplantation. Among all the mesenchymal stem cell sources, BMMSCs and 
ADSCs are the most extensively explored, which exhibited satisfying results both in 
the lab and in the clinics. 
Therefore, in this study, mesenchymal stem cell has been utilised as cell source for 
SMC generation. Specifically, MSCs from human umbilical cord, rather than those 
from bone marrow or adipose cells, were chosen to further explore in my experiments, 
as hUCMSCs demonstrate better proliferative capacity and higher multi-potent 
differentiation potential (Kern et al., 2006). In addition, hUCMSCs displayed strong 
SMC differentiation potential in vitro in differentiation conditions with low serum and 
addition of TGFβ1. Importantly, these differentiated cells exhibited the capacity to 
migrate inside the decellularised vessel wall while maintaining the expression of SMC 
markers after the seeded vessel was connected back to the bioreactor system.  
In addition to directly differentiating the stem cells towards SMCs and seeding them 
onto vascular scaffolds, much effort has also been invested into the improvement of 
graft performance. Extracellular matrix protein coating has been explored in the 
capacity to induce SMC differentiation, with fibronectin showing the ability to increase 
SMC marker expression of BMMSCs, which implies the potential of fibronectin 
coating in improving SMC differentiation in vascular grafts (Shudo et al., 2016). Pre-
treatment of SMCs utilised for vascular tissue engineering with miR-29a inhibitors 
performed better than TGFβ1 in promoting the production of elastin, which is a 
prominent component of extracellular matrix and contributes significantly to the 
mechanical strength of engineered vessel (Rothuizen et al., 2016). 
Mechanistic study of the differentiation process showed the importance of miR-503 
and miR-222-5p in SMC differentiation. Implication from the in vitro study was that 
miR-503 mimics and miR-222-5p inhibitors might have the potential in augmenting 
the performance of vascular grafts by promoting the differentiation of hUCMSCs 
towards SMCs. In the induction of SMC markers with TGFβ1, unintended signalling 
pathways and effects might be induced since TGFβ1 was well-known to be a potent 
growth factor with activation of diverse signalling pathways and potentiation of diverse 
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downstream effects. Future efforts might include the exploration of miR-503 mimic or 
miR-222-5p inhibitor treatment in other types of mesenchymal stem cells or even 
other types of stem cells to promote or augment the SMC differentiation.  
Efforts in differentiating the hUCMSCs towards the endothelial lineage have not been 
successful in vitro (Data was not shown). For this reason, the endothelial layer was 
not included in the vascular grafts. However, in our lab, methods to engineer vascular 
grafts with both the smooth muscle layer and endothelial layer have been successful 
thus far (Campagnolo et al., 2015a; Karamariti et al., 2013a). Feasibility of endothelial 
adhesion to the grafts would be further achieved with mature endothelial cells such 
as HUVECs. When examining engineered vascular grafts in vivo, those grafts seeded 
with both the smooth muscle layer and the endothelial layer should be utilised to 
increase the patency rate for further inspection of the vascular mechanical property 
and in vivo integration. 
In conclusion, hUCMSCs prove to be a promising choice of cell source for providing 
functional SMCs for engineering vascular grafts, which display extensive clinical 
potential to serve as vessel replacements in treating coronary artery diseases and 
peripheral artery diseases. MiR-503 mimics or miR-222-5p inhibitors carry the 
potential to improve the performance of these vascular grafts. 
 
4.6 Summary and perspective 
In summary, this is the first study to utilise hUCMSCs to generate functional SMCs 
with TGFβ1 and to engineer small diameter vascular grafts. Furthermore, we 
illustrated the differentiation mechanism involving miRNAs. It was established in vitro 
that miR-503 could target Smad7 to promote MSC-SMC differentiation and miR-222-
5p could target ROCK2 to inhibit the differentiation process. However, there are 
several limitations about this project and future works might need to be conducted. 
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First, the interaction of the two miRNAs that was shown to affect SMC differentiation 
should be further studied to provide additional information about the collaborative 
control of differentiation to uncover another miRNA-related layer of the complex SMC 
differentiation regulation network. In addition to the approaches to study the miRNA 
interaction as depicted in the discussion part by checking the level of one miRNA 
after the mimic or inhibitor transfection of the other one in my specific experimental 
system, broader overlook of the miRNA interaction might be explored by putting the 
miRNAs to already established signalling pathways, checking the interaction of these 
signalling pathways and studying the possibilities of miRNA interaction as well as 
pathway interaction in pathological conditions. For example, a study has previously 
shown the interaction of PDGF-BB signalling pathway and TGFβ1-Smad signalling 
pathway with the connection point of miR-24 (Chan et al., 2010a). Furthermore, it was 
shown that miR-222 could be induced by PDGF-BB to modulate SMC phenotypic 
switching (Davis et al., 2009; Liu et al., 2009). Although the miR-222 explored in both 
studies were the mature strand miR-222-3p, it is reasonable to postulate that upon 
transcription of miR-222, both strands including miR-222-3p and miR-222-5p would 
be upregulated at least temporarily. As miR-222-5p was shown in this study to be 
targeting ROCK2, it would be interesting to study the possible interaction of PDGF-
BB and ROCK2 given the potent function of both in a broad range of pathological 
conditions.  
Secondly, miR-503 was demonstrated here to target Smad7 which is an important 
negative regulator of TGFβ1-Smad signalling pathway. Through the promotion of 
SMC contractile marker expression, theoretically vascular grafts with better functions 
would be expected if cells treated with miR-503 mimics were seeded onto the scaffold 
compared to cells treated with miRNA mimic control. However, further experiments 
need to be performed to test this hypothesis and elucidate the ultimate effect of miR-
503 in further improvement of vascular graft performance.  
As to vascular graft construction, apart from examining the potential of miR-503 in 
replacing or augmenting the effect of TGFβ1, it is also essential that the vascular 
grafts need to be properly endothelialised before being transplanted in vivo. Due to 
191 
 
the unsuccessful differentiation of hUCMSCs towards ECs, future work includes short 
term HUVEC seeding in the inner side of the decellularised vascular graft after 
culturing the hUCMSC-derived SMCs seeded graft in the bioreactor. Subsequently, 
the performance of engineered vascular graft could be investigated by the patency 
rate and vascular integration in in vivo transplantation experiments. The effect of 
TGFβ1 and miR-503 on the production of the extracellular cellular matrix also requires 
further exploration. 
Lastly, miR-503 was shown to be involved in various pathological conditions. It has 
been shown to be secreted by ECs and could be transferred to adjacent SMCs to 
mediate the EC–SMC crosstalk. In pulmonary hypertension, decreased secretion of 
miR-503 from ECs leads to the downregulation of miR-503 in vascular SMCs that 
prompts the de-repression of targets related to the cell proliferation and therefore 
promotes subsequent SMC proliferation (Kim et al., 2013). In diabetic conditions, 
hyperglycemia induces upregulation of miR-503 in endothelial cells. It could be 
transported in exosomes to pericytes and exert inhibitory effect on αSMA expression, 
subsequently affecting the pericyte coverage in micro-vessels (Caporali et al., 2011). 
Thus, the effect of miR-503 on SMCs in different pathological conditions was different. 
To achieve a balance is crucial in maintaining normal vascular function. Further 
examination of miR-503 function in different cell types might be pertinent in unraveling 
the cell-specific function of miR-503. Apart from the in vivo examination of miR-503, 
exploration of miR-503 function in different pathological models might also be 
informative. In this study, further work might include the inspection of miR-503 in 
improving the vascular graft performance given its role in promoting SMC 
differentiation in vitro. In addition, its therapeutic potential could also be explored. 
Other pathological models such as hindlimb ischemia could also be used to provide 
clues about the vascular regeneration potential of miR-503 as a novel therapeutic 
choice.  
In conclusion, although future experiments are in need to further elucidate the 
therapeutic potential of miRNAs in addition to exploring the interaction of multiple 
signalling pathways, the present study has achieved the initial aims in establishing 
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the differentiation of SMCs from hUCMSCs and in elucidating the underlying 
mechanisms. Briefly, hUCMSCs were demonstrated to have the potential to 
differentiate towards SMCs and hUCMSC-derived SMCs can be utilised to generate 
vascular grafts. Furthermore, the SMC differentiation mechanism involving miRNAs 
was explored and illustrated. In future, miRNAs can be utilised to enhance SMC 
differentiation from MSCs while avoiding possible off-target effects from the use of 
TGFβ1 and the resultant cells seeded on decellularised scaffold have the potential in 
generating therapeutically useful vascular grafts with better patency to replace 
damaged vessels in patients with major vascular abnormalities like coronary artery 
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